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ABSTRACT  
Vel is a universal antigen present on the red blood cells (RBCs) membrane, which 
defines the Vel-blood group system. The identification of Vel-encoding gene, SMIM1, 
suggested that this is a regulator of erythropoiesis. Its role in RBCs and potential role in 
other cells, however, remains largely unknown.  
 
Here, I aimed to characterise the role of SMIM1 in haematopoietic lineages and other 
organs by using two main approaches (in vivo and in vitro) and three models (human 
volunteers, mouse and cell lines). First, using available datasets, I showed that SMIM1 
is expressed in megakaryocytes (MKs), platelets, neutrophils and naïve, memory and 
class-switched B-lymphocytes. I further demonstrated that SMIM1 localisation and the 
type of multimers it forms in some of those cells are cell type dependent.  
 
Second, I assessed the effect of the absence of SMIM1 in qualitative and quantitative 
blood traits in two human cohorts (Vel-negative blood donors recruited in this study and 
Vel-negative/weak individuals of the 400,000 UK Biobank study) and in a Smim1 
mutant mouse model. Small but significant alterations were observed in RBC, platelets 
and neutrophils counts in Vel-negative individuals and Smim1 mutant mice, however, 
the directionality of these changes and their significance was model specific.  
 
Third, I investigated the role of SMIM1 in platelets formation and function. I showed 
that SMIM1 is phosphorylated during platelet activation in humans and its ablation in 
male mouse platelets leads to a reduction of P-selectin surface expression on resting 
platelets. These findings suggest a role for SMIM1 during platelet activation. 
Furthermore, I described a novel metabolic phenotype both in human and mouse 
SMIM1 knockouts. I showed that SMIM1 absence leads to an increase in body weight 
(and consequently in body mass index (BMI)) in male Vel-negative donors and female 
Smim1-/- mice.  
 
 
Altogether, these findings provide new insights into the role of SMIM1 and the 
biological processes it is involved, which may have the potential to reveal unknown 
clinical phenotypes related with SMIM1 ablation and to inform their prevention and 
treatment. 
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1.1 An overview of haematopoiesis 
Haematopoiesis is the developmental process that gives rise to blood cells. These 
represent approximately one-quarter of all the human cells and, every second of our life, 
millions of blood cells are replaced to maintain our haematopoietic system. All these 
cells are produced from hematopoietic stem cells (HSCs), which have the capacity to 
self-renew and to generate all the blood lineages through a series of increasingly 
committed progenitors (Figure 1.1). This process is highly conserved between 
vertebrates (reviewed in [1]). 
 
In the developing vertebrate embryo, haematopoiesis occurs in two discrete waves, 
termed primitive and definitive. The primitive wave takes place during early embryonic 
development in the yolk sac and generates transitory haematopoietic cell populations 
(HSC independent) of primitive nucleated red blood cells (RBCs, also named 
erythrocytes), macrophages and megakaryocytes (MKs, which are more proliferative 
and have lower ploidy level (modal ploidy class at 4n) than adult MKs)[2-6]. Primitive 
RBCs facilitate tissue oxygenation during embryo development, while macrophages and 
MKs are important for tissue remodelling [7, 8]. The definitive wave originates later in 
development when multipotent HSCs capable of self-renewing and generating all the 
different blood lineages of the adult organism are produced [7, 9]. HSCs are generated 
between day 27 and day 40 of gestation in the aorta-gonad-mesonephros in an 
evolutionarily conserved process [9, 10]. These cells sequentially colonize the foetal 
liver, the thymus and finally the bone marrow, where adult HSCs live and give rise to 
all blood lineages [9, 10]. Additionally, in most organisms, between these two waves, 
there is a transient wave of definitive haematopoiesis, called the pro-definitive wave. 
During this wave, erythroid-myeloid progenitors emerge in the yolk sac and then 
migrate to the foetal liver [11]. Also, a subset of B-lymphocytes (B-1a cells) and T-
lymphocytes have been detected during this wave [8, 12]. 
 
In the classical model of haematopoiesis, adult HSCs go through a multipotent 
progenitor stage that can commit into common lymphoid progenitor (CLP) and common 
myeloid progenitor (CMP). CLPs undergo differentiation into B-lymphocytes, T-
lymphocytes and natural killer (NK) cells. While committed CMPs can be differentiated 
into granulocyte-macrophage progenitors (GMPs) or megakaryocyte-erythrocyte 
progenitors (MEPs) (Figure 1.1). Following a series of specification steps, GMPs give 
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rise to neutrophils, eosinophils, basophils and monocytes, whereas MEPs are 
differentiated into progenitor cells, named erythroblasts (EBs) and megakaryoblasts, 
which are then matured into RBCs and MKs, respectively. Mature MKs will later give 
rise to platelets [13]. The differentiation of CMPs towards MEPs or GMPs is regulated 
by two major transcription factors, GATA1 and PU.1. The increased expression of 
GATA1 together with the decreased expression of PU.1 lead to the specification of 
CMPs towards MEPs [14]. Since the megakaryocyte and the erythrocyte lineages derive 
from a common precursor (MEP), they share several transcription factors that are 
critical for their development, such as GATA1, FOG1 (GATA1 cofactor), TAL1 and 
GFI1b [15, 16]. 
 
 
Figure 1.1 – The classic model of haematopoiesis. Schematic representation of the 
blood cells progeny (Figure from Prof. Owehand’s group). 
 
Several more recent studies have shown that the HSC population is highly 
heterogeneous. This heterogeneity results in a number of HSC subtypes that have 
different functional properties, including different self-renewal abilities [17, 18], cell 
cycling status [19] and multilineage differentiation output [20-22]. These studies have 
led to the formulation of several alternatives and more complex hierarchical models of 
haematopoiesis [23-25]. However, Velten et al. have recently proposed a new model 
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that challenges the classic hierarchical model, suggesting that HSC differentiation 
instead, occurs through a mechanism of continuous lineage priming. This model 
suggests that CLOUD-HSPCs, which is a pool of uncommitted hematopoietic stem and 
progenitor cells (HSPCs) in transitory states, progressively acquire transcriptomic 
unilineage priming and directly differentiate in unilineage progenitors and, ultimately, 
into distinct mature blood lineages [26]. 
 
1.2 Megakaryopoiesis 
Megakaryopoiesis is the process that leads to the production of MKs, whose function is 
the production of platelets (section 1.3). MKs are amongst the rarest and largest 
nucleated cells in the bone marrow. They represent 0.01% of the total blood nucleated 
cells and have 50-100 μm diameter in the human and 20-30 μm diameter in the mouse 
[27-29]. 
 
Megakaryopoiesis is a complex process involving the commitment of MK lineage, MK 
progenitor (MK-p) proliferation and, finally, MK maturation (Figure 1.2 – A). As 
described above MK-p are generated through the commitment of HSCs to CMP and 
then to MEP [30]. However, recent studies demonstrated that MKs can also be 
generated by an alternative unipotent pathway, in which MK-biased HSCs directly 
differentiate into MK-p [31]. The physiological role of this alternative pathway is not 
fully understood but it is thought that it might play an important physiological role 
during platelet acute situations [31]. Subsequently, MK-p undergoes a maturation 
process including polyploidisation and cytoplasmic maturation and expansion, which 
results in the production of 1,000-5,000 platelets per MK (reviewed in [32]). During this 
process, MKs undergo endomitosis, initiating multiple cycles of DNA replication 
without completing cytokinesis [33], resulting in a geometric increase of ploidy that 
ranges up to 128n. The production of platelets can occur at any ploidy level; however, 
increased platelets production is correlated with higher ploidy levels. It has been 
demonstrated that steady-state platelet production in the bone marrow corresponds to 
16n ploidy [3, 34]. Polyploidisation results in gene amplification, which is thought to be 
essential to increase protein and lipid synthesis and to the cell enlargement required for 
platelets formation and function [35]. At the same time, cytoplasm maturation and 
expansion take place, with the acquisition of all the necessary components for platelet 
formation and function. During the final maturation stages, an increase in non-specific 
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structures and organelles has been observed, such as endoplasmic reticulum, Golgi 
bodies, mitochondria, vesicles, microtubules and actin filaments. As well as 
MK/platelet-specific organelles, such as alpha- (α-) granules and dense- (δ-) granules in 
the cytosol (reviewed in [32]). Additionally, an increase of heterochromatin has been 
observed (reviewed in [32]) and the dispersion throughout the cytoplasm of the 
demarcation membrane system (DMS) [36]. During MKs terminal differentiation at the 
bone marrow sinusoids, mature MKs form cytoplasmic projections, named proplatelets, 
that are extended into the bloodstream and subsequently fragmented into platelets (this 
process is called thrombopoiesis, and it is described in section 1.3, Figure 1.2 - A-B). 
Although megakaryopoiesis occurs mainly in the bone marrow, it has been suggested 
that MKs also circulate to other locations, such as lungs and spleen [37, 38].  
 
 
Figure 1.2 - Megakaryopoiesis and thrombopoiesis. Schematic representation of 
megakaryopoiesis and thrombopoiesis. A – Schematic representation of 
megakaryopoiesis. The differentiation of MEPs into mature MKs is followed by a 
decrease in surface expression of c-KIT and CD34, and an increase in surface 
expression of MK-specific markers (CD41, CD61 and CD42), which is accompanied by 
the rise of ploidy and synthesis of granular content. B – Schematic representation of 
thrombopoiesis. Fully mature MKs form and release proplatelets into the bone marrow 
sinusoids. Preplatelets, which are smaller fragments originated by proplatelet fragment 
fission, are further fragmented by shear stress to form mature platelets. MEP – 
megakaryocyte-erythrocyte-progenitor; MK – megakaryocyte; MK-p – MK progenitor.  
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1.2.1 Regulation of megakaryopoiesis 
Megakaryopoiesis is regulated by several transcription factors such as GATA1, 
RUNX1, TAL1, NFE2 and FLI1, and by the bone marrow niche, including, chemokines 
and cytokines, such as interleukin-3 (IL-3), IL-6, IL-11, leukaemia-inhibitor factor 
(LIF), stem-cell factor (SCF) erythropoietin (EPO) and thrombopoietin (TPO) [39-51]. 
TPO is the primary growth factor of the megakaryocytic lineage, and is required for 
proliferation and differentiation of MKs [39]. TPO also induces transcription factors 
(GATA1 and NFE2) to drive MK development and thrombopoiesis [52]. This factor is 
produced in the liver and binds to the myeloproliferative leukaemia protein (MPL; c-
Mpl), a receptor on MK and platelet membranes [53, 54]. Binding of TPO to c-Mpl 
activates it and induces its conformational change that initiates a signal transduction via 
activation of Janus Kinase 2 (JAK2). JAK2 phosphorylates the receptor’s tyrosine 
residues, activating downstream signal pathways and signal transducers and activators 
of transcription such as mitogen-activated protein kinases (MAPKs), phosphoinositol-3-
kinase (PI3K) and signal transducer and activator of transcription (STATs), important 
for cell survival and proliferation [46]. TPO regulates MKs development through a 
concentration-dependent compensatory response: increased levels of free TPO stimulate 
MKs maturation and proplatelet formation [55]. c-Mpl or TPO-deficient mice, however, 
still produce platelets, which suggests a compensatory mechanism from other regulators 
[54, 56, 57]. In fact, Nishimura et al. have demonstrated that platelet release from MKs 
could occur by an alternative mechanism, triggered by IL-1α, which leads to higher 
platelet number. It has been proposed that this mechanism occurs during acute platelet 
requirement, which explains how MKs can maintain platelet equilibrium and quickly 
restore platelet numbers under acute needs [58]. Furthermore, it has been shown that 
TPO is also essential for the regulation of HSC production and functions [59]. Notably, 
two studies demonstrated that MKs regulate HSCs quiescence through a C-X-C motif 
ligand 4 (CXCL4) or through the transforming growth factor-beta (TGF-β) [60], and 
HSCs proliferation through fibroblast growth factor 1 (FGF1)) [61].  
 
1.2.2 Megakaryocytes: cell-surface markers 
During megakaryopoiesis, several surface receptors and other surface proteins important 
for MK development and platelet formation/function are produced. Early in MK lineage 
commitment and progenitor maturation, a down-regulation of CD34 (cell-cell adhesion 
factor expressed on haematopoietic progenitor cells), c-KIT (SCF receptor), CD150 
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(glycoprotein expressed in HCSs), Tie-2 (angiopoietin receptor) and CD45 (receptor-
linked protein tyrosine phosphatase) markers is observed. Simultaneously, a progressive 
up-regulation of MK-specific cell surface markers is observed; such as c-Mpl (TPO 
receptor), glycoprotein IIb/IIIa (GPIIb/IIIa – also known αIIbβ3 integrin or 
CD41a/CD61 complex, a fibrinogen receptor crucial for MK migration and adhesion) 
and GPIb-V-IX complex (GPIbα, GPIbβ, GPIX and GPV also known as CD42a, b, c 
and d, which is a von Willebrand factor (VWF) receptor important for platelet function). 
The expression of CD42 is initiated at a later differentiation step and therefore is used a 
final maturation marker. CXCR4, the receptor of stromal derived factor-1 (SDF-1), is 
expressed during all stages of differentiation [32, 46, 62]. 
 
1.3 Thrombopoiesis 
Thrombopoiesis is the name of the process that gives rise to platelets, which play a 
fundamental role in maintaining haemostasis and thrombosis but also have roles in 
angiogenesis [63], inflammation [64], infection [65], tissue repair and regeneration [66], 
wound healing and in cancer biology [67-69]. Platelets are small, discoid, anucleate 
cells with 1.5-3.0 μm of diameter in human and 0.5 μm of diameter in the mouse. They 
are the second most abundant blood cell type with normal counts around 150-400 x 109 
platelets per litre of blood in humans and 1000-1500 x 109 platelets per litre of blood in 
mice [29, 70]. Platelets have a short lifespan, they circulate in the blood for 7 to 10 days 
in humans and 4 to 5 days in mice, after which they are removed in the spleen or liver 
[27, 29, 71, 72]. Platelet count in an adult human is maintained by the daily production 
of approximately 1011 platelets in steady-state though platelet production can increase 
more than 10-fold under states of stress such as traumatic blood loss [73].  
 
Platelet formation has been studied for many years and several theories on how this 
process works have been proposed, which includes i) platelet budding from the MK 
surface, ii) cytoplasmic fragmentation of MK via the DMS/”platelet fields” and iii) 
proplatelet formation [74]. The latter is currently the most widely accepted theory, 
which postulates that at the bone marrow sinusoids mature MKs undergo drastic 
cytoskeleton reorganisation to produce long, branching pseudopods cytoplasmic 
projections, called proplatelets. Each MK forms 10-20 proplatelets, which virtually 
carry all the intracellular content of MKs (cytoplasm and organelles, including pre-
packaged granules) [27]. After proplatelet formation, the bare multilobed nucleus of the 
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MK is eventually extruded and degraded [75]. Proplatelets are formed by multiple 
platelet-sized swellings (which contain the organelles and granules essential for their 
haemostatic function) connected by thin cytoplasmic bridges [76]. After proplatelets are 
released in the peripheral blood they are fragmented to produce mature platelets. The 
fission of these large proplatelet fragments results in smaller fragments, named 
preplatelets, which undergo further fission to form mature platelets. It is thought that 
this process is facilitated by blood flow–induced shear stress [77, 78] (Figure 1.2 - B). 
This is supported by several observations such as: i) in the lung capillary bed, the 
proplatelet counts are higher in pre pulmonary vessels than in post pulmonary vessels 
[79], while platelet counts are higher in the latter and ii) in vitro platelet formation is 
accelerated by shear stress [80, 81].  
 
The understanding and characterisation of platelet formation has greatly improved with 
the study of inherited disorders related to impaired platelet formation, as well as with 
the advance of methodologies to study platelet biogenesis, such as the development of 
in vitro megakaryocyte culture systems and, more recently, in vivo imaging of bone 
marrow using intravital two-photon microscopy [82-85]. Nevertheless, the signals that 
trigger proplatelet formation in MKs, as well as the final stages of proplatelet 
maturation and platelet release, remain poorly understood.  
 
Proplatelet formation and platelet release are mediated by the drastic reorganisation of 
the cytoskeletal proteins, including microtubules, actin and spectrin [75, 86]. Platelet 
size is also limited by microtubule bundling, elastic bending, and actin-myosin-spectrin 
cortex forces [70]. Studies of impaired proplatelet formation in congenital 
thrombocytopenia have identified several genes as regulators of this process, such as 
MYH9 [87, 88], ACTN1 [89], TUBB1 [90, 91], RUNX1[92] (for review [83, 84]). 
Recently, the polarization of MK and the proplatelet release have been shown to be 
regulated by the crosstalk of GPIbα receptor with the two small GTPases, cell division 
cycle 42 (Cdc42) and RhoA. The functional mutation of Cdc42 or GPIbα receptor 
results in impairment of proplatelet formation, while in contrast the ablation of RhoA 
results in increased Cdc42 activity and transmigration of MKs into the sinusoids lumen 
[93]. Moreover, it has been shown that a fine balance of GPIbα receptor and filamin A 
expression is important to regulate platelet size. Ablation of filamin A in MKs leads to a 
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premature release of large platelets, which is associated with a decrease of GPIbα 
receptor expression [94].  
 
It has been shown that platelet formation is also regulated by the microenvironment in 
the bone marrow: the osteoblastic and the vascular niches. The osteoblastic niche plays 
a role in MK differentiation and maturation, and suppresses proplatelet formation by the 
binding of collagen to the GPIa/IIa (also known as α2β1 integrin) [95, 96]. The 
migration of mature MKs from the osteoblastic niche to the vascular niche, has been 
suggested to be promoted by a gradient of the chemokine SDF-1 and by its receptor 
CXCR4 on MKs membrane [97, 98]. A gradient of transendothelial sphingosine 1-
phosphate (S1P) has been also suggested to guide the directional formation of 
proplatelets into the bone marrow sinusoids [99]. However, a recent study suggests that, 
contrary to what was previously thought, there is a vessel-biased MK pool within the 
bone marrow and that these MKs have a reduced capacity of migration. Therefore, it has 
been proposed that thrombopoiesis is mainly regulated by the bone marrow vasculature 
[100].  
 
In the vascular niche, the interaction of MKs with extracellular proteins such as 
fibrinogen [101], fibronectin [102] and VWF [103], seems to promote the later stage of 
MK maturation and proplatelet formation. Moreover, high S1P concentrations in the 
blood, as well as its receptor S1pr1, seem to be important for platelet release. S1pr1 
knockout mice have a drastic reduction of proplatelet formation and release. It has been 
further shown that activation of S1pr1 directly stimulated the release of new platelets 
through activation of the Gi/Rac GTPase signalling cascade [99]. 
 
Several observations (such as the ones described above - observation of circulating 
MKs and platelets release in the lung) suggest that apart from the bone marrow 
sinusoids, the lung capillary bed is also a primary site of platelet release. Recently, mice 
MKs were shown to release proplatelets in the lung, and it was suggested that as much 
as 50% of platelet formation in mice could occur in the lungs [104-108]. 
 
1.3.1 Platelet structure 
As described above, platelets acquire most of their RNA, proteins and numerous 
organelles including α-granules, δ-granules, peroxisomes, lysosomes, and mitochondria 
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from the MKs, but while platelets mature, they also endocytose some proteins from the 
environment, such as fibrinogen and vascular endothelial growth factor (VEGF) [109-
111]. Furthermore, during platelet formation, platelets develop defining features such 
as: i) a delimited plasma membrane; ii) a dynamic and bipolar marginal coiled 
microtubule band, which is responsible for its discoid shape at resting state; iii) an open 
canalicular system (OCS), which is formed by invaginations of the surface membrane 
(the OCS is a reservoir of membrane for platelet spreading and enables the uptake and 
release of granule contents) [112]; iv) a dense tubular system (DTS), which is an 
endoplasmic reticulum membrane system that is important for the regulation of platelet 
activation; v) a spectrin-based membrane skeleton and an actin-based cytoskeletal 
network, both also important for platelet shape change and spreading during platelet 
activation [113]. 
 
The resting platelet can be divided into three zones: i) the peripheral zone, which 
regulates platelet adhesion and aggregation. This zone includes the plasma membrane 
that expresses receptors important for platelet activation and signalling; a glycoprotein 
coat that is concentrated in the inner part of the membrane at rest and cytoskeleton; ii) 
the sol-gel zone, which facilitates contraction and supports the microtubule network. 
This zone comprises the OCS and the DTS; and iii) the organelle zone, which contains 
all the platelet organelles and molecules present in the cytoplasm, such as calcium, 
platelet factor 4 (PF4), glycogen granules, α-granules and lysosomal granules [113, 
114]. 
 
Platelet secretory granules  
Platelets contain four types of secretory granules: α-granules, δ-granules, lysosomes and 
T-granules, which play critical roles in platelet function.  
i) α- granules 
α- granules are the most abundant, with 50 to 80 α-granules per platelet, and also the 
largest, with a diameter ranging from 200 to 500 nm. α-granules contain hundreds of 
proteins including adhesive and healing proteins that mediate different processes, such 
as: i) haemostasis and coagulation (e.g. VWF, fibrinogen, fibronectin, thrombospondin-
1 (THBS1) and prothrombin (inactive precursor of thrombin) factor V, XI and XIII); ii) 
inflammation (e.g. PF4, β‐thromboglobulin (CXCL7) and IL-8 [115, 116]) and iii) 
angiogenesis (e.g. VEFG (pro-angiogenic regulators) and endostatin (anti-angiogenic 
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regulator)). In their membrane they express several proteins that are also expressed on 
the platelet membrane such as GPIb-V-IX, GPVI, GPIIb/IIIa and P-selectin [117, 118]. 
The formation of α-granules is initiated in MKs, but its maturation continues in platelets 
[119]. During platelet activation α-granules are secreted via a complex process, which 
involves SNARE (soluble NSF [N-ethylmaleimide-sensitive factor] attachment protein 
receptors), SNARE-associated proteins, and membrane lipids. In this process their 
membranes fuse with the platelet membrane, enabling the release of their constituents to 
the extracellular environment and the expression of other constituents such as P-selectin 
on the platelet membrane [117, 120]. It has been shown that platelets contain distinct 
subpopulations of α-granules that undergo differential secretion during platelet 
activation [121]. Nevertheless, both the α-granule biogenesis and its selective secretion 
is not yet fully understood. 
ii) δ-granules 
δ-granules are the second most abundant secretory granule, with three to eight δ-
granules per platelet, and have a diameter of approximately 150 nm. Their name results 
from the characteristic dense/dark appearance on electron microscopy. δ-granules 
contain mainly small molecules such as ADP, ATP, serotonin and calcium that are 
released upon platelet activation and are important for homeostasis [117, 120]. 
Moreover, δ-granules also contain lysosomal membrane proteins such as CD63 
(LAMP-3) and LAMP-1/2, and membrane proteins that are mainly expressed in α-
granules, such as P-selectin and GPIb [122]. Upon platelet activation, these membrane 
proteins are translocated to the platelet membrane. The secretion mechanism of δ-
granules is comparable to those in α-granules, but differences have been reported [123]. 
The biogenesis of δ-granules is initiated in MKs but only completed in platelets, 
although the underlying mechanism is also not fully understood [117, 120]. 
iii) Lysosomes 
Lysosomes are less abundant, with a maximum of three per platelet, and with a diameter 
ranging from 200 to 250 nm. They are not platelet-specific and contain hydrolytic 
enzymes, such as proteases and glycosidases, which digest cellular components. Like δ-
granules they are characterised by CD63 and LAMP-1/2 on their membrane. Lysosome 
function in platelets is not fully characterised. It is thought that they are released in a 
similar fashion to the other granules but during greater platelet activation. It has been 
suggested that they play a role in the regulation of thrombus formation and in 
remodelling the extracellular matrix [117, 120]. 
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iv) T-granules 
T-granules were recently described. They have a tubular morphology and contain toll-
like receptor-9 (TLR9), vesicle-associated membrane protein-7/8 (VAMP-7/8) and 
protein disulphide isomerase (PDI) [124]. PDI has been shown to be released from 
activated platelets and plays a role in thrombus formation [125].  
 
1.3.2 Platelet function  
The primary function of platelets is maintaining homeostasis and thrombus formation at 
vascular injury sites. Circulating platelets are in a resting state, which is continuously 
mediated by the vascular endothelium through several mechanisms, which include: i) a 
physical barrier of endothelial cells in the blood vessels; ii) the endothelial surface 
expression of ectonucleotidases (which degrade ATP and ADP) [126] and 
thrombomodulin (which inactivates thrombin) [127]; and iii) the release of inhibitory 
factors from endothelial cell such as nitric oxide (NO, which increases intracellular 
levels of cyclic GMP (cGMP) and consequently activates PKG) and prostaglandin I2 
(PGI2, which binds to platelet IP receptor and leads to an increase of intracellular cyclic 
adenosine monophosphate (cAMP) levels and consequently activates PKA). The release 
of both NO and PGI2 increases the threshold for platelet activation by the mediated 
mechanisms described above [128-130]. The exposure of the subendothelial 
extracellular matrix at the site of vascular injury leads to platelet activation and 
thrombus formation, through a series of sequential steps. These steps can be divided 
into: platelet adhesion, platelet activation and aggregation, and thrombus stabilization 
[114, 131, 132].  
 
Platelet adhesion 
Platelet adhesion is initially mediated via the binding of GPIb platelet receptor (which is 
part of GPIb-V-IX complex) to activated VWF immobilized on exposed collagen at 
high shear rates. This initial and loose adhesion is important to slow down platelet 
velocity, which subsequently enables stable platelet adhesion [133]. At low shear rates a 
stable adhesion is mediated via the direct and synergistic binding of GPVI and activated 
GPIa/IIa platelet receptors to collagen [131, 134, 135]. This stable adhesion leads to 
platelet activation.  
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Platelet activation 
Collagen binding to GPIV and GPIa/IIa platelet receptors stimulates the activation of 
multiple intracellular signalling pathways, which are regulated by important signalling 
molecules such as phospholipase C (PLC), protein kinase C (PKC), PI3K. The 
activation of this intricate network of positive and negative regulatory signals, which 
involves signalling adapters and regulators, known as platelet signalosome, leads to an 
increase of the intracellular level of calcium, and underpins drastic platelet shape 
change, spreading and secretion [136]. 
 
The change of platelet shape from discoid to spiny spheres, as well as their spreading, 
results from the reorganisation of the microtubule band and by an increase of 
microtubule polymerisation, which produces filopodia as the platelet spreads [137]. 
This reorganisation of the cytoskeleton is calcium-dependent and mediated by the 
activation of myosin light chain kinase via small GTPase-Rho [136]. It has been also 
shown that platelet spreading is mediated by distinct isoforms of PKC proteins which 
have differential effects on platelet spreading [138].  
 
Upon activation, platelets undergo degranulation and secretion/release of their granule’s 
constituents and other secondary mediators, such as thromboxane A2 (TxA2). This 
enables the recruitment and stimulation of new platelets and leads to subsequent 
activation of the coagulation pathway at the platelet surface, which is critical for clot 
growth and stabilization [139]. 
 
As described above, platelet granules have a high concentration of factors that are 
important to mediate/amplify platelet activation, such as ADP and prothrombin. Also, 
TxA2 is a strong platelet activator, which is synthesised upon platelet activation through 
the conversion of arachidonic acid by several enzymes including cyclooxygenase‐1 
(which is the target of aspirin). These secondary mediators act by binding to G-protein-
coupled receptors, which activates PLCβ and in turn amplifies platelet activation [136]. 
ADP binds to the transmembrane domain of P2Y1 and P2Y12 purinergic platelet 
receptors, while TxA2 binds to thromboxane receptor (TP) α and TPβ [140].  
 
Platelet activation also stimulates the exposure of phosphatidylserine on the platelet 
plasma membrane. This enables the assembly of the prothrombinase complex (part of 
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the coagulation pathway) on the platelet surface, which catalyses the transformation of 
prothrombin into thrombin [141]. Thrombin is a potent platelet activator that can 
stimulate and amplify thrombus formation via its binding to protease-activated receptor 
(PAR) 1 and PAR4 platelet receptors in humans and PAR3 and PAR4 in mouse [142, 
143]. Furthermore, thrombin production can also be mediated via tissue factor. Tissue 
factor is a membrane protein constitutively expressed on several cells of the vessel wall. 
At the injury site tissue factor gets exposed and forms a complex with the activated 
coagulation factor VII present in the bloodstream. The formation of this complex 
activates factor IX, which initiates a coagulation cascade involving several blood 




During platelet activation, the GPIIb/IIIa platelet receptor undergoes conformational 
changes that mediate its activation, which in turn supports platelet aggregation. The 
activated GPIIb/IIIa receptor binds to adhesive proteins such as fibrinogen and VWF, 
which form bridges between two GPIIb/IIIa receptors on adjacent platelets. The 
formation of these bridges allows platelets to aggregate and form a haemostatic plug 
[145, 146]. 
 
Thrombus growth and stabilisation 
Platelet aggregates and their secreted/produced secondary mediators, together with the 
vascular endothelium, other blood cells and coagulation factors, promote the growth and 
the stabilisation of the thrombus through signalling events and formation of a fibrin 
mesh [131]. 
 
The stabilisation of the growing thrombus is mainly mediated by the formation of a 
fibrin mesh around platelets. This fibrin mesh is formed by the accumulation of fibrin 
which is produced through the cleavage of circulating and platelet-secreted fibrinogen 
by thrombin [144]. Platelet-neutrophil interactions mediate another important 
mechanism for thrombus growth and stabilisation. Upon platelet activation, P-selectin 
gets exposed on platelets membrane and mediates platelet-neutrophil interaction via its 
binding to P-selectin glycoprotein ligand-1 (PSGL-1) on neutrophils [147]. In turn, this 
interaction facilitates neutrophil activation through the binding of the transmembrane 
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receptor RAGE on neutrophils to the high motility group box-1 protein (HMGB-1) 
exposed on platelet membrane [148]. Neutrophil activation is followed by a complex 
mechanism, named NETosis, which culminate with the formation of neutrophil 
extracellular traps (NETs). NETs are networks of extracellular chromatin fibres 
surround by histones and bound to granular and cytoplasmic proteins. It has been 
suggested that these NETs mediate platelet activation, directly through their histones 
and by the direct stimulation of the coagulation cascade [149-152] (see [153] for 
review). Hence, platelet-neutrophil interaction enhances thrombus growth and 
stabilisation. Furthermore, thrombus growth and stabilisation are controlled by a 
negative feedback loop, which involves compensatory molecules and signalling events 




Erythropoiesis is the process that leads to the production of RBCs, whose primary 
function is tissue oxygenation. RBCs are anucleate, circular, biconcave and small, with 
a diameter of 6-8 μm [154]. The lack of nucleus allows an increased storage of 
haemoglobin (Hb) and, consequently, more oxygen transported. The biconcave shape 
increases the surface area for the diffusion of oxygen, and their small size and flexibility 
(deformability capability) enables the RBCs to pass through small blood vessels. RBC 
shape and deformability are dependent on the two-dimensional network of spectrin 
(cytoskeleton) to which their phospholipid bilayer membrane is bound [155]. RBCs are 
the most abundant cells in the blood (~5 million RBCs per microliter of blood) and 
remain in the bloodstream in average 120 days until they are removed by macrophages 
in the spleen and liver [156]. The number of RBCs remains relatively constant through 
the balance between their continuous loss and production and it has been estimated that 
approximately 2.4 million RBCs are produced per second [154]. 
 
As mentioned above in section 1.1, during development there are primitive and 
definitive erythropoiesis. Although it is still debatable whether both processes have 
completely separate origins, it is well established that both give rise to erythropoietic 
cells which can be distinguished by their morphology, surface markers, cytokine 
responsiveness, growth kinetics, gene expression and Hb [157]. Three different types of 
Hb have been described: embryonic (Hb-Grower I, Hb-Grower II and Hb-Portland; 
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from the primitive wave), foetal (HbF; from the definitive wave) and adult (HbA and 
HbA2; from the definitive wave) [158, 159]. Here, I will briefly describe definitive 
erythropoiesis. 
 
Erythropoiesis occurs mainly in red bone marrow. Under erythroid stress conditions, 
however, extramedullary erythropoiesis can happen in the spleen [160]. RBCs, like 
MKs, are generated through a similar series of commitment steps, HSC, CMP, and 
MEP. Then, erythroid progenitors undergo proliferation and differentiation through a 
series of stages until they become mature RBCs [154]. The different stages of erythroid 
lineage differentiation are shown in Figure 1.3. The presence of two progenitor types 
characterises early stages of erythropoiesis: initially, the burst-forming unit (BDU-e) 
and, later, the colony-forming unit (CFU-e). During later stages, from the differentiation 
of pro-erythroblast to reticulocyte, there is an increase of membrane and cytoskeletal 
proteins production (including Band3, Duffy, GPA and ankyrin-1) and the cells 
experience a reduction in size, an increase of cytoplasm, and a reduction of the nucleus, 
which is then expelled, forming reticulocytes. Reticulocytes contain residual RNA and 
mitochondria, their maturation is initiated in the bone marrow but as they mature, they 
lose adhesion receptors and become more deformable, which enables their release from 
the bone marrow and subsequently final maturation into RBCs in the bloodstream [154, 









Figure 1.3 - Erythropoiesis. Expression of most commonly used cell surface markers 
to identify the various stages is indicated by the bars. Cells at the CFU-E and pro-
erythroblast stage are the most sensitive to, and dependent on, the presence of EPO. 
Gray - low expression; black - high expression; HSC - hematopoietic stem cell; CMP - 
common myeloid progenitor; MEP - megakaryocyte-erythroid progenitor; BFU-e - 




Figure of erythropoiesis removed for copyright reasons. Copyright holder is Cold 
Spring Harbor Perspectives in Medicine. 
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1.4.1 Regulation of erythropoiesis 
Erythropoiesis is dependent on transcription factors (e.g. GATA2, GATA1, FOG1, 
GPI1b and EKLF) [162-164], growth factors, hormones and cytokines, which are 
mainly induced by the microenvironment of stromal and immunoregulatory cells 
(fibroblasts, fat cells, endothelial cells, smooth muscle cells, monocytes, macrophages 
and lymphocytes) [157]. The early progenitors are responsive to cytokines, such as 
TPO, IL-3, IL-11 and SCF [154]. In later stage erythroid progenitors, SCF acts 
synergistically with EPO [165]. EPO is secreted by renal Epo-producing cells (REP 
cells) [166] and has been described as the most critical cytokine for erythropoiesis [167-
169], regulating proliferation [170], differentiation [171] and inhibition of apoptosis 
[172] during this process. In response to low levels of oxygen, kidneys release EPO, 
which triggers erythropoiesis by binding to EPO receptor (EPOR) and by signalling to 
committed erythroid progenitors [173]. Binding of EPO to its receptor induces 
conformational changes of the receptor and subsequently activation of JAK2 and 
downstream activation of signal pathways and signal transducers and activators of 
transcription [157, 174, 175]. EPO expression is regulated by hypoxia-inducible factors 
(HIFs), which are the key transcription factors for oxygen-dependent gene regulation 
[176].  
 
1.4.2 Erythroid cell: cell-surface markers 
Erythroid progenitors and precursors express distinct cell-surface proteins, which reflect 
their different signalling programmes. The common cell-surface markers used to 
distinguish the different erythroid precursors are: CD34 (adhesion factor expressed early 
in haematopoiesis) and c-KIT (SCF receptor), which are present until the formation of 
BFU-Es; EPOR (EPO receptor), which is expressed in low levels in BFU-Es and in high 
levels in CFU-Es and pro-erythroblast; TfR (transferrin receptor, CD71; responsible for 
iron uptake), which is highly expressed in cells that are actively synthesizing Hb and 
then its expression levels decrease during terminal differentiation, being absent in 
mature RBCs; adhesion molecules, intercellular adhesion molecule 1 (ICAM-1, a 
member of the immunoglobulin superfamily) and α4β1 integrin (CD49d/CD29) that 
interacts with fibronectin, are highly expressed in the early precursors and, then, lost as 
maturation occurs; toward the later stages of erythroid differentiation several important 
surface proteins are expressed such as GPA (CD235a, which is used as a surface 
marker), rhesus (Rh) protein and Rh-associated glycoprotein (RhAG) [157, 161, 177]. 
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Most of the proteins on the RBC membrane are glycosylated and belong to a blood 
group system.  
 
1.5 Blood group systems  
Until the beginning of the last century, it was thought that blood was identical among 
individuals. However, with haemolytic disease of newborns as well as frequent severe 
haemolytic reactions and fatal transfusions, it was possible to determine the presence of 
different antigens on RBCs and later establish different blood groups [178]. A blood 
group system is described by the International Society of Blood Transfusion, as one or 
more antigens encoded at a single gene locus, or by two or more very closely linked 
homologous genes with small or no observable recombination between them [179]. 
Although the ABO and Rhesus-D are the most critical and characterised blood systems, 
so far more than 300 antigens in RBCs have been described, and most of these are 
clustered in 36 blood group systems by the International Society of Blood transfusion 
[180] (http://goo.gl/56j3Np). One of these antigens is the Vel-antigen, which was 
recently defined as the Vel-blood group system.  
 
1.5.1 Vel-blood group system 
The Vel-antigen was first recognised in 1952 when Sussman and Miller reported a Vel-
negative blood type phenotype in a patient, named Mrs Vel [181, 182]. Mrs Vel 
suffered a severe haemolytic reaction after a transfusion with Vel-positive blood. It was 
subsequently shown that Mrs Vel had an antibody in her serum that agglutinated the 
blood cells of all but four of 10,000 individuals [181, 182].  
 
It has been shown that Vel-negative blood type is inherited as an autosomal recessive 
trait [183, 184]. Overall, the frequency of Vel-negative blood type, as estimated in 
several studies and different populations, is approximately 0.04%, even though regional 
differences exist [184-187]. Estimated frequency in Europe is 0.025%, while in northern 
Scandinavia is 0.06% [184-187]. This low frequency makes Vel-negative a rare blood 
group system and therefore of high clinical relevance. Maintaining Vel-negative blood 
stocks is challenging due to the reduced number of Vel-negative donors, but it is 
absolutely required for safe transfusion of individual carrying this rare blood group. The 
locus encoding the Vel antigen and the genetic variation responsible for the Vel-
negative phenotype has remained unknown for more than six decades. Recently, using 
Chapter 1 
   19 
different approaches, three research groups were able to identify the gene that underlies 
the Vel antigen, Small integral membrane protein 1 (SMIM1), and to determine the 
polymorphism responsible for the Vel-negative phenotype [182, 186, 188].  
1.5.1.1 SMIM1 underlies the Vel blood group  
SMIM1 is a small gene composed of four exons and is located in chromosome 1p36.32 
in humans. This gene encodes three protein-coding transcripts. Two small transcripts of 
5 and 37 amino acids and a longer transcript of 78 amino acids encodes a small integral 
membrane protein 1 (SMIM1, Figure 1.4).  
 
According to the most recent data available at the Human Gene Organization (HUGO - 
https://www.genenames.org/) and Gene CardsÒ – Human Gene Database 
(https://www.genecards.org/), SMIM1 belongs to a collection of 44 unrelated SMIMs 
that have a single predicted transmembrane domain and low theoretical molecular 
weight (ranging from 5.8 kDa up to 20 kDa). Most of these proteins are of unknown 
function (Table 8.1 – Chapter 8). Moreover, SMIM5 and SMIM7, are highly expressed 
at the mRNA level in platelets (Figure 8.1 – Chapter 8). 
 
SMIM1 coding exons are highly conserved among several vertebrate species as shown 
in the alignment in Figure 1.4 [186, 188]. In mice, Smim1 gene is located in 
chromosome 4 and has 13 protein-coding transcripts (https://goo.gl/8kvnAs). The 
mouse Smim1 longer transcript encodes a protein with 78 amino acids, which has 81% 
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Figure 1.4 – SMIM1 gene underlies the Vel blood group. A - Schematic 
representation of SMIM1 location, highlighted in red, in chromosome 1. SMIM1 
comprises four exons that are represented by orange boxes and the 17-bp frameshift 
deletion in exon three, marked in blue, has been identified as the cause of the Vel-
negative phenotype. In purple are represented two common variants responsible for the 
Vel-weak phenotype; B - SMIM1 gene encodes a 78 amino acid protein. C - Alignment 
of human SMIM1 and vertebrate’s orthologues, shows a high level of amino acid 
conservation between species. Conserved amino acids are coloured according to their 
properties (green, hydrophobic nonpolar; yellow, polar uncharged; orange, acidic; blue, 
basic), and non-conserved amino acids are uncoloured. Bars indicate the degree of 
conservation (Figure adapted from [188]). 
 
A homozygous 17-bp frameshift deletion in the third exon of SMIM1 gene (c.64_80del 
encoding p.S22Qfs, represented in blue in Figure 1.4), responsible for the abolishment 
of SMIM1 protein expression, was identified as the cause for the Vel-negative 
phenotype [182, 186, 188]. Moreover, it was also shown that Vel-antigen expression 
could vary between strong, weak and negative [186]. The variation of Vel expression 
has been attributed to different genetic variants. In particular, the weak expression of 
Vel was characterised by a heterozygous 17-bp frameshift deletion (c.64_80del 
encoding p.S22Qfs) or by a heterozygous missense mutation at the amino acid Met51 
(two different missense mutations at Met51 were described, c.152T>A encoding 
p.Met51Lys and c.152T>G encoding p.Met51Arg ) (Figure 1.4) [186]. The 
heterozygous missense mutation c.152T>G has a dominant negative effect on Vel 
expression [182]. This missense mutation is close to the predicted transmembrane 
domain of SMIM1 and may potentially lead to the formation of a non-functional protein 
without the ability to incorporate the membrane, or to the alteration of the protein’s 
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epitope, decreasing significantly the binding of anti-Vel [186]. Furthermore, it has been 
shown in an expression quantitative trait locus (eQTL) that rs1175550 (minor allele 
frequency, MAF= 0.23), a common variant in intron 2 of SMIM1, also contributes to the 
variable expression of Vel antigen [186]. Here, the major allele A was associated with 
decreased SMIM1 expression levels when compared with the minor allele G [186]. This 
common variant is in an erythroid-specific regulatory element, to which several 
transcription factors such as GATA-1, GATA-2 and TAL1 bind [186, 188-190]. 
Although this common variant does not disrupt any transcription factor binding motif, it 
seems to affect SMIM1 expression by altering DNA-shape characteristics, that 
consequently interfere with transcription factor binding affinity. GATA-1 and TAL-1 
binding seems to be favour by minor allele G [189, 190]. 
 
The Vel blood group is clinically relevant because of: i) severe haemolytic reactions 
that occur in Vel-negative individuals transfused with Vel-positive RBCs, and ii) 
haemolytic disease of newborns of Vel-negative mothers [183, 188, 191-194]. As the 
biological function of SMIM1 remains unknown, additional phenotypes may yet be 
uncovered. Currently, the two challenges that health care providers face when dealing 
with Vel-negative individuals are the ability to maintain blood stocks for safe 
transfusions and to perform the correct serologic typing. The latter is particularly 
challenging due to the high variability of Vel expression across individuals. 
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1.6 Thesis aims and overview 
Even though SMIM1 has been identified as the gene underlying the Vel-blood group, its 
biological functions remain largely unknown. The overall objective of my thesis work 
was to improve the current knowledge of the role of SMIM1. This knowledge may be 
essential to reveal unknown clinical phenotypes related to SMIM1 absence and to 
inform their prevention and treatment. The approaches I have taken in this thesis were: 
i) to characterise the role of SMIM1 in haematopoietic lineages and ii) to investigate the 
role of SMIM1 in other organs. 
 
This thesis is divided into three results chapters: 
 
In Chapter 3, I characterised SMIM1 gene expression throughout the haematopoietic 
lineage and SMIM1 protein localisation in some blood cell types.  
 
In Chapter 4, using two cohorts of human SMIM1 naturally occurring knockouts and 
an Smim1 mutant mouse model, I investigated the effect of SMIM1 absence in different 
blood traits and other organs.  
 
In Chapter 5, I further assessed the role of SMIM1 in megakaryopoiesis and platelet 
function in vitro.  
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This chapter is divided into three main sections in accordance with the three models 
used in this study: human, mice and cell lines. However, some methods were used 
across the different models. 
 
2.1  Human samples 
2.1.1  Vel-negative and control donors recruitment and sample 
collection  
Recruitment and sample collection of Vel-negative donors were carried out under the 
project “A BluePrint of Blood Cells”, ethically approved by Cambridge University 
Hospitals NHS Trust research ethics committee (REC number 12/EE/0040). Vel-
negative blood donors living in the United Kingdom (UK) that participated in a 
previous Vel study (n=39) [186], were contacted to take part in this study. Out of these, 
27 accepted and signed the consent form. The donor recruitment was coordinated by Dr 
Karola Rehnstrom, Study Coordinator for the Ouwehand group. Blood samples were 
collected by a research nurse and the blood tubes were processed accordingly based on 
the test to be performed. A 2 mL ethylenediaminetetraacetic acid (EDTA) blood tube 
was collected to re-test the Vel status by serologic test (test performed by NHS Blood 
and Transplant (NHSBT)) and for genomic DNA extraction to confirm the null allele by 
Sanger sequencing. Other samples were collected, processed and analysed as described 
below. 
 
The control blood donors used in this study were members of the NIHR Cambridge 
BioResource (http://www.cambridgebioresource.org.uk/) with informed consent (REC 
12/EE/0040) at NHSBT, Cambridge. Details of the control donor cohort used for full 
blood count comparison with the Vel-negative donors are described in [195]. Vel-
negative and weak individuals in the original control donor cohort were removed for 
this study. Full blood count was performed as described below for Vel-negative donors.  
2.1.1.1  Human full blood counts and blood smears 
Full blood counts were performed in blood collected in EDTA tubes using Sysmex XE-
5000 hematology analyzer. Blood smears of blood collected in EDTA were performed 
by spreading 2.5 μl of whole blood across a microscope slide. The slides were then 
stained with Romanowsky staining at Haematopathology and Oncology Diagnostic 
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Service, Haematology Department, Cambridge University Hospitals NHS Foundation 
Trust. 
 
2.1.2  UK Biobank cohort 
UK Biobank is a prospective cohort study of approximately 500,000 participants aged 
between 40 and 69 years, which were recruited across the UK between 2006 and 2010. 
Each participant answered an extensive questionnaire focused on questions of health 
and lifestyle and have undergone physical measurements and provided blood, urine and 
saliva samples for analysis. This cohort, however, is not representative of the general 
population. UK Biobank participants lived within 25 miles of one the assessment 
centres and were more likely to be female, older, and to live in less socioeconomically 
deprived areas than the non-participants. Moreover, the participants in this cohort 
represent a healthier population when comparing with the general population 
(https://www.ukbiobank.ac.uk). 
 
In this thesis, an association analysis of 26 blood traits with Vel-negative European 
ancestry individuals (part of the release 400,000 participants of UK Biobank) was 
performed by Dr William Astle, Lecturer in Haematological Genomics at University of 
Cambridge. The phenotypes were prepared according to the quality control (QC) 
outlined described in section “Phenotype Measurement, QC, and Processing” in the 
supplementary text in Astle et al. [196]. The genotype QC was performed in the 
Cardiovascular Epidemiology Unit at the University of Cambridge according to the 
technical report in Chapter 8 – Figure 8.2. The QC included removal of sex mismatches, 
removal of participants with a low genotyping call rate and with outlying levels of 
heterozygosity. The subset of European ancestry individuals was then used for 
statistical analysis fitting the following linear regressions: 
a) ! = # + %& + '( + ) 
where T is the trait value, s indicates the sex of the individual (0=female, 1=male), x is a 
0,1,2 variable counting the number of copies of the deletion the individual has and e  
represents normally distributed noise. (  can be interpreted as the averaged additive 
effect of the of the deletion allele (i.e. the average effect across all individuals in the UK 
Biobank sample) estimated by EFFECT_average. P_average corresponds to a two tailed 
t-test a (is non-zero. 
b) ! = #* + %&* + '(* + %'+ + )′  
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where, again, T is the trait value, s indicates the sex of the individual (0=female, 
1=male), x is a 0,1,2 variable counting the number of copies of the deletion the 
individual carries and e’ represents normally distributed noise. ( can be interpreted as 
the additive effect of the deletion allele in females (estimated by EFFECT - female) and 
( + + can be the additive effect of the deletion allele in males (estimated by EFFECT - 
male). P_sex_interaction corresponds to a t-test that theta is non-zero. 
 
2.1.3 Characterisation of SMIM1 transcription profile in multiple 
blood lineages 
Transcription profile of SMIM1 in multiple blood cells was assessed using the available 
blueprint datasets, generated as part of the Blueprint project 
(https://blueprint.haem.cam.ac.uk/mRNA/) [197]. Briefly RNA-sequencing was 
performed in highly pure samples of progenitor and precursor blood cells (including 
HSC, CLP, CMP, GMP, MEP, MK, EB, platelet, neutrophil,  monocyte, macrophage 
M0, macrophage M1, T helper cell, central memory T cell, effector memory T cell, 
cytotoxic (killer) T cell, terminally differentiated effector memory T cell, regulatory T 
cell, natural killer cell, mesenchymal stem cell, blood outgrowth endothelial cell and 
human umbilical vein endothelial cell). EBs and MKs were generated by differentiation 
of CD34+ HSCs, as previously described [186]. HSCs and other progenitor and 
precursor cells were purified from the mononuclear cell fraction of human cord or 
venous blood by fluorescent-activated cell sorting (FACS) using cell-type specific 
antibodies, as previously described [186]. Purified samples (with 20,000 to 100,000 
cells) were collected into TRIzol® (Invitrogen) and total RNA was extracted using the 
RNeasy mini kit (Qiagen). RNA-sequencing libraries were obtained using SMARTer 
Ultra Low Input RNA for Illumina sequencing and Advantage 2 PCR kit (Clontech) 
using 100 pg of total RNA as input. Paired-end sequencing was performed on a HiSeq 
2000 system with TruSeq reagents (Illumina), according to the manufacturer’s protocol. 
Sequencing results were analysed as previously described and the gene expression was 
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2.1.4 Characterisation of SMIM1 localisation 
2.1.4.1  Human platelet-rich plasma and washed platelets 
Blood anticoagulated in sodium citrate was centrifuged at 150 g for 15 minutes 
(acceleration and brake 0) to obtain platelet-rich plasma (PRP). Two volumes acid 
citrate dextrose (ACD, Sigma-Aldrich) and 1 μM prostaglandin E1 (PGE1, Sigma-
Aldrich) were added to 1/3 of PRP and gently inverted to mix. PRP was centrifuged at 
1000 g for 15 minutes. Platelet pellet was washed with platelet washing buffer (36 mM 
citric acid (Sigma-Aldrich), 103 nM sodium chloride (Sigma-Aldrich), 5 mM potassium 
chloride (Fisher Scientific), 5 mM EDTA (Sigma-Aldrich) and 5.6 mM D-glucose 
(VWR)) supplemented with 0.1 μM PGE1 to prevent platelet activation. After 
centrifugation at 1000 g for 10 minutes the platelet pellet was washed again and then 
resuspended as required.  
2.1.4.2  Human platelet fractionation 
Platelet fractionation was performed by Louisa Mayer, a colleague in the laboratory. In 
brief, washed platelets were lysed in lysis buffer supplemented with protease inhibitor 
through consecutives freeze-thaw cycles. Lysate was then placed on a sucrose gradient 
of 30% to 60%, at 5% increments and centrifuged for 90 minutes at 200.000 g at 4 °C. 
The different gradient fractions were carefully collected in individual tubes and protein 
was precipitated from the sucrose gradient by incubation with 1:10 of 100% 
trichloroacetic acid on ice for 2 hours, following washing with cold acetone. Protein 
pellets were resuspended with 1X NuPAGE® LDS sample buffer and 1X NuPAGE® 
reducing agent (Invitrogen) and then processed as described in section 2.2.8.   
2.1.4.3  Human RBCs isolation and lysis for western blot 
For RBCs isolation, blood anticoagulated in EDTA was centrifuged as mentioned above 
and PRP and peripheral blood mononuclear cells (PBMCs) removed. RBCs were then 
diluted with 1 volume of D-PBS and centrifuged at 2000 g for 10 minutes. RBCs were 
washed three times with D-PBS by centrifugation at 2000 g for 10 minutes and stored at 
-20 °C. RBCs were then lysed by successive washes with cold RBC buffer (5 mM 
sodium phosphate dibasic (Sigma-Aldrich), 1 mM EDTA (Sigma-Aldrich), pH 8) 
supplemented with complete EDTA-free protease inhibitor (Roche) followed by ultra-
centrifugations at 4 °C until the supernatant was completely clear. RBCs pellet was 
resuspended in RBC buffer and processed as describe in western blot section 2.2.8. 
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2.1.4.4  Whole blood flow cytometry 
1% whole blood diluted in HEPES buffered saline (HBS, Table 2.9), PRP or PBMCs 
was incubated with anti-SMIM1 at room temperature (RT) for 45 minutes. Cells were 
washed once with D-PBS-1% bovine serum albumin (BSA) at 600 g for 6 minutes and 
then incubated with secondary antibody and when adequate with conjugated-cell-type 
specific antibodies, in the dark for 25 minutes (Table 2.1). Cells were washed with D-
PBS-1% BSA and centrifuged at 600 g for 6 minutes. After the third wash, cells were 
fixed with 0.2% formyl saline (Table 2.9) and analysed. Flow cytometry was performed 
on FC-500 cytometer and analysed using Kaluza Analysis Software v.1.5a (Beckman 
Coulter). 
 
Table 2.1 - Antibodies used for flow cytometry of whole blood.  
Antibody Manufacturer Dilution 
Human anti-human SMIM1 [SpG213Dc human 
monoclonal antibody – recognises the C-terminal of 
SMIM1] 
Gift from Yannic Danger, 
LNPRM, FR 10 µg/ml  
Goat anti-human IgG H&L - FITC Ab98524 1:50 
 
2.1.4.5  Differentiation of human CD34+ cells into MKs 
CD34 progenitor cells were isolated from apheresis cones in two steps: first 
mononuclear cells were isolated by a density gradient centrifugation and then CD34 
progenitor cells were enriched by positive selection using the CD34 MicroBead Kit 
human (Miltenyl Biotec). In brief, blood was diluted up to 100 ml with buffer 1 (D-PBS 
(Sigma-Aldrich), 13 mM trisodium citrate (Sigma-Aldrich), and 0.2% HAS (Seralab)). 
25 ml of diluted blood was carefully layered on top of 12.5 ml of Ficoll-PaqueTM (GE 
Healthcare, 17-5442-03). Sample was centrifuged at 800 g for 15 minutes (acceleration 
8 and brake 0). PBMC layer was carefully collected into a 50 ml tube and washed with 
buffer 1. After centrifugation at 600 g for 6 minutes (at 4 °C, acceleration 5 and brake 
3), supernatant was removed, and cells resuspended up to 50 ml with cold buffer 4 (D-
PBS (Sigma-Aldrich), 2 mM EDTA (Sigma-Aldrich), and 0.2% HAS (Seralab)). An 
aliquot was used for determination of cell count in a haemocytometer using trypan blue 
solution (Sigma-Aldrich, T8154) and the remaining cells were pelleted at 600 g for 6 
minutes (at 4 °C, acceleration 5 and brake 3). Pelleted cells were resuspended in 150 μl 
of buffer 4 per 108 cells. 50 μl of FcR bloking reagent and 50 μl of CD34 microbeads 
per 108 cells were added and sample was incubated at 4 °C. After 30 minutes, 20 ml of 
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buffer 4 was added and sample was centrifuged at 300 g for 6 minutes (at 4 °C, 
acceleration 5 and brake 3). Cells were then resuspended in 500 μl of buffer 4 per 108 
cells and purified on the AutoMacs machine following manufacture’s protocol. 
Enriched sample was collected directly on CellGRO SCGM (CellGenix). Cells were 
counted as described above and purity was determined by flow cytometry. Cells were 
cultured with a density of 1x105 per ml in MK medium (CellGRO SCGM (CellGenix) 
supplemented with 100 ng/ml TPO (CellGenix) and 10 ng/ml IL1b (R&D) in 12-well 
plates. Cells were examined regularly and when needed (up to day 5) split or topped up 
with fresh medium with the correct concentration of cytokines for total volume. From 
day 6 cell’s maturity was monitored by looking at CD41 and CD42 expression by flow 
cytometry. When the percentage of double positive cells was higher than 70%, MKs 
were used for proplatelet assay, western blot (section 2.1.4.6 and 2.2.8) and 
immunostaining. For immunostaining, 30-50x104 MKs were spun on microscope slides 
at 400 rpm for 5 minutes using a Shandon Cytospin 4 machine and then stained as 
described in section 2.1.4.7. For flow cytometry, 3x103 unstained cells and stained with 
anti-CD34-FITC (to confirm sample purity - 1:10, BD Pharmingen), anti-CD41a-APC 
and anti-CD42a-FITC (to confirm MK maturity – 1:10, BD Pharmingen) where 
incubated in the dark for 20 minutes. Fixed samples with 600 μl 0.2% formyl saline 
(Table 2.9) were then processed using a FC-500 cytometer and analysed using Kaluza 
Analysis v.1.5a (Beckman Coulter). 
2.1.4.6  Proplatelet assay 
Sterile glass coverslips were coated in 200 µg/ml fibrinogen (F3879, Sigma-Aldrich) in 
D-PBS overnight at 4 °C. Coverslips were washed with D-PBS and MKs diluted 
0.5x106 MKs/ml in CellGRO SCGM. 300 µl or 150 µl of MKs were seeded per well of 
a 24-well plate or 12 µm well chamber (ibidi), respectively. Cells were examined 
regularly and when proplatelet formation was seen they were fixed in 1% 
paraformaldehyde (PFA) in D-PBS for 10 minutes at RT. Cells were washed three times 
with D-PBS and the plate kept at 4 °C until staining as described in section 2.1.4.7.  
2.1.4.7  Immunostaining 
Cells were quenched with 50µM ammonium chloride in D-PBS (Sigma-Aldrich) for 5 
minutes at RT. Then cells were permeabilised three times for 5 minutes with D-PBS 
containing, 0.1% w/v saponin and 0.2 w/v gelatin (both form Sigma-Aldrich). Cells 
were incubated at RT with primary antibody diluted in saponin-gelatin-PBS for 1 hour, 
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followed by three times 5 minutes washes with saponin-gelatin-PBS. Then cells were 
incubated in the dark at RT with secondary antibody in saponin-gelatin-PBS for 1 hour 
(Table 2.2). Cells were again washed twice with saponin-gelatin-PBS and incubated for 
10 minutes with 1 μg/ml 4’,6-diamidino-2-phenylindole (DAPI) or Hoechst 33342 
(Thermo Fisher Scientific) followed by two washes with PBS. Cells were mounted with 
hydromount (National Diagnostics) overnight in the dark. Images were acquired using a 
Leica DMi8 fluorescent microscope with DFC7000T camera or Leica Sp5 confocal 
microscope (Leica microsystems). Images captured were analysed using ImageJ 
software. 
 
Table 2.2 - Antibodies used for immunostaining. 
Antibody clone Manufacturer Dilution 
Rabbit anti-SMIM1 Polyclonal – recognises the N-terminal of SMIM1 
HPA069088 - Atlas antibodies - 
Sigma 1:200  
Mouse anti-β Actin   AC15 Ab6276 - Abcam 1:200 
Phalloidin-A555  A34055 – Thermo Fisher Scientific 1:20 
Mouse anti-THBS1 [A6.1] Ab1823 - Abcam 1:200 
Mouse anti-Lamp3-PECy5  BD561982 1:50 
Mouse anti-Lamp-2 [H4B4] Sc-18822 1:20 
Mouse anti-58K-Golgi  Abcam 1:50 
Mouse anti-IgG-A633   Thermo Fisher Scientific 1:500 
Rabbit anti-IgG-A555   Thermo Fisher Scientific 1:500 
Rabbit anti-IgG-A488   Thermo Fisher Scientific 1:500-1:1000 
 
2.1.5  Human platelet activation and SMIM1 analysis by flow 
cytometry and western blot 
This protocol was optimised in order to control for platelet activation during sample 
manipulation. Blood was collected in sodium citrate and 1 μM PGE1, 0.5 U/ml apyrase 
and 100 μM aspirin was immediately added to the negative control sample. The PRP 
was then prepared as described in section 2.1.4.1 and 2 ml samples of the obtained PRP 
were either inhibited (1 μM PGE1, 0.5 U/ml apyrase and 10 % ACD v/v (Sigma-
Aldrich)) or stimulated with thrombin-receptor agonist peptide-6 (TRAP-6, Tocris) and 
centrifuged at 800 g for 10 minutes. Samples were then washed twice with platelet 
washing buffer (section 2.1.4.1) and centrifuged at 800 g for 10 minutes. Negative 
control sample was always washed with platelet washing buffer supplemented with (1 
μM PGE1 and 0.25 U/ml apyrase). 5 μl of each sample was collected for analysis by 
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flow cytometry and remaining sample was pellet for lysis and western blot as described 
in section 2.2.8. For Western blot the following alterations were applied: lysed samples 
were divided and treated with: complete EDTA-free protease inhibitor (Roche) or 
protease and phosphatase inhibitors (Thermo Scientific). Samples treated with protease 
inhibitor were then incubated at 30 °C for 1 hour with Lambda protein phosphatase 
(P0753S, NEB) following manufacture’s protocol. Platelet activation was assessed by 
flow cytometry, measuring the level of P-selectin exposure. Flow samples were 
incubated for 20 minutes in the dark with anti-CD62-PE-Cy5 (AK-4, 551142, BD 
Pharmingen) and IgG1- PE-Cy5 isotype control (555750, BD Pharmingen). The 
expression level of SMIM1 was determined as described in section 2.1.4.4. Fixed 
samples in 0.2% formyl saline (Table 2.9) were processed using a FC-500 flow 
cytometer and analysed using Kaluza Analysis Software v.1.5a (Beckman Coulter). 
 
2.2 Mouse model 
2.2.1  Mouse husbandry 
Smim1 mutant colony was established using heterozygous (Smim1+/-) mice generated by 
Wellcome Trust Sanger Institute as part of the International Mouse Phenotyping 
Consortium (http://mousephenotype.org/). Mice used in all experiments were bred and 
housed at Central Biomedical Services - University of Cambridge, a specific pathogen-
free facility. Mice had ad libitum access to food and water. Normal diet was used, 
unless otherwise specified. General mouse care and ear notches for identification and 
genotyping were performed by in-house animal technicians. All mice were genotyped 
after weaning (at four to six weeks of age). Experimental protocols used in this study 
were performed in accordance to the United Kingdom Home Office regulations under 
the project licence 70/8850.  
 
2.2.2  Generation of Smim1 mutant mice 
Smim1 mutant mice were generated in C57BL/6N genetic background using 
CRISPR/Cas9 technology at Wellcome Trust Sanger Institute. Briefly, four guide RNAs 
(Table 2.3) were used to mediate a deletion of critical exons, present in all Smim1 
transcripts. The resulting deletion has 865 bp, and its genomic location is at 
chromosome 4:154023124 – 154023988 (Figure 2.1 – genomic region highlighted in 
light grey).  
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Table 2.3 - gRNAs used to generate Smim1 mutant mice. gRNAs sequence and 
chromosome location. 
gRNA ID Sequence Chr Chr Start Chr End 
1 CCTGTGTGACTCTCGCTGGTGGC 4 154023132 154023154 
2 CTTGGGTCTACCCTGTGTACTGG 4 154023176 154023198 
3 CCTGACCCTCGGGAATGTAAGTA 4 154024001 154024023 
4 CCCTCGGGAATGTAAGTAAGCCT 4 154024006 154024028 
 
The deletion was confirmed using two genotyping techniques: by end-point PCR and by 
loss of wildtype allele qPCR assay. Genotyping end-point PCR was done through a 
combination of two separate PCR reactions that detect the smim1 wildtype allele and the 
mutant allele. PCR was carried out with 50-100 ng of genomic DNA, 10 μM of primers 
pairs (Table 2.4) and Platinum Taq (Invitrogen), with the following amplification 
conditions: 94 °C for 5 min, then cycled 34 times between 94 °C for 30 seconds, 58 °C 
for 30 seconds and 72 °C for 1:30 seconds followed by a 72 °C 5-min final extension 
step. Reactions were then analysed on agarose gels. Genotyping by loss of wildtype 
allele qPCR assay was done using smim1 probe (Table 2.4, Invitrogen) and FAM-
labelled custom qPCR TaqMan® assay, VIC® labelled endogenous control assay 
following manufactory’s protocol (Table 2.4, Invitrogen).   
 
Table 2.4 - Primers used to genotype Smim1 wildtype and mutant alleles at 
Wellcome Trust Sanger Institute. 
Primer name Fwd /rev Sequence (5' - 3') Target/assay 
Smim1_DF1  fwd TGGCAGCTACACTTTCCTGG  Smim1 wildtype– PCR  
Smim1_ER1 rev ACTAGCTCAGGGTCACATCAG  Smim1 wildtype– PCR 
Smim1_DR1 rev CTCAGCTGGAGCTTAGCCTAGT  Smim1 mutant– PCR 
Smim1_qPCR_1 fwd GGAGTTACCTATCTGCTCAAAGG  LoA qPCR assay 
Smim1_qPCR_2 rev CCAGCAGCTCCCACTGA LoA qPCR assay 
Smim1_qPCR_p probe CTGGGCTTGAACAAAG  LoA qPCR assay 
 
Nevertheless, CRISPR/Cas9 gRNAs off-target analysis was not performed. Therefore, 
one cannot exclude the possibility that other genes may also be affected. 
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Figure 2.1 - Highlighting 
deleted region in Smim1 
mutant mice. Overview of 
mouse Smim1 transcripts in 
chromosome 4 and schematic 
representation of Smim1 deletion 
generated by CRISPR/Cas9 
system in Smim1 mutant mice. 
Four gRNAs (binding site 
represented in green) were used 
to delete Smim1 region 
highlighted in grey (chr 
4:154023124 – 154023988) 





154023988) on 2018.11.20.  
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2.2.3 Mouse genotyping 
Genotyping of mice was performed by combination of two separate PCR reactions 
using 0.2 µM of specific primers (Table 2.5) that detected Smim1 wildtype and mutant 
allele. Genomic DNA was extracted from ear notches using PureLink Genomic DNA 
Kit (Invitrogen), following manufacturer’s protocol. PCR was carried out with KAPA 
HiFi HotStart Ready mix (Biosystems), with the following amplification conditions: 95 
°C for 5 min, then cycled 35 times between 98 °C for 20 seconds, 68 °C for 30 seconds 
and 72 °C for 15 seconds followed by a 72 °C 5-min final extension step. PCR products 
were resolved by electrophoresis as described in section 2.3.5.6. 
 
Table 2.5 - Primers used to genotype Smim1 wildtype and mutant alleles in this 
study. 
Primer name Fwd /rev Sequence (5' - 3') Target/assay 
Smim1_F_U fwd CCTGCACAGAAAGATTTGAGGCCC Smim1 universal– PCR  
Smim1_R_wt rev TCCCCATCTCCAGTACACAGGGTA Smim1 wildtype– PCR 
Smim1_R_ko rev CAGAGGCCCCAGTTGTAAATGCAG Smim1 mutant– PCR 
 
2.2.4  Mouse blood collection 
Mouse blood was collected from inferior vena cava, directly into anticoagulant. For 
inferior vena cava bleeds, mice were sacrificed by exposure to increasing volumes of 
carbon dioxide and blood collected using a 25G x 1” needle (Terumo) and 1ml soft-
jectâ syringe (Henke Sass Wolf) into 100 μl 0.5 M EDTA (CIMR) or 100 μl acid 
citrate dextrose (ACD; Table 2.9) to prevent coagulation. 
 
2.2.5  Mouse full blood count and blood smears 
Mouse full blood counts were done using a Scil Vet ABC Plus animal blood analyser 
(scil animal care company), using blood collected into EDTA. Blood smears were done 
by spreading 2.5 μl of whole blood across a microscope slide. Dry blood smears were 
then stained with Rapid Romanowsky staining kit (TCS biosciences) following the 
manufacturer’s protocol. 
 
2.2.6  Mouse histology 
Mouse was dissected, tissues collected and fixed immediately in 10% neutral formalin 
solution (Sigma-Aldrich) for 24h-48h at RT. Fixed hind legs bones were washed with 
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D-PBS and decalcified with 10% EDTA (pH 7.4) for 7-10 days. Tissues were then 
dehydrated through series of graded ethanol baths and paraffin-embedded. 4 µm 
sections were cut and stained with haemotoxylin and eosin (H&E) and periodic acid-
Schiff (PAS). Mouse histology was performed by James Warner at histology core - 
Wellcome Trust-MRC Institute of Metabolic Science. Tissue morphology and specific 
stains were evaluated using Leica DMi8 fluorescent microscope with DFC7000T 
camera (Leica microsystems) or imaged using Zeiss Axioscan Z1 Slidescanner and 
analysed using HALOÔ image analysis software. Professor Gary Hoffman (University 
of Western Australia), kindly gave me his feedback regarding general tissue 
morphology.  
2.2.6.1  Assessment of glycogen content in mouse liver using PAS/DPAS staining  
PAS/DPAS staining was done in two consecutive liver slices. In brief, one of the two 
slides was pre-treated with diastase, an enzyme that specifically breaks down glycogen, 
and then both slides were stained with PAS (untreated - PAS and treated-DPAS). All 
mouse liver samples for comparison were treated and stained at the same time. Slides 
were imaged using Zeiss Axioscan Z1 Slidescanner and analysed using HALOÔ image 
analysis software with a convolution neural network classifier. Three classifiers (tissue, 
vessels and background) and a fixed margin were used to avoid blood vessel and margin 
effects, and to specifically detect areas of PAS stain. DPAS sample was used to set up 
the threshold of a weak stained area and the PAS sample was used to define strongly 
stained areas. Steatosis areas were also quantified, and its areas subtracted to total tissue 
area. The same analysis settings were applied to all samples. PAS stained areas were 
calculated in a ratio of tissue intensity area to tissue area, and then expressed as a 
percentage. Results were presented in total PAS stained area, weak PAS stained area, 
moderate PAS stained area and strong PAS stained area. To specifically quantify 
glycogen area, the quantification of the PAS stain area in the DPAS sample was 
subtracted from the quantified PAS area in the PAS sample. Slides scanning and 
HALOÔ analysis was performed at Wellcome Trust-MRC Institute of Metabolic 
Science in collaboration with Professor Toni Vida-Puig, Dr Michele Vacca and Dr Vian 
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2.2.6.2 Quantification of megakaryocytes in mouse bone marrow  
Sections of mouse hind legs bones stained with H&E were imaged using Leica DMi8 
fluorescent microscope with DFC7000T camera (Leica microsystems). Quantification 
was performed manually in ten fields per mouse, using ImageJ software. 
 
2.2.7  Mouse platelet isolation for western blot and platelet spreading  
Mouse whole blood was collected from the inferior vena cava (IVC) and anticoagulated 
with EDTA or ACD. Blood was diluted with 1.5 volumes of Tyrode’s buffer (Table 2.9) 
and PRP was carefully collected after centrifugation at 100 g for 10 minutes (with 
acceleration and brake zero). PRP was washed with Tyrode’s buffer containing 1 μM of 
PGE1 and 0.5 U/ml of apyrase to prevent platelet activation and centrifuged at 1000 g 
for 10 minutes. Platelet pellets were washed with the Tyrode’s buffer containing 1 μM 
of PGE1 and 0.5 U/ml of apyrase and centrifuged at 1000 g for 10 minutes, and then 
resuspended in Tyrode’s buffer for spreading assay or lysis buffer (RIPA buffer with 
protease inhibitors – section 2.2.8) for western blot. 
 
2.2.8  Western blot  
Cells were lysed using RIPA buffer (150 mM sodium chloride,60 mM Tris pH8, 0.6% 
w/v sodium deoxycholate, 0.1% w/v sodium dodecyl sulfate, 1% v/v NP-40) with 
complete EDTA-free protease inhibitor (Roche) for 15 to 30 minutes at 4 °C. Cell 
lysates were then centrifuged at 13000 rpm for 15 minutes at 4 °C. Supernatant proteins 
were quantified by Bradford protein assay (Bio-Rad) following the manufacturer’s 
protocol. Protein samples were prepared with 1X NuPAGE® LDS sample buffer and 1X 
NuPAGE® reducing agent (Invitrogen), following heating at 70 °C for 10 minutes. 
Protein samples and PageRuler prestained protein ladder (Thermo Scientific) were 
loaded onto a NuPAGE® 4-12 % Bis-Tris gel and run in NuPAGE® MES or MOPS 
SDS running buffer with NuPAGE® Antioxidant (Invitrogen) at 200 V. Proteins were 
transferred onto PVDF membrane (Millipore) by XCell II blot module (Invitrogen) at 
30 V for 1 hour, following the manufacturer’s protocol. Membranes were blocked with 
5 % non-fat dry milk (Sigma-Aldrich) in TBS-T buffer (1X Tris buffered saline with 0.1 
% Tween20) or Odyssey Blocking Buffer (LI-COR®) at RT for 1 hour. Then, 
membranes were incubated with primary antibodies (Table 2.6) diluted in 3 % non-fat 
dry milk (Sigma-Aldrich) prepared in TBS-T or Odyssey Blocking Buffer, overnight at 
4 °C. After primary antibody incubation, membranes were washed three times in TBS-T 
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or Odyssey Blocking Buffer for 10 minutes and then incubated with secondary antibody 
(Table 2.6) in 1.5 % non-fat dry milk (Sigma-Aldrich) prepared in TBS-T or Odyssey 
Blocking Buffer supplemented with 0.1% Tween20 for 1 hour at RT. Then, the 
membranes were washed three times in TBS-T and developed. Antibody incubations 
and washes were performed with gentle rotation and rocking. For secondary-HRP 
antibodies, membranes were developed with Pierce™ ECL Plus Western Blotting 
Substrate (Thermo Scientific) following the manufacturer’s protocol and exposed to 
photographic film in the dark room. The films were developed and the image was 
digitalized. When using LI-COR® Odyssey imaging system, washed membranes were 
imaged with Odyssey Fc OFC-1095 version 1.0.36 imaging system (LI-COR; IRDye. 
680RD and IRDye. 800CW conjugated). When needed the membranes were stripped 
with stripping buffer (2% SDS, 63 mM Tris-HCl pH 6.8, 114 mM β-Mercaptoethanol) 
for 45 minutes at 50 °C, washed several times with TBS-T at RT, and then blocked and 
processed as mentioned above. Stripping of membranes used with LI-COR® Odyssey 
system, was performed according manufacture’s protocol. 
 
Table 2.6 - Antibodies used for western blot. 
Antibody clone Manufacturer Dilution 
Rabbit anti-SMIM1 Polyclonal – recognises the N-terminal of SMIM1 HPA069088 - Atlas antibodies 1:2000  
Rabbit anti-CD62P Polyclonal Ab59738 - Abcam 1:2000 
Rabbbit anti-VEGFA [VG-1] Ab1316 - Abcam 1:5000 
Mouse anti- THBS1 [A6.1] Ab1823 - Abcam 1:5000 
Rabbit anti-VWF Polyclonal A0082 - Dako 1:5000 
Rabbit anti- CD42b Polyclonal Sc-292722 Santa Cruz 1:1000 
Rabbit anti-human CRLF3 Polyclonal Atlas antibodies 1:1000 
Rabbit anti-human GAPDH 14C10 Cell Signalling Techonology 1:1000 
Mouse anti- β Actin   AC15 Ab6276 - Abcam 1:10000 
Pierce goat anti-rabbit IgG Poly -
HRP   32260 – Thermo Scientific 1:10000 
Pierce goat anti-mouse IgG Poly-
HRP  32230 – Thermo Scientific 1:10000 
IRDye 800CW Donkey anti-rabbit 
IgG  LI-COR
® 1:10000 
IRDye 800CW Goat anti-mouse 
IgG  LI-COR
® 1:10000 
IRDye 680LT Goat anti-rabbit IgG  LI-COR® 1:10000 





38   
2.2.9  Mouse platelet spreading 
Fibrinogen coated coverslips were prepared in advance by incubation with 200 μg/ml of 
fibrinogen (Sigma, F3879) overnight at 4°C. Coverslips were then washed twice with 
D-PBS and blocked with D-PBS-1 % BSA (Sigma-Aldrich) for at least one hour at RT. 
After washing twice with D-PBS, coverslips were washed with Tyrode’s buffer 
supplemented with 2 mM calcium chloride. Washed platelets were diluted in Tyrode’s 
buffer supplemented with 2 mM calcium chloride and adjusted to a concentration of 
25x103 platelets/μl. Adjusted platelets, after incubation for 30 minutes at 37°C, were 
supplemented with 0.01 U/ml of thrombin to induce platelet activation/spreading, and 
immediately added to the coverslip previously coated with fibrinogen. After incubation 
for 30 minutes at 37°C, unbound platelets were removed by washing twice with PBS. 
Spreading platelets were fixed with 4 % PFA for 15 minutes at RT and then washed 
twice with D-PBS. Platelet immunostaining was performed as described in section 
2.1.4.7, using Alexa Fluor® 555 phalloidin (1:20 dilution - Invitrogen, A34055). Ten 
pictures per coverslip were taken in Leica DMi8 microscope with DFC7000T camera 
(Leica microsystems). Percentage of attached and spread platelets was determined 
manually using ImageJ software.  
 
2.2.10 Mouse platelet transmission electron microscopy (TEM) 
Blood collected from IVC was diluted in 1.5 volumes of 0.9% sodium chloride (Sigma-
Aldrich) and PRP obtained after centrifugation at 100 g for 10 minutes. Washed PRP in 
0.9% sodium chloride (Sigma-Aldrich) was centrifuged at 1000 g for 10 minutes. After 
centrifugation, the obtained platelet pellet was resuspended in primary fixation buffer 
(0.5% glutaraldehyde, in 0.1M sodium cacodylate buffer, pH 7.4 – gift from Cambridge 
Advanced Imaging Centre) and incubated overnight at 4 °C. Fixed platelets were then 
processed by Dr James McMillan at Cambridge Advanced Imaging Centre. In brief, 
platelets were resuspended in secondary fixative buffer (2% glutaraldehyde, 2% 
formaldehyde in 0.05 M sodium cacodylate buffer containing 2 mmol/L calcium 
chloride, pH 7.4) and incubated overnight at 4 °C. Then, fixed platelets were incubated 
serially in buffers containing 1% osmium tetroxide and 1.5% potassium ferricyanide, 
1% thiocarbohydrazide, 2% osmium tetroxide and finally 2% uranyl acetate in 0.05 M 
maleate buffer, pH 5.5. Samples were then dehydrated through washes in ascending 
series of ethanol solutions (50%, 70%, 90% and 100%), followed by treatment with dry 
acetone and dry acetonitrile, and infiltration with Quetol 651 epoxy resin. Sections were 
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cut at 60 nm using a diamond knife with a Leica UCT ultramicrotome. Sections were 
imaged using a FEI Tecnai G2 TEM, AMT XR60B camera and Deben software. 
Professor Kathleen Freson (University of KU LEUVEN), kindly gave me her feedback 
regarding platelet ultrastructure.  
 
2.2.11 Mouse platelet activation assay 
Mouse platelet response to different agonists was assessed by flow cytometry, 
measuring the level of P-selectin exposure and fibrinogen binding. ACD anticoagulated 
blood diluted in 200 μl Tyrode’s buffer (Table 2.9) was diluted 1:10 with HBS (Table 
2.9) supplemented with an antibody mix and either no agonist, 10 mM EDTA, cross-
linked collagen related peptide (CRP-XL, gift from Dr Richard Farndale, University of 
Cambridge) or thrombin (Sigma-Aldrich). Thrombin stimulated samples were treated 
with 1.2 mM of Gly-Pro-Arg-Pro (GPRP, Sigma) to inhibit thrombin-induced fibrin clot 
formation and platelet aggregation [198]. Samples were mixed and incubated for 20 
minutes at RT in the dark. The reaction was stopped by fixing the samples with 1:10 of 
0.2% formyl saline (Table 2.9) for 10 minutes in the dark. Samples were further diluted 
to 1:30 with 0.2% formyl saline and processed using Gallios flow cytometer and 
analysed using Kaluza Analysis Software version 1.5a (Beckman-Coulter), within 1 
hour of fixation. Blood collection and sample manipulation were performed carefully in 
order to avoid platelet activation. 
 
The samples were incubated either without antibody, with antibody mix or with an 
isotype. The antibody mix was composed by: anti-human fibrinogen-FITC (1:25, 
F0111, Dako), anti-mouse P-selectin- PE (1:10, clone Wug.E9 emfret) and anti-mouse 
CD41-APC (1:25, clone eBioMWReg30, eBioscience). And the isotypes used were: 
anti-human IgG-FITC (1:25, F0215, Dako), IgG-PE isotype control (1:10, P190-2 
emfret) and IgG1-APC (1:25, clone eBRG1, eBioscience). AbC Total Compensation 
Capture beads were used for compensation (A10497, Thermo Fisher Scientific). 
 
Flow cytometry analysis was performed using logarithmic scale for platelet detection 
and differentiation in the light-scatter and fluorescence channels. Platelets were 
identified by their light-scatter profile and by the binding of anti-CD41-APC, which 
binds to platelet glycoprotein IIb regardless of platelet activation and doesn’t affect 
fibrinogen binding. Five thousand individual platelets per sample were acquired. 
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Untreated platelets stained with IgG-PE isotype were used to set up P-selectin-PE gate, 
and CD41-positive platelets treated with EDTA, were used to set up the fibrinogen-
FITC gate, both according to pick shape. The results were expressed as the percentage 
of P-selectin and fibrinogen-positive platelets for untreated (basal activation) and treated 
samples. Representation of gating strategy and flow cytometry results is shown in  
Figure 2.2.  
 
 
Figure 2.2 - Flow cytometry analysis of mice platelet activation. Mouse whole blood 
was treated with different agonists and platelet activation determined by P-selectin 
exposure and fibrinogen binding. Platelets were identified by their size and granularity 
distribution using side light scatter (SS) vs. forward light scatter (FS) area (first gate – 
platelets) and by expression of glycoprotein IIb - positive staining with CD41-APC 
(second gate –CD41+ platelets). The percentage of P-selectin exposure and fibrinogen 
binding was determined in individual CD41-positive platelets (third gate –CD41+ 
platelets singlets), in all the samples - untreated (resting platelets) and treated with the 
different agonists. 
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2.2.12 Mouse platelet isolation for RNA extraction 
EDTA anticoagulated whole blood was diluted with 1.5 volumes of Tyrode’s buffer 
(Table 2.9) containing 1 μM of PGE1 and 2 mM EDTA, to prevent platelet activation. 
Blood was centrifuged at 100 g for 10 minutes (acceleration and brake 0) to obtain PRP. 
PRP was diluted 1:1 with the same buffer and centrifuged at 100 g for 10 minutes to 
remove white blood cells excess. PRP was further purified by incubation, for 20 
minutes at RT, with 50μl of Dynabeads (Invitrogen, 11035) previously prepared with 
0.75 μg anti-TER-119 (BD Pharmingen, 550565) and 1.5 μg anti-CD45 (BD553086), to 
deplete residual red blood cells and leukocytes, respectively. PRP was magnetised twice 
and purified platelets were quantified by animal blood analyser (Scil Vet ABC Plus). 
The purified platelet pellet was lysed in TRIzol® (Invitrogen) and stored at -80 °C until 
RNA extraction. Platelet lysates of two to three mice per genotype were pooled to 
obtain enough RNA to perform RNA-Sequencing. 
 
2.2.13 RNA extraction 
Platelet lysate was transfer to a 2 ml heavy phase lock tube (5prime) and homogenised 
with 0.2 ml of chloroform per 1 ml of TRIzol® (Invitrogen) used. Post incubation for 3 
minutes at RT, the sample was centrifuge at 12,000 g for 15 minutes at 4 °C. The upper 
aqueous phase containing the RNA was collected and RNA was co-precipitated with 10 
μg of glycogen by adding 0.5 ml of isopropanol per 1 ml of TRIzol® (Invitrogen). After 
incubation at RT for 10 minutes, the sample was centrifuged at 12,000 g for 10 minutes 
at 4 °C. RNA pellet was washed twice with 1 ml of ice cold 75 % ethanol per 1 ml of 
TRIzol® (Invitrogen), following centrifugation at 8000 g for 10 minutes at 4 °C. The 
air-dry RNA pellet was then resuspended in RNAse free water (Qiagen). RNA was 
quantified using Qubit RNA HS Assay (Invitrogen) or Qubit RNA BR Assay 
(Invitrogen), following manufacturer’s protocol. RNA quality was accessed on the 
Agilent 2100 Bioanalyzer, using Agilent RNA 6000 Pico Kit (Agilent Technologies). 
 
2.2.14 RNA-sequencing and analysis 
Mouse platelet RNA libraries were prepared by Ms Frances Burden, Research Associate 
in Prof. Ouwehand group. Libraries were made using KAPA Stranded RNA-Seq Kit 
with RiboErase (Human/Mouse/Rat) Illumina®plataform (KAPABiosystems), with the 
following modifications to the manufacturer’s protocol: step 15 – library amplification 
clean-up was performed with 0.9X SPRI® clean-up beads instead of 1X, and libraries 
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were resuspended in water. Libraries were quantified by RTqPCR using the KAPA 
Library Quantification Kit (KAPABiosystems). Sequencing was performed by 
Genomics core facility at Cancer Research UK Cambridge Institute using HiSeq4000. 
RNA-sequencing data processing and quality control was performed by Dr Denis 
Seyres, Research Associate in Prof. Ouwehand group. In brief, mouse 
GRCm38.71(mm10) reference genome was used to build a Kallisto transcriptome index 
and a pseudoalignment of transcripts was done using Kallisto [199]. Then, transcript 
abundance estimates were summarized to gene level using Tximport (R package), which 
is a more relevant and stable method to compare replicates and experiments. Finally, 
differential analysis was performed with DESeq2 using gene counts and at a 5% false 
discovery rate. Principal component analysis (PCA) was performed using the transcript 
per million (TPM) data obtain with Kallisto.  
 
2.2.15 Mouse RBCs real-time deformability cytometry (RT-DC) 
EDTA anticoagulated blood was collected from IVC and processed within 30 minutes. 
Sample processing and analysis was performed by Ms Katie Bashant, PhD student at 
Professor Dr. Edwin Chilvers laboratory, Department of Medicine, University of 
Cambridge. In summary, 25 μl of whole blood was diluted 1:20 in PBS containing 0.5% 
(w/v) methylcellulose, which increases sample density and viscosity, hence, reduces cell 
sedimentation during the experiment and allow higher shear forces at lower flow 
velocities, respectively. Samples were loaded into a microfluidic chip (flic20 – normally 
used for human whole blood analysis, which did affect the quality of the measurements) 
and passed through a 20 μm microfluid constriction channel under pressure gradients 
and shear stresses that induce cell deformation. Cells were captured with a high-speed 
camera and mechanical proprieties were determined using a cell-tracing algorithm and 
offline ShapeOut software. Data acquisition was carried out at the rear part of the 
constriction channel, where the cell shape reaches a steady state. The following 
mechanical proprieties were quantified: area, deformability and surface smoothness. A 
cell-tracing algorithm was applied, which uses cell contour to derive cell cross-sectional 
area (A) and perimeter (l), and then, calculates cell circularity (!, ! = 2√&' (⁄ ), which 
is used to determine cell-deformability. Deformation was determined by cell deviation 
from circularity when constricted in the channel (,-./01234/5 = 1 − !)	(product of 
cell size and stiffness). A perfect circular object has ! =1	so, a deformable object ! < 1. 
[200]. Area ratio, which corresponds to surface smoothness, was calculated from the 
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ratio of convex hull area (cell size (μm2)) and cell area. Three different RT-DC gating 
strategies were used: 5/80/80 to analyse red blood cells, (constant flow rate for 1 
minute); 3/80/80, for leukocytes (constant flow rate for 7 minute); and 1/30/30 for 
platelets (constant flow rate for 5 minutes). These basic gates indicate to the RT-DC 
camera which size of cell to capture and refer to (minimum cross-sectional 
length/maximum horizontal cross-section length/maximum vertical cross-section 
length) 0/80/80 is a completely open gate. As reference, the circularity of non-deformed 
cells was determined in the reservoir (30 seconds x 3) in all the experiments. Minimum 
of 5000 RBCs were analysed using the gating strategy referred above. RBCs were 
identified on the basis of size and brightness and 1-1.07 area ratio was used to calculate 
size and deformation in smooth cells, and 1-1.2 area ratio was used to calculate 
roughness. These area ratio maximum gates eliminated red blood cell doublets from 
analysis.  
 
2.3  Cell lines 
2.3.1  Generation, maintenance and manipulation of human induced 
pluripotent stem cells (hiPSCs) 
In this study two hiPSC lines were used: S4-SF5 and A1ATD1-c (referred as S4 and 
Bobc for simplicity, respectively). Both cell lines were a gift from Dr Cedric Ghevaert 
group at Department of Haematology, University of Cambridge. These hiPSC lines 
were derived from human skin fibroblasts through a non-integrating method by using 
Sendai virus vectors (SeVs; encoding for Yamanaka’s factors OCT4, SOX2, KLF4 and 
MYC) [201, 202]. Bobc line was derived from a patient with a mutation in the alpha1 
anti-trypsin gene, which was corrected as described by Yusa et al. [202]. 
2.3.1.1 Maintenance of hiPSCs 
hiPSCs were maintained on vitronectin-coated plates (Invitrogen, A14700). When in 
single-cell state, hiPSCs were seeded onto irradiated mouse embryonic fibroblast (MEF) 
feeder plates to avoid differentiation. The cells were kept in an incubator at 37 °C, 5% 
CO2 and daily fed with AE8 medium (AE6 medium supplemented with FGF2 and 
Activin A (Cambridge Stem Cell Institute, Tissue culture facilities)) or with Essential 8 
medium (E8, Gibco). hiPSCs were observed daily under an inverted light microscope 
(Leica) and photographed using EVOS® FL Cell Imaging System (Life Technologies).  
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2.3.1.2  Preparation of vitronectin and feeder plates 
The vitronectin-coating plates were prepared using 5 μg/ml rhVTN (Invitrogen, 
A14700) prepared in D-PBS for 1 hour at RT. To prepare MEFs feeders, the wells were 
firstly coated with 0.1% gelatin prepared in water from embryo transfer (G2500, W1503 
- Sigma-Aldrich) for 25 minutes at RT. Then, a vial of D4 IRR MEFs (Cambridge Stem 
Cell Institute, Tissue Culture Facilities) was thawed in water bath at 37 °C and 
transferred drop-wise to a tube containing pre-warmed MEF medium (150 ml 
Dulbecco’s modified Eagle medium (DMEM)/F12 (Life technologies), 1.66 ml L-
Glutamine (Invitrogen), 16.6 ml fetal bovine serum, 1.16 µl b-mercaptoethanol). The 
cells were centrifuged at 200 g (acceleration and brake 5) for 5 minutes and then the 
pellet was resuspended in MEFs medium. Approximately 0.15x105 cells/well were 
seeded in a 6-well plate. MEF feeder plates were used within one week to maintain 
hiPSCs in an undifferentiated state. 
 
2.3.1.3  Passaging, freezing and thawing of hiPSCs 
hiPSCs were passaged or frozen when 70-90% of confluence was reached to avoid cell 
differentiation. Cells were dissociated with pre-warmed D-PBS/ EDTA (5 mM EDTA 
in D-PBS) for 5 minutes at RT. After removing the D-PBS/EDTA, cells were washed 
and gently resuspended with pre-warmed wash medium (Table 2.9). Cells were then 
centrifuged at 200 g (acceleration and brake 5) for 5 minutes. When cell splitting was 
required, hiPSCs pellets were gently resuspended with pre-warmed AE8 medium and 
seeded in a vitronectin-coated plate (ratio 1/3 to 1/20). When preparing hiPSC for 
freezing, hiPSCs pellets were resuspended in pre-warmed freezing medium (Table 2.9) 
and placed into cryovials which were then transferred to a Mr. Frosty™ (Fisher 
Scientific) and placed at -80 °C or -150 °C for long-term storage. Culture of 
cryopreserved hiPSCs was performed by partially thawing cryopreserved hiPSCs in a 
water bath at 37 °C and transferring drop-wise into a tube with pre-warmed wash 
medium. Wash medium (table 2.9) was then added drop-wise into cryovials to recover 
the remaining cells. The cells were centrifuged at 200 g (acceleration and brake 5) for 5 
minutes and then gently resuspended with pre-warmed AE8 medium and seeded in a 
vitronectin-coated plate.  
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2.3.2  Generation of SMIM1 knockout hiPSC cell line using 
CRISPR/Cas9n 
SMIM1 knockout line was created using CRISPR/Cas9n technology in S4 hiPSC line. 
2.3.2.1  Design and cloning of CRISPR-RNA guides 
CRISPR (Clustered regulatory interspaced short palindromic repeats) guide sequence 
consists of a 20-bp oligonucleotide located immediately upstream of a 5’-protospacer 
adaptor motif (PAM, 5’-NGG motif) [203]. All the gRNA sequences were identified in 
the human genome (GRCh37) via online CRISPR design tools from the Wellcome 
Trust Sanger Institute, Cambridge, UK (http://www.sanger.ac.uk/htgt/wge/crispr), 
DNA2.0, Inc. (https://www.dna20.com/products/crispr) and Zhang Lab, MIT 
(http://crispr.mit.edu/). The results of the different online tools were compared and the 
best-rated guide sequences/pairs, according to off-targets, offset (0 to 20 bp) and also 
binding site, were chosen (Table 2.7). To clone the gRNAs, a forward (Fwd) and 
reverse (Rev) oligonucleotide containing the restriction site of BbsI endonuclease was 
designed. A guanine (G) base was added to the beginning of each gRNA sequence to 
improve its expression under U6-promoter. The oligonucleotides were designed without 
the PAM sequence (Table 2.10). gRNA annealing and cloning were done as previously 
described [204-206]. Briefly, gRNA oligonucleotides were phosphorylated and 
annealed in a 10 μl reaction (10 μM of each oligonucleotide, 1x T4 DNA ligase buffer 
10x (NEB, B0202S) and 10 U of T4 polynucleotide kinase (NEB, M0201S)) by a 
thermal cycler using the following parameters: 37 °C for 30 minutes; 95 °C for 5 
minutes; ramp down to 25 °C at 5 °C minutes-1. Then, GRNAs were diluted 1:200 in 
water at RT and cloned into pSpCas9n(BB)-2A-Puro (PX462) (Addgene plasmid 
#48141, gift from Feng Zhang). A simultaneous digestion and ligation were performed 
to clone RNA guide into PX462. A 20-μl reaction (100 ng of PX462, 2 μl of diluted 
gRNA, 1x Tango buffer 10x (Fermentas/Thermo Scientific, BY5), 0.5 mM 
dithiothreitol (DTT, Thermo Scientific, R0861), 1 μl FastDigest BbsI 
(Fermentas/Thermo Scientific, FD1014)) was placed into a thermocycler with the 
following parameters: 6 cycles of 37 °C for 5 minutes and 21 °C for 5 minutes. Then, 11 
μl of ligation was treated with PlasmidSafe exonuclease (Epicentre, E3101K) in a 15-μl 
reaction (1x Plasmid buffer 10x, 1 mM ATP, 10 U PlasmidSafe exonuclease) at 37 °C 
for 30 minutes, followed by 30 minutes at 70 °C [206]. Finally, 2 μl of treated plasmid 
was used to transform E.coli DH5α high-competent cells (NEB) as described in section 
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2.3.5.1. All cloned gRNAs were expanded. Sequence and orientation were confirmed by 
Sanger sequencing, using U6-Fwd and/or hGATA4-Rev primers (Table 2.10). 
 
Table 2.7 - Guide RNA used to target SMIM1 in hiPSC. The reverse sequence is 
represented for guide sequences targeting the bottom strand. The sequence in bold 
corresponds to the PAM motif. The target region refers to the localization of the guide 
sequence in GRCh37 human genome. 
Guide name Target strand Sequence (5’-3’) Target region 
SMIM1_CR_1 Bottom ATAGTGGACGTGGCTCTCCT-GGG 1:3691945-3691967 
SMIM1_CR_2 Top CAGGGACGGAGTCAGCCTAG-GGG 1:3691988-3692010 
SMIM1_CR_3 Bottom CGTCCTCCCACCTACTATAG-TGG 1:3691961-3691983 
SMIM1_CR_4 Top GCAGGGACGGAGTCAGCCTA-GGG 1:3691987-3692009 
SMIM1_CR_5 Bottom CCCACCTACTATAGTGGACG-TGG 1:3691955-3691977 
 
2.3.2.2  Nucleofection, colony picking and screening of hiPSC 
S4 cells were fed with pre-warmed AE8 medium complemented with 10 µM ROCK 
inhibitor (Y-27632, Sigma-Aldrich) 12-24h before nucleofection. hiPSCs were washed 
twice with D-PBS and then incubated at 37 °C for 5 minutes with cell dissociation 
solution (StemPro® Accutase®, Life Technologies, A1110501). Cells were gently 
resuspended to form 3-4 cell clumps and collected into wash medium; then, cells were 
centrifuged for 5 minutes at 200 g (acceleration and brake 5) and resuspended in pre-
warmed AE8 medium complemented with 10 µM ROCK inhibitor. Approximately 
1.5x106 S4 cells were resuspended with a mix of 100 µl of Human Stem Cell 
Nucleofector® Kit 2 (Lonza, VPH-5022), and 2 µg, 10 µg or 20 µg of sgRNA/Cas9n-
enconding plasmids and donor vector (equimolar concentrations of each sgRNAs and 
donor vector). Cells were promptly electroporated using Amaxa™ Nucleofector™ II – 
program B-016 (Lonza). Immediately after nucleofection, 600 µl AE8 medium 
complemented with 10-µM ROCK inhibitor was added and cells transferred onto 3 
wells of a 6-well MEFs-coated plate with AE8 medium complemented with 10 µM 
ROCK inhibitor and incubated. 24h post-nucleofection (day 1), nucleofection efficiency 
was determined by monitoring green fluorescent protein (GFP) expression using 
EVOS® FL Cell Imaging System. Antibiotic selection with 1 µg/ml puromycin 
(Clontech 631305) was also initiated. Selection was carried out for 2 days to eliminate 
all cells without sgRNA/Cas9n-plasmid. Small colonies started to appear 8-12 days 
after nucleofection. On days 14-18, colonies were manually picked into vitronectin-
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coated 24-well plates, expanded for genomic DNA (gDNA) extraction (described in 
section 2.3.5.2) and culture was continued. 
 
Identification of targeted clones was carried out by PCR screening of genomic DNA 
(gDNA), using specific primers (Table 2.10) and MyTaq (Bioline) (described in section 
2.3.5.4). PCR products were analysed by agarose gel electrophoresis (described in 
section 2.3.5.6). Sanger sequencing of the PCR product was undertaken to access the 
specific mutation of each positive clone. When required, the PCR product of each clone 
was cloned into pGEM-T easy vector (Promega), according to the manufacturer’s 
instructions, and several colonies were sequenced using Sp6 and T7 primers (Table 
2.10). 
 
2.3.3  Forward programming of hiPSC to megakaryocytes 
Forward programming of hiPSCs into MKs was undertaken following the method 
published by Moreau et al [207]. However, alterations have been made to improve the 
published protocol by Dr Tomas Moreau, Research Associate at Department of 
Haematology, University of Cambridge. Therefore, two different models of forward 
programming were used, according to the cell line used. A 3D model was used to 
forward programming S4 hiPSCs and a 2D model for Bobc hiPSCs.  
 
In brief, in the 3D model on day 0 an AggrewellÔ400 plate (Stemcell technologies), 
was prepared by washing the aggrewells with 500 µl of Aggrewell Rinse solution 
(Stemcell technologies). Following plate centrifugation at 2000 g for 5 minutes it was 
added 500 µl of transduction medium, EB1 medium (AE6 media supplemented with 10 
µM ROCK inhibitor Y-27632 (Sigma-Aldrich), 10 ng/ml bone morphogenetic protein 4 
(BMP4, R&D) and 10 µg/ml protamine sulfate (Sigma-Aldrich)) per aggrewell and the 
plate was incubated at 37 °C, 5% CO2. A sub-confluent hiPSC culture was dissociated 
to single cell with TrypLE (Thermo Fisher Scientific) and 1x106 cells per aggrewell 
were resuspended in 200 µl of EB1 medium supplemented with GATA1, FLI1 and 
TAL1 lentiviral vectors (multiplicity of infection (MOI) 20, Vectalys). Plate was 
centrifuged at 100 g for 3 minutes and incubated at 37 °C, 5% CO2. 24 hours after 
transduction (day 1), the embryoid bodies (EBs) formed in the aggrewells were 
collected and washed in washing medium. After centrifugation at 20g for 1 minute, EBs 
were resuspended in 2 ml of mesoderm medium, EB2 (AE6 medium supplemented with 
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10 ng/ml BMP4 and 5 ng/ml FGF), seeded in 1 well of a 6 well ultra low binding plate 
(Corning) and incubated. 24 hours later (day 2), EBs were washed in 10 ml D-PBS and, 
after centrifugation at 20g for 1 minute, resuspended in MK1 medium (CellGRO SCGM 
(CellGenix) supplemented with 100 ng/ml TPO (Bio-Techne) and 25 ng/ml SCF 
(Gibco)) and, split in 2 wells of a 6 well ultra low binding plate and incubate at 37 °C, 
5% CO2. Half of media volume was replaced every two days with fresh 2x MK1 
medium (day 5 and 8). Ten days after transduction, EBs were collected, washed in 10 
ml D-PBS at 300 g for 5 minutes and then dissociated with 1 ml of 1:1 1 mg/ml 
Collagenase IV (Life Technologies) and Dispase II (Life Technologies) by gently 
pipetting and incubated for 45 minutes at 37 °C. Cells were then washed with 10 ml D-
PBS and resuspended (mixed every 2 minutes up to 10 minutes) with 300 µl of cell 
dissociation buffer (Life technologies), to generate a single cell suspension. Cells were 
washed with CellGRO SCGM (CellGenix) at 300 g for 5 minutes, resuspended with 
MK2 medium (CellGRO SCGM supplemented with 20 ng/ml TPO (Bio-Techne) and 
50 ng/ml SCF (Gibco)), cells were then cultured in suspension on tissue culture plates 
or flasks. Half of the MK2 medium was changed every two days until cells were used 
for further studies (maximum 25 days post transduction).  
 
For the 2D system, a sub-confluent hiPSC culture was dissociated to single cell with 
TrypLE (Thermo Fisher Scientific) and 2.5x105 cells resuspended in AE8 medium 
supplemented with 10 µM ROCK inhibitor Y-27632 (Sigma-Aldrich) were seeded onto 
vitronectin coated 6 well plates and incubated at 37 °C, 5% CO2. After 24 hours, cells 
were washed with D-PBS and transduced with GATA1, FLI1 and TAL1 lentiviral 
vectors (MOI 20, Vectalys) suspended in transduction media (AE6 supplemented with 
20 ng/ml of FGF, 10 ng/ml BMP4 and 10 µg/ml protamine sulphate). 4 hours post-
transduction (day 1), medium was removed, cells were washed with D-PBS and 
mesoderm medium (AE6 medium supplemented with 10 ng/ml BMP4 and 20 ng/ml 
FGF) was added. After 24 hours (day 2), cells were washed with D-PBS and fed with 
MK medium (CellGRO SCGM supplemented with 20 ng/ml TPO (Bio-Techne) and 25 
ng/ml SCF (Gibco)). On days 5 and 8 half of media volume was replaced by new 2x 
MK medium. On day 10, cells in suspension were collected and the adherent cell layer 
was split with TrypLE (Thermo Fisher Scientific) at 37 °C for 10 minutes. All cells 
were pooled and washed with 10 ml D-PBS at 300 g for 5 minutes. Cells were 
resuspended in MK medium (CellGRO SCGM supplemented with 20 ng/ml TPO (Bio-
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Techne), 25 ng/ml SCF (Gibco)) and cultured in suspension tissue culture plates or 
flasks. Half of MK medium was changed every two days until cells were used for 
further studies (maximum 25 days post-transduction). For both 3D and 2D systems, MK 
maturation was monitored by flow cytometry from day 10 up to day 25. 
2.3.3.1  MK maturation analysis by flow cytometry 
Cells were directly stained with a mix of CD235a, CD41a and CD42a (APC, PE and 
FITC) for 20 minutes in the dark at RT. Cells were washed in flow buffer (D-PBS 
(Sigma-Aldrich), 0.5% BSA and 2mM EDTA) and resuspended in flow buffer 
supplemented with 0.5% PFA and 0.1 μg/ml Hoechst 33342 (Thermo Fisher Scientific) 
to gate viable cells. An unstained mix and isotype controls were used to visualise cells 
and set gates. Single stained AbC Total Compensation Capture beads were used for 
compensation (A10497, Thermo Fisher Scientific). Flow cytometry was performed 
using Beckman Coulter Gallios Cytometer and analysed with Kaluza Analysis v.1.5a 
(Beckman Coulter). Results were expressed as the percentage of positive cells for each 
marker and/or double positive cells. Gating strategy representation and flow cytometry 
analysis are shown in Figure 2.3.  
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Figure 2.3 - Flow cytometry analysis of hiPSC forward programming into MKs. A- 
Gating strategy used for the analysis of forward programming. First, cells were gated 
according to their size and granularity using forward side scatter. Then, singlets were 
gated using forward scatter area and width. Finally, live singlets were gated using 
Hoechst staining. Expression (%) of MK markers was then determined in live singlets. 
B - Representative time course of 2D forward programming of Bobc-TAP-SMIM1 into 
MKs, showing MK progenitor (%CD41a+/CD235a+ cells) and MK maturation 
(%CD42a+ cells) from whole culture.  
 
Table 2.8 -Antibodies used for iMKs flow cytometry. 
Antibody clone Manufacturer Dilution 
Mouse anti-Human CD41a-APC HIP8 559777, BD Pharmingen 1:20 
Mouse anti-Human CD42a - PE ALMA.16 558819, BD Pharmingen 1:20 
Mouse anti-Human CD42b – PE/APC HIP1 555473, 551061 BD Pharmingen 1:20 
Mouse anti-Human CD235a –PE GA-R2 555570, BD Pharmingen 1:50 
Mouse anti-Human CD235a –FITC GA-R2 559943, BD Pharmingen 1:50 
Mouse IgG2b, k isotype -FITC 27-35 555742, BD Pharmingen 1:20 
Mouse IgG1, k isotype -APC MOPC-21 555751, BD Pharmingen 1:20 
Mouse IgG1, k isotype -PE MOPC-21 555749, BD Pharmingen 1:20 
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2.3.3.2  Ploidy analysis by flow cytometry 
Fixed cells with 4% PFA for 10 minutes at RT were stained with CD41a and CD42a as 
described above and then incubated in PBS 0.1% Tween with 1 μg/ml Hoechst 33342 
(Thermo Fisher Scientific) for 15 min at RT. Samples were processed on Beckman 
Coulter Gallios Cytometer and analysed with Kaluza Analysis v.1.5a (Beckman 
Coulter). Ploidy was assessed by gating positive cells for Hoechst and double positive 
for CD41 and CD42.  
 
2.3.4  Overexpression of SMIM1 with a tandem affinity purification 
(TAP) in human hiPSCs 
2.3.4.1  Cloning of TAP-SMIM1 
TAP-SMIM1 insert was synthesized by IDTÒ and digested with NdeI and PacI. 
Digested insert was cloned into pWPI-TAP vector digested with NdeI and PacI (gift 
from Dr Jose Guerrero, Research Associate in Prof. Ouwehand group). Ligation 
reaction (section 2.3.5.3) was transformed in DH5a competent cells (section 2.3.5.1). 
Plasmid sequence was confirmed by sanger sequencing (section 2.3.5.7) using specific 
primers (Table 2.10), and the plasmid was expanded as described in section 2.3.5.2. 
Figure 2.4 - Plasmid used for overexpression of TAP-SMIM1. 
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2.3.4.2 TAP-SMIM1 lentivirus production and transduction in human hiPSCs 
Lentivirus production was undertaken in HEK293T cell line (laboratory stock). In brief, 
4x106 HEK293T cells were cultured in complete medium (DMEM (D6429, Sigma-
Aldrich) supplemented with 10% foetal bovine serum (FBS) heat inactivated (Sigma-
Aldrich) and 1% penicillin-streptomycin (Thermo Fisher Scientific)). Four hours after, 
20 µg of pWPI-TAP-SMIM1 or pWPI-TAP were individually mixed with packaging 
system (8 µg PAX2 and 2.5 µg VSVG) in 1 ml of DMEM (D6429, Sigma-Aldrich) and 
75 µl 1 mg/ml PEI (Sigma-Aldrich) and incubated at RT for 20 minutes. The mixture 
was spread drop wise over the cells and cells were incubated at 37 °C, 5% CO2. 24 
hours post-transduction the medium was changed. Virus were collected 48 and 72 hours 
post-transduction and concentrated using Lenti-XÔ Concentrator (Clontech). Virus 
were resuspended in AE8 medium and stored at -80 °C. 60%-70% confluent hiPSCs 
were transduced with different volumes of virus, expanded and sorted for GFP positive 
cells using the BD FACSDiva 8.0.1 from NIHR Cambridge BRC Cell Phenotyping 
Hub. 
 
2.3.5 Preparation, manipulation and analysis of DNA 
2.3.5.1  Bacterial culture and transformation  
Bacteria were cultured at 37 °C for 9–18 hours either in shaking liquid culture (Luria 
Bertani (LB) medium) or solid culture (streaking on LB agar). When required, cultures 
were supplemented with 100 μg/ml of ampicillin. 
 
Chemically DH5α high-competent cells (NEB, C2987H) were incubated with DNA on 
ice for 20 minutes. Cells were heat-shocked for 45 s at 42 °C and returned to ice for 2 
minutes. Then, 600 μl LB was added and bacteria were cultured for 60 minutes in a 
shaker at 37 °C, before plating onto LB agar with appropriate antibiotic.  
2.3.5.2  Isolation of plasmid and genomic DNA 
Bacterial cells from liquid culture were pelleted and plasmid DNA using QIAprep Spin 
Miniprep Kit (Qiagen, 27104) or with the PureYield™ Plasmid Maxiprep System 
(Promega, A2393), according to the manufacturer’s instructions. Genomic DNA of 
hiPSCs was isolated and purified using Wizard® SV Genomic DNA Purification Kit 
(Promega, A2360), according to manufacturer’s protocol.  
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2.3.5.3  Restriction endonuclease digestion and DNA ligation 
DNA was digested at 37 °C for 1-3 h with restriction enzymes (NEB and Fermentas) in 
the provided buffers, according to the manufacturer’s instructions. Typically, 10 units of 
enzyme were used per 1 μg of DNA. Cut and uncut fragments were analysed on an 
agarose gel. DNA fragments were ligated as required with 3:1 or 7:1 molar ratio of 
fragment to vector using T4/T7 DNA ligase (NEB, M0202) or Quick Ligase™ kit 
(NEB, M2200). Reactions were left for 30 min at 16 ºC when used T4/T7 DNA ligase 
and 10 min at RT when used Quick Ligase™ Kit.  
2.3.5.4  Polymerase chain reaction and colony PCR 
For a typical PCR reaction, 10 μM of forward and reverse primer were used along with 
2x MyTaq (Bioline, BIO-25041) or Phusion PCR kit (NEB, E0553S). PCR reactions 
were heated to 95 °C for 2 min, then cycled between 95 °C for 10 s, Tm -5 °C for 30 s 
and 72 °C for 30 s/kb followed by a 5-min final extension step on a thermocycler 
Veriti® Thermal Cycler (AppliedBiosystems). Reactions were then analysed on agarose 
gels. More specifically, to avoid non-specific amplifications a touchdown PCR was 
used for the amplification of SMIM1 gene: 95 °C for 3 min, then 15 cycles of 95 °C for 
30 s, 70 °C for 1 min Touchdown 1 degree/cycle and 72 °C for 30 s followed by 25 
cycles of 95 °C for 30 s, 55 °C for 1 min and 72 °C for 30 s and final extension step of 
72 °C for 5 min. To screen bacterial colonies, individual colonies were picked and 
placed in 100 μl miliQ water. PCR was carried out as above with ~5 μl colony 
suspension. The remaining ~95 μl from the positive colonies were used to inoculate 
liquid culture. 
2.3.5.5  Purification and gel extraction of DNA 
As required, DNA was purified by selective binding to a silica membrane using 
QIAGEN QIAquick PCR Purification Kit® (Qiagen, 28104) or QIAquick Gel 
Extraction Kit® (Qiagen, 28704), according to the manufacturer’s instructions. 
Resolved DNA bands were visualised through an orange filter under 470-nm light in a 
transilluminator. DNA bands were excised and agarose melted at 50 °C according to the 
manufacturer’s instructions. 
2.3.5.6  Agarose gel electrophoresis 
Nucleic acids were mixed with loading buffer (NEB, B7024S), resolved on 1% or 1.5% 
agarose in 1X Tris-Borate-EDTA (TBE) buffer and supplemented with SYBR® Safe 
DNA Gel Stain (Life Technologies, S33102). GeneRuler 1 kb DNA ladder (Life 
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Technologies, SM0312) was used. Typically, gels were run at 90 V in 1X TBE. Nucleic 
acid was visualised with trans-UV light and photographed. 
2.3.5.7  Determining the concentration of nucleic acid and sequencing 
Nucleic acid concentration was determined by its A260 with an ND-1000 
spectrophotometer (NanoDrop Technologies, Inc.). An extinction coefficient of 50 was 
used for double strand DNA. Purity was determined by the profile of the sample on an 
agarose gel and/or the A230:260:280. Sanger sequencing with appropriate primers was done 
by Source Bioscience service. Sequence files were blasted in the NCBI tool 
(www.blast.ncbi.nlm.nih.gov/) and were aligned with the multiple alignment server 
clustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/) or the SNAPgene software using 
human genome GRCh37 as the reference genome.  
 
2.4 Solutions and primers 
2.4.1  Solutions 
Solutions were autoclaved or filtered with a 0.22 μM PES corning filter as required. 
Solutions were stored at RT or 4 °C (*) (Table 2.9). 
 
Table 2.9 - List of solutions. 
Name Composition 
MEF Medium* DMEM (Invitrogen, 11965118), 10% v/v FBS (Hyclone, SH30070.01), 2 mM L-Glutamine (Invitrogen, 25030156) 
AE6 * 
DMEM/F12 (Invitrogen, 11330057), 2X Insulin–Transferrin-Selenium (Invitrogen 41400-
045), 0.054% NaHCO3, 7.5% (Life technologies, 25080-094), 320 μg/ml L-Ascorbic acid 2-
phosphate sesquimagnesium salt hydrate (Sigma-Aldrich, A8960-5G) 
AE8 * AE6, 5 μg/ml bFGF2 (Cambridge Stem Cell Institute, Tissue culture facilities), 10 μg/ml hActivin A (Cambridge Stem Cell Institute, Tissue culture facilities) 
Wash Medium* Advanced DMEM/F12 (Life Techonologies) 
Freezing Medium* 90% v/v KOSR (Invitrogen, 10828028), 10% v/v  dimethyl sulfoxide (DMSO, Sigma-Aldrich, D-2650) 
HBS* 150 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium sulphate, 10 mM HEPES, pH 7.4 – all from Sigma-Aldrich. 
Tyrode’s buffer* 
134 mM sodium chloride, 2.9 mM potassium chloride, 0.34 mM sodium phosphate dibasic, 12 
mM sodium bicarbonate, 20 mM HEPES, 1mM magnesium chloride and 5 mM glucose 
(VWR), pH 7.3 – all the other from Sigma-Aldrich 
ACD* 111mM glucose (VWR), 71mM citric acid, 116mM sodiumcitrate (Sigma-Aldrich) 
0.2 % formyl saline 0.2% formaldehyde, 0.85% sodium chloride (Sigma-Aldrich) 
TBE 1x 89 mM Tris base, 89 mM boric acid 2 mM EDTA 
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2.4.2 Primers 
Purified primers (Sigma-Aldrich) were resuspended to 100-μM stock concentrations 
and stored at -20 °C. Typically, 10 μM primers were used per reaction (Table 2.10). 
 
Table 2.10 -Primers used in this study. 
Primer name Fwd/rev Sequence (5' - 3') Target/used for 
SMX1F2 fwd CCCTTAGTGCCCCTCTCCTA  SMIM1 exon 3 - PCR/Sequencing 
SMIM1_4b-R rev GTGTGCCCAGCTGTTTGTAGGT SMIM1 exon 4 - PCR/Sequencing 
SMX1R1 _3d-R rev GTTTGCTGAGCTGCTGGAC SMIM1 exon 3 - PCR/Sequencing 
SMIM1_CR_1_Bottom fwd AAACAGGAGAGCCACGTCCACTATC Guide seq. +BbsI 
SMIM1_CR_1_Bottom rev CACCGATAGTGGACGTGGCTCTCCT Guide seq. +BbsI 
SMIM1_CR_2_Top fwd CACCGCAGGGACGGAGTCAGCCTAG Guide seq. +BbsI 
SMIM1_CR_2_Top rev AAACCTAGGCTGACTCCGTCCCTGC Guide seq. +BbsI 
SMIM1_CR_3_Bottom fwd AAACCTATAGTAGGTGGGAGGACGC Guide seq. +BbsI 
SMIM1_CR_3_Bottom rev CACCGCGTCCTCCCACCTACTATAG Guide seq. +BbsI 
SMIM1_CR_4_Top fwd CACCGGCAGGGACGGAGTCAGCCTA Guide seq. +BbsI 
SMIM1_CR_4_Top rev AAACTAGGCTGACTCCGTCCCTGCC Guide seq. +BbsI 
SMIM1_CR_5_Bottom fwd AAACCGTCCACTATAGTAGGTGGGC Guide seq. +BbsI 
SMIM1_CR_5_Bottom rev CACCGCCCACCTACTATAGTGGACG Guide seq. +BbsI 
U6-Forward fwd GAGGGCCTATTTCCCATGATTCC Sequencing PX462 
hGATA4 -Rev rev ATTGTGGATGAATACTGCC Sequencing PX462 
TAP_Fwd  fwd GGATATCATATGCCCGGGCAAGGATCCATGGAGAAGAGGCGGTGGAAG Sequencing pWPI  
pEF1a_Fwd fwd ATTTGCCCTTTTTGAGTTTGG  Sequencing pWPI 
T7 fwd TAATACGACTCACTATAGGG PCR/Sequencing 
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2.5 Statistics 
Data are presented as mean ± standard deviation (SD). Statistical analysis was 
performed using GraphPad Prism 7 scientific, R (version: 3.4.4, packages: carData and 
caTools). Data normality was tested using D'Agostino & Pearson and/or Shapiro-Wilk 
test and/or diagnostic Q-Q plots as required. For data following normal distribution, 
one-way ANOVA with Tukey's HSD test was used to compare the differences between 
three experimental groups. Studies with two experimental groups were evaluated using 
unpaired two-way Student's t-test. Non-normal distributed data were analysed by non-
parametic tests: Kruskal-Wallis with Dunn’s multiple comparison test, when comparing 
three groups and Mann-Whitney, when comparing two groups. When required 
multivariable analysis was performed using additive models. Statistical analysis of 
unbalanced additive models was performed using Anova type II. Results were 
considered statistically significant if P-value < 0.05. 
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CHAPTER 3 | MOLECULAR 
CHARACTERISATION OF SMIM1 
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3.1 Introduction 
SMIM1 is a small transmembrane protein of unknown function that was identified as 
the gene encoding the Vel antigen, a universal antigen on the surface of RBCs [182, 
186, 188]. The SMIM1 protein is formed by 78 amino acids, has a theoretical molecular 
weight of 8,7 kDa (Figure 3.1) and its preliminary characterisation has been performed 
in human RBC cell membrane and erythroid cell lines by genetic, proteomic and 
biochemistry studies.  
 
Proteomic and biochemistry studies suggested that SMIM1 is a type II membrane 
protein, in which the transmembrane domain functions as a non-cleavable signal peptide 
and is located towards the C-terminus [182, 208]. The N-terminus of SMIM1 was 
initially predicted to reside in the extracellular domain [188]. However, recent 
biochemical studies described by Arnaud et al. have shown that the predicted SMIM1 
C-terminal (67 to 76 amino acid) is the extracellular domain that forms the Vel antigen 
(Figure 3.1) [182, 188, 208]. Flow cytometry analysis of erythroleukemia cells 
expressing N-or C-terminally Flag-tagged SMIM1, as well as a C-terminal mutant of 
SMIM1 protein and a KELVEL chimera confirmed that the C-terminus was crucial for 
Vel-antigen exposure [208]. Moreover, proteomic and biochemistry studies showed that 
SMIM1 N-terminal undergoes post-translational modifications. Acetylation and 
phosphorylation of different residues in the N-terminal of SMIM1 were also identified 
(Figure 3.1) [208-211]. However, studies performed with the KELVEL chimera and 
with different N-terminal SMIM1 mutants suggested that the SMIM1 N-terminal is not 
crucial for Vel-antigen exposure [208]. 
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Figure 3.1 – Schematic representation of SMIM1 at mRNA and protein level. The 
four exons by which it is composed are represented by orange boxes and the coding 
region is delineated by dash lines. SMIM1 protein sequence with underline of 1) three-
cysteine residues potentially involved in complex formation; 2) serine, tyrosine and 
threonine residues subjected to phosphorylation; and 3) methionine subject to 
acetylation. Serine and methionine highlighted in blue and purple respectively, 
represents the amino acids where the 17-bp frameshift deletion (blue) and the missense 
mutation (purple) responsible for the Vel-negative and Vel-weak phenotype occur. 
Representation of protein structure displaying transmembrane domain and GXXXG 
motif at amino acid position 67 to 71 (predicted to mediate the transmembrane 
dimerization) (Adapted from [188]). 
 
Despite disagreement on SMIM1 molecular weight and membrane orientation among 
the literature, its ability to form oligomers is well established [182, 188, 208, 212]. In 
the literature, it has been suggested that SMIM1 has the ability to form oxidation-
dependent molecular complexes (homodimers or others) through the three cysteine 
residues present in SMIM1 (Cys35 and Cys43 in the N-terminal half, and Cys77 in the 
C-terminal) [182, 188, 208]. Furthermore, it has been also suggested that oxidation-
independent dimerization might be mediated by the GxxxG motif in the transmembrane 
domain via helix-helix association [188]. 
 
Different multiprotein complexes have been identified in the RBC membrane, such as 
the Band 3 complex and the Rh complex. These multiprotein complexes are 
functionally regulated by a hierarchy of protein expression dependencies [213]. Since 
SMIM1 is a membrane protein, Haer-Wigman et al. investigated if Vel/SMIM1 
expression on RBC membrane was dependent on the expression of other important 
RBC membrane proteins and vice-versa [187]. However, analysis of SMIM1 expression 
level on RBCs of individuals lacking different blood group systems and analysis of 
different important RBC membrane proteins in Vel-negative, weak and positive 
individuals, revealed that SMIM1 expression level on RBCs is not dependent and does 
not affect the expression levels of the RBC membrane proteins tested so far [187]. 
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As mentioned above, SMIM1 was first described as a protein on RBC membrane, 
therefore, the biochemical characterisation of SMIM1 performed so far was done in 
RBC cell membrane or in erythroid cell line models. Nevertheless, RNA-sequencing of 
human blood cell progenitors and precursors showed that SMIM1 transcripts are highly 
expressed in other blood cell types: MEP and MK [186]. However, SMIM1 is also 
expressed in non-haematopoietic tissues as shown in Figure 3.2 [188]. Testis, atrial 
appendage of heart and pituitary are the human tissues with highest expression levels 
when examining the data present in GTEx portal (https://gtexportal.org/home/). SMIM1 




Figure 3.2 – SMIM1 expression in different human tissues. Representation of Log10 
TPM- transcripts per kilobase million of SMIM1 across different human tissues. This 
data/figure was obtained from https://gtexportal.org/home/.on 2018.10.25.  
 
3.2 Chapter aims and overview  
In this chapter I had two aims: i) to characterise SMIM1 gene expression in the 
haematopoietic lineages and ii) further investigate SMIM1 protein subcellular 
localisation in other blood cells expressing SMIM1.  
 
First, I have described SMIM1 expression throughout the haematopoietic lineages and 
showed that SMIM1 is specifically expressed in naïve, memory and class-switched B-
lymphocytes, neutrophils, EB, MKs and platelets by RNA-sequencing analysis and 
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western blot. Using flow cytometry and immunofluorescence microscopy, I have further 
shown that SMIM1 subcellular localisation in the white blood cell (WBC), RBC, MKs 
and platelets seems to differ.  
 
3.3 Results 
3.3.1 SMIM1 is expressed in different cell-types 
Using RNA-sequencing data of primary human blood precursor and progenitor cells 
obtained as part of the Blueprint project [197], I investigated SMIM1 expression level 
across the haematopoietic system. Firstly, I have observed that human SMIM1 is 
expressed at a low level throughout the haematopoietic tree (Figure 3.3). An increase of 
SMIM1 expression level was observed towards the myeloid branch. Additionally, 
analysis of expression patterns of SMIM1 and other genes encoding membrane proteins 
that are important for MK/platelet (glycoprotein IV - GP6 and Integrin subunit alpha 2b 
- ITGA2B (CD41b) [214]) and EBs/RBC (glycoprotein A, GYPA [215]) biological 
functions, suggested the relevance of SMIM1 in MK and EB specification and therefore 
possibly in the biological function of these cells (Figure 3.3). 
  
 




Figure 3.3 – Overview of SMIM1 expression in haematological lineages. Expression 
of SMIM1 (dark green), ITGA2B (light blue), GP6(dark blue), and GYPA (light green) 
transcripts in the haematological lineage using RNA-sequencing data from the Blueprint 
project [197]. SMIM1 is expressed throughout blood lineages but is highly expressed in 
myeloid lineage, specifically in MEP, as well as in EBs. Thickness of line represents the 
expression level. HSC- haematopoietic stem cell; MPP- multi-potent progenitor CMP- 
common myeloid progenitor; CLP- common lymphoid progenitor; GMP- granulocyte-
macrophage progenitor; MEP- megakaryocyte-erythroid progenitor; EB- erythroblast 
and MK- megakaryocyte. Data obtained through https://blueprint.haem.cam.ac.uk using 
tools-river plot.  
 
Secondly, I performed a detailed analysis of SMIM1 expression level in the different 
blood cell types. Here, I observed that among other cells, EB, MK and platelets were the 
cells with higher SMIM1 expression (Figure 3.4). SMIM1 expression was also detected 
in naïve, memory and class-switched B-lymphocytes, and neutrophils.   
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Figure 3.4 - SMIM1 expression level in blood cells. Expression levels of SMIM1 
larger transcript in different blood cell types based on RNA-sequencing data from the 
Blueprint project [197]. SMIM1 is expressed in neutrophils, and naïve, memory and 
class-switched B-lymphocytes, but it is highly expressed in erythroblasts, 
megakaryocytes and platelets. Grey dots- biologic replicates for each cell type; Log2 
(Fpkm+1)- fragments per kilobase million; Vb- venous blood; Cb- cord blood; MSC- 
mesenchymal stem cells; BOEC- blood outgrowth endothelial cells; HUVEC- human 
umbilical vein endothelial cells; Plat- platelet; MK- megakaryocyte; EB- erythroblast; 
Neut- neutrophil; Mono- monocytes; M0- macrophage; M1- macrophage M1; CD4+ T-
cell- T helper cell; CM- central memory T cells; EM- effector memory T cell; CD8+ T 
cell- cytotoxic (killer) T cell; CD8 TDEM- terminally differentiated effector memory T 
cell ; T-reg- regulatory T cell; NK-natural killer cell. Data obtained through Blood 
RNAexpress- https://blueprint.haem.cam.ac.uk/mRNA/. 
 
As SMIM1 encodes three transcripts (described in section 1.5.1.1), I then characterised 
the expression of the three different SMIM1 transcripts in the blood cells with higher 
SMIM1 expression (EB, MKs and platelets). The expression of the three SMIM1 
transcripts was detected in EB, MK and platelets (Figure 3.4). However, the larger 
transcript, encoding the 78 amino acid protein, was the most abundant across the three 
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Figure 3.5 - Expression of SMIM1 at mRNA and protein level. A - Heat map of 
expression level (Log2(fpkm+1)) of the three human SMIM1 transcripts in erythroblasts 
(EB), megakaryocytes (MK) and platelets using RNA-sequencing data from Blueprint 
project [197] (heat map made by Dr Luigi Grassi – Research associate in Prof. 
Ouwehand group). Larger transcript, encoding 78 amino acid protein, is the highest 
transcript among the three cell types. Fpkm - fragments per kilobase million. B - 
Western blot in reduced conditions (lysates treated with DTT) of SMIM1 polyclonal 
and b-actin antibodies in MK (29 µg), platelet (increased concentration: 5, 10, 20, 30, 
40 and 50 µg) and RBC lysates (increased concentration 10, 20 and 28 µg). C - Western 
blot in non-reduced conditions (lysates not treated with DTT) of SMIM1 polyclonal, 
GAPDH and b-actin antibodies in MK (29 µg), platelet (increased concentration: 5, 10, 
20, 30, 40 and 50 µg) and RBC lysates (increased concentration 10, 20 and 28 µg). In 
non-reduced conditions SMIM1 monomer is present in platelets and MKs but not in 
RBCs. Multimers are present across cell types. 
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SMIM1 protein expression was characterised by western blot. RBC, MK and platelet 
lysates from Vel-positive blood donors were resolved by SDS-PAGE followed by 
blotting in a membrane and incubation with polyclonal anti-SMIM1 antibody. MKs 
were obtained through in vitro differentiation of CD34-positive cells towards MKs. 
Platelet and RBC protein lysates were loaded in increasing concentrations, while MK 
lysate was loaded only at maximum protein concentration obtained. In agreement with 
SMIM1 expression results, SMIM1 protein was detected in RBCs, MKs and platelets 
(Figure 3.5 - B-C). Under reducing conditions, a band of approximately 14 kDa was 
identified in the three cell types. This 14 kDa band corresponds to the monomer form of 
SMIM1 protein, which presents a higher molecular weight than its theoretical molecular 
weight. RBCs also presented a less abundant band of approximately 25 kDa (Figure 3.5 
- B). Interestingly, under non-reducing-conditions distinct forms and distribution of 
SMIM1 between the three cell types was observed, suggesting formation of cell-specific 
protein complexes. In the platelet lysate, as seen under reducing conditions, a faint band 
at approximately 14 kDa was detected (Figure 3.5 - C). Additionally, higher molecular 
weight and more intense bands were observed between the 18 and 26 kDa range, which 
possibly correspond to post-translational modifications of the monomer, homodimers or 
other protein complexes. Several bands with different intensities between 25 kDa and 
48 kDa, were detected in RBCs. On the other hand, intense bands at approximately 18 
kDa, 26 kDa and 65 kDa were detected in MKs, suggesting the presence of similar 
molecular complexes found in platelets and RBCs, and a MK-specific molecular 
complex. Also, two other faint bands at approximately 30 and 35 kDa were detected in 
MKs (Figure 3.5 - C). The pattern of RBC western blot detected in both reducing and 
non-reducing conditions resembles the pattern described in previous studies, though 
with subtle differences in molecular weights. In summary, SMIM1 disulfide-bond-
dependent complexes were detected in RBCs, MKs and platelets. However, these 
complexes seem to be different in the three cell types. 
 
3.3.2 SMIM1 localisation is cell-type dependent 
SMIM1 subcellular localisation in RBCs is well established [188, 208, 212]. However, 
its subcellular localisation in other blood SMIM1-expressing cells has not been 
characterised so far. Because SMIM1 has been described as a membrane protein, I 
started to investigate SMIM1 membrane exposure in platelets and WBCs by flow 
cytometry. As expected, whole blood of Vel-positive donors and of wildtype mice 
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incubated with the human monoclonal anti-SMIM1 antibody (that recognises the C-
terminal of SMIM1 – SpG213Dc human mAb [212]) revealed SMIM1 exposure on 
RBC membrane (Figure 3.6 – A-B). SMIM1 membrane expression was also detected in 
WBCs, in both human and mice. To further explore which WBCs were expressing 
SMIM1, different WBC purification strategies and WBC markers were used. However, 
due to a high unspecific binding of the secondary antibody on purified WBCs, I was 
unable to obtain a conclusive result (data not shown). Interestingly, SMIM1 was not 
detected on the platelet’s membrane by flow cytometry (Figure 3.6), suggesting that 
SMIM1 does not migrate to the plasma membrane in these cells or that the epitope is 
not recognized due to allosteric constraints. 
  
Figure 3.6 (A) - Localisation of SMIM1 in whole blood. Representative flow 
cytometry dot plot for forward and side scatter and histograms of SMIM1 expression for 
red blood cells (RBCs), platelets and white blood cells (WBCs), against secondary 
FITC (negative control – dotted histograms) in human whole blood.  
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Figure 3.6 (B) - Localisation of SMIM1 in whole blood. Representative flow 
cytometry dot plot for forward and side scatter and histograms of SMIM1 expression for 
red blood cells (RBCs), platelets and white blood cells (WBCs), against secondary 
FITC (negative control – dotted histograms) in mouse whole blood.  
 
Given that SMIM1 was not detected on the platelet’s membrane, I then investigated 
SMIM1 exposure in platelet precursor cells by flow cytometry and immunofluorescence 
microscopy. Flow cytometry analysis of MKs derived from CD34-positive cells stained 
with the human monoclonal anti-SMIM1 antibody (SpG213Dc human mAb – that 
recognises the C-terminal of SMIM1) shown that, as in platelets, SMIM1 is not detected 
on MKs surface (Figure 3.7 - A). Immunofluorescence microscopy of MKs stained with 
the polyclonal anti-SMIM1 antibody (that recognises the N-terminal of SMIM1 - 
Sigma), revealed that SMIM1 is broadly expressed in MK cytoplasm and forms some 
cytoplasmic accumulations near to the nucleus (Figure 3.7 - B). To further investigate 
SMIM1 cytoplasmic accumulations and localisation in MKs, I performed co-
localization studies of SMIM1 with α-granule´s proteins (THBS1) and d-
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granules/lysosomes (LAMP-3, LAMP-2) and Golgi protein (58K-Golgi). 
Immunofluorescence microscopy of these co-localisation studies indicated that SMIM1 




Figure 3.7 (A) – Characterisation of SMIM1 subcellular localisation in MKs 
derived from CD34+ cells. Flow cytometry analysis of day 10 MKs. MKs were gated 
according to cell size and granularity using forward and side scatter. 68 % of the MKs 
were double positive for maturation markers, CD41 conjugated with APC and CD42 
conjugated with PE. SMIM1 expression was assessed in mature MKs using a human 
monoclonal anti-SMIM1 antibody that recognises the C-terminal of SMIM1. Overlay 
plot of the control sample (mature MKs stained with secondary anti-FITC antibody) and 
test sample (mature MKs stained with anti-SMIM1 and secondary anti-FITC) showed 
that SMIM1 expression was not detected on MKs membrane.  
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Figure 3.7 (B) – Characterisation of SMIM1 subcellular localisation in MKs 
derived from CD34+ cells. Immunofluorescence microscopy of cytospin MKs stained 
with the polyclonal anti-SMIM1 and secondary A488 antibody (green), β-actin and 
secondary A633 antibody (red) and Hoechst 33342 (DNA staining, blue), showing 
cytoplasmic expression of SMIM1. First panel – wide-field fluorescence microscopy; 
second panel - confocal microscopy. Scale bar – 50 μm.  
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Figure 3.7 (C) – Characterisation of SMIM1 subcellular localisation in MKs 
derived from CD34+ cells. Immunofluorescence microscopy of cytospin MKs co-
stained with polyclonal anti-SMIM1-A488 (green) and THBS1-A633 (red); polyclonal 
anti-SMIM1-A488 (green) and LAMP 2-A633 (red); polyclonal anti-SMIM1-A488 
(green) and LAMP3-PECy5 (red); and polyclonal anti-SMIM1-A488 (green) and 58K-
A633 (red). Scale bar – 100 μm. 
 
Platelets are formed through the extension of cytoplasmic protrusions in mature MKs, 
called proplatelets, into the bone marrow sinusoids [75]. During proplatelet 
development, several crucial structural alterations occur, including packing of granules 
and organelles on the distal end of the proplatelet. These structural rearrangements 
provide the newly-formed platelet with all the components necessary for its biological 
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function [75]. Possible alteration of SMIM1’s localisation upon proplatelet formation 
was examined by immunofluorescence microscopy of MKs seeded onto fibrinogen for 
48 hours to induce proplatelet formation. Although previous studies have shown that 
fibrinogen is one of the strongest proplatelet inducers, regulating proplatelet formation 
and release in vitro [101], I was unable to induce a strong proplatelet formation of 
CD34 derived MKs. The reduced proplatelet formation observed probably results from 
the concentration of fibrinogen used. Nevertheless, confocal analysis of fixed 
fibrinogen-induced proplatelets, shown that SMIM1 is located in the cytoplasm (Figure 
3.8- white arrows) and was also detected in the distal end of the proplatelet, suggesting 
its migration towards that region. However, due to poor proplatelet induction, this 
observation may not be representative and additional experiments should be performed 
to confirm this observation.  
 
 
Figure 3.8 – Confocal analysis of SMIM1 localisation in proplatelets. Fibrinogen-
induced proplatelets stained with polyclonal anti-SMIM1 and secondary A488 antibody 
(green), β-actin and secondary A633 antibody (red) and Hoechst 33342 (DNA staining, 
blue). Scale bar – 50 μm. 
 
I further investigated the localisation of SMIM1 in platelets by subcellular fractionation 
of human platelets in a sucrose gradient. Subcellular fractionation studies attempting to 
correlate the localisation of different proteins with specific organelles have been 
reported in the literature and although this is not the most precise methodology to access 
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protein localisation, may provide important insights in protein localisation. Here using a 
membrane of subcellular fractionation of human platelets performed by Louisa Mayer – 
PhD student in Prof. Ouwehand group, I showed that the first fractions (Figure 3.9, 
fractions 1 to 5) were enriched for cytoskeleton proteins such as α-tubulin, β-actin and 
cytokine receptor-like factor 3 (CRLF3), and for the platelet plasma membrane protein, 
glycoprotein Iba (CD42b – larger form of approximately 200kDa). Proteins present in 
α-granules, such as THBS1 and CD42b (short form of approximately 130 kDa – present 
on the alpha granule membrane) were enriched in fractions 7 and 8 (Figure 3.9). 
Interestingly, SMIM1 co-localised in the fractions enriched for α-granule´s proteins, 
suggesting that SMIM1 has an intracellular distribution similar to these proteins. 
 
Figure 3.9 - Localization of SMIM1 in platelets. SDS-PAGE separated fractions 1 to 
12 of human platelet fractionation by sucrose gradient centrifugation (performed by 
Louisa Mayer). Western blot of SMIM1 (polyclonal antibody that recognises the N-
terminal) and other specific antibodies: CD42a, THBS1, tubulin, CRLF3, actin, 
GAPDH. SMIM1 is expressed in fractions 7 and 8 of platelet fractionation, like CD42b 
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3.4 Discussion 
In this chapter, I have characterised SMIM1 expression throughout the haematopoietic 
lineage and showed that SMIM1 gene is expressed in naïve, memory and class-switched 
B-lymphocytes, neutrophils, RBCs, MKs and platelets. Moreover, I have demonstrated 
that SMIM1 protein subcellular localisation and form is cell-type dependent. RBCs and 
WBCs express SMIM1 on the membrane, whereas platelets and MKs seem to express 
SMIM1 only in the cytoplasm. RBCs, MKs and platelets present different molecular 
complexes of SMIM1. Altogether, these findings may indicate that SMIM1 function is 
cell-type dependent. 
 
Previous studies were mainly focused in SMIM1 characterisation on RBCs, where the 
protein was originally identified. However, with the public availability of gene 
expression data of different cells and tissues, it is now known that SMIM1 is not only 
expressed in different blood cell types, but also in non-haematopoietic tissues.  
 
In this chapter, I have shown for the first time that SMIM1 is expressed in WBC cell 
types, more specifically in naïve, memory and class-switched B-lymphocytes and 
neutrophils. Analysis of WBCs according to cell size and granularity (forward and side 
scatter) by flow cytometry of whole blood incubated with SMIM1 antibody, suggested 
that neutrophils and B- lymphocytes, like RBCs, express SMIM1 on the plasma 
membrane. Storry et al. previously suggested that SMIM1 is not expressed at the 
protein level in non-erythroid bone marrow sorted cells, including neutrophils and B-
lymphocytes [188]. The discrepancy of our and Storry et al. findings may be explained 
by the fact that SMIM1 is expressed at low level in these cells and consequently its 
detection in the presence of high abundance proteins is more challenging. Low level of 
loaded protein extract, accordingly to the faint bands detected in the loading control, as 
well as the low detection of SMIM1 in CD235a-positive cells (marker expressed by 
erythroid precursors and erythrocytes) in the western blot present in Storry et al. 
suggests that SMIM1 expression was below the detection threshold [188].  
 
Striking differences in SMIM1 expression throughout the haematopoietic lineage, with 
an increase in expression towards myeloid lineage (MEP, EB and MKs), may suggest a 
possible role of SMIM1 in EB and MK specification. MEP specification is highly 
regulated at the transcriptional level through a fine balance between two key 
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transcription factors, GATA1 and PU.1. Interestingly, SMIM1 expression is also 
regulated by GATA1 [190]. On the other hand, high levels of SMIM1 expression 
observed in both EB and MKs, may also suggest a possible role of SMIM1 in 
erythropoiesis and megakaryopoiesis respectively. These observations were previously 
described by Cvejic et al. and the former hypothesis was investigated in the same study 
using zebrafish as the animal model [186]. This hypothesis and the previous studies are 
further explored in Chapters 4 and 5. 
 
It has been reported that SMIM1 forms detected in RBCs are related to either post-
translational modifications, disulfide-independent complexes and disulfide-dependent 
complexes [182, 188, 208]. In this chapter, I showed for the first time that SMIM1 is 
expressed at the protein level in MKs and platelets and that SMIM1 in these cells also 
form disulfide-dependent complexes (Figure 3.5 – B-C). Under reducing conditions, all 
the bands detected in platelets and MKs collapse into a single band of approximately 14 
kDa, corresponding to the monomeric form of the protein. Analysis under non-reducing 
conditions suggest that SMIM1 can form homodimers and other multimers in RBCs, 
MKs and platelets. Contrary to RBCs, the monomer form of SMIM1 is also detected 
under non-reducing conditions in MKs and platelets. Moreover, the presence and 
abundance of different bands in the three cell types suggests that SMIM1 undergoes 
different modifications and different protein-complexes are formed in RBCs, MKs and 
platelets. As reported in different studies, I also observed that SMIM1 does not migrate 
at its theoretical molecular weight. Observed differences in molecular weight could be 
explained by the hydrophobic nature of SMIM1 transmembrane domain (Figure 3.5 – 
B-C), since hydrophobic transmembrane domains have reduced affinity to SDS 
molecules, the complete denaturation of proteins with transmembrane domains is 
impaired and therefore the migration of membrane proteins often deviate from their 
theoretical molecular weight [216]. Moreover, it has been shown that SMIM1 is 
subjected to post-translation modifications, such as acetylation and phosphorylation. 
The four phosphorylation sites identified in SMIM1 N-terminal (Ser6, Ser17, Ser22 and 
Ser27), rather than the predicted O-glycosylation site, seem to contribute for the 
observed difference in molecular weight [182, 188, 208, 212]. Additionally, the 
conditions (gel type and running buffer) used in the SDS-PAGE may contribute to 
different migration patterns observed in the different studies. 
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Considering the small size of SMIM1 together with its ability to form different 
complexes detected by western blot, I hypothesise that SMIM1 interacts with different 
proteins in RBCs and MKs/platelets, which in turn are specific and important for 
SMIM1 function in those cells. To date, the investigation performed in RBCs was 
unable to identify the possible partners of SMIM1. Haer-Wigman et al. showed that 
SMIM1 membrane exposure was not affected in RBCs lacking membrane proteins that 
are part of different blood group systems (e.g. Rh, Kell, RHAH and others). Moreover, 
they also showed that Vel-negativity did not impair exposure of other important 
membrane proteins (such as GPA, GPB, CD71 and others) [187]. Arnaud et al. also 
observed that the N-terminal of SMIM1, which is subject to post-translational 
modifications (acetylation and phosphorylation), is not required for SMIM1 membrane 
exposure [208]. Although SMIM1 exposure is not affected and does not impair 
expression of these membrane proteins, one cannot exclude that SMIM1 presence is 
important for the biological function of those complexes or that SMIM1 is part of a 
different complex that has not yet been identified. The identification of SMIM1 
interactors will be important in order to dissect SMIM1 function. SMIM1 interactors 
will be probably cell-type specific, and therefore this investigation should be performed 
for each cell type.  
 
Interestingly, exposure of SMIM1 on MK and platelet membrane was not detected by 
flow cytometry. Using immunofluorescence microscopy, I was able to detect SMIM1 in 
MK cytoplasm, as well as the presence of some accumulations, suggesting a possible 
interaction of SMIM1 with an organelle or structure present in MK’s cytoplasm. On the 
other hand, using human platelet fractionation, I have shown that SMIM1 in platelets 
has an intracellular distribution similar to α-granule´s proteins. While these findings 
have shed new light on SMIM1 localisation in MKs and platelets, an obvious drawback 
of the investigation I described in this chapter is the inability to identify the precise 
localisation of SMIM1 in platelets. Co-localization studies in platelets using 
immunofluorescence microscopy are quite challenging due to the small size of platelets. 
Therefore, an alternative experiment to overcome this problem and determine the 
precise localisation of SMIM1 in platelets would be the analysis of immunogold 
labelled platelets with SMIM1 antibody by transmission electron microscopy.  
 
Altogether, these findings suggest that SMIM1 may be important for platelet function 
and raises new questions regarding whether Vel-negative individuals present a not yet 
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recognised haematological feature and/or disease. This hypothesis is further investigated 
in Chapters 4 and 5. On the other hand, the fact that SMIM1 is not detected on the 
platelet’s membrane indicates that SMIM1 expression in platelets will not be clinically 
relevant for platelet transfusion medicine, contrary to what occurs with RBCs.  
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CHAPTER 4 | INVESTIGATION OF 
THE EFFECTS OF SMIM1 KNOCKOUT 
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4.1 Introduction 
The Vel-negative blood group is rare but clinically relevant, as individuals with this 
blood type are at risk of haemolytic transfusion reactions and rarely of haemolytic 
disease of newborns. No other clinical phenotypes have been ascribed to the absence of 
the Vel antigen, or its gene, SMIM1. However, the SMIM1 coding sequence is highly 
conserved among vertebrate [186, 188] and the gene is highly expressed in multiple 
blood cells and non-haematopoietic tissues, as shown in the previous chapter. This 
suggests that SMIM1 may have additional, yet undiscovered, importance.  
 
In the existing literature, there are only a few studies aimed at the characterisation of 
SMIM1 biological role, these have shown strong evidence indicating that SMIM1 has 
an effect on RBC formation. Meta-analysis of a genome-wide association study of six 
RBC parameters in approximately 72,000 individuals (62,553 people of European 
ancestry and 9,308 people of South Asian ancestry) showed that the major allele of the 
common variant rs1175550, responsible for decreased of Vel/SMIM1 expression [186], 
is also associated with decreased mean haemoglobin concentration in RBCs (MCHC, p 
=8.6 x 10-15) [217]. At the time of this meta-analysis SMIM1 had not been annotated 
and consequently CCDC27 and LRRC48, located nearby in the genome, were proposed 
candidate genes [217]. Further statistical analysis of this study showed that rs1175550 is 
also associated with a decrease in related parameters: RBC count (RBC, p=0.005), 
haemoglobin concentration (HGB, p=0.001) and mean RBC volume (MCV, p=4.5 x 10-
6) [186]. A subsequent genome-wide association analysis of 36 blood parameters in 
173,480 individuals of European ancestry in two large studies (UK Biobank and 
INTERVAL), showed that the major allele of rs1175550 is associated with the decrease 
of both mature and immature RBC parameters (RBC count, MCHC, reticulocyte count 
and percentage, immature reticulocyte fraction, and high light scatter reticulocyte count 
and percentage) [196]. This study also revealed that the 17-bp deletion responsible for 
the Vel-negative phenotype (homozygous and heterozygous individuals – rs566629828, 
MAF=0.014), is positively associated with red blood cell distribution width (RDW) 
[196]. The evolutionary importance of smim1 is supported by studies of morpholino 
knockdown in zebrafish, that show a reduction in RBC formation [186]. Interestingly, 
knockdown of smim1 in CD41-transgenic zebrafish led to a reduction of thrombocyte 
formation (equivalent to platelets in humans), suggesting for the first time that SMIM1 
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also regulates megakaryopoiesis, and by inference, may have a role in human platelet 
formation (unpublished data; Prof. Ouwehand’s group).  
 
Quantitative and qualitative alterations in blood cells traits are critical indicators of 
change in physiological processes such as differentiation and maturation and/or cell 
function. Quantitative alterations of blood parameters occur due to altered production, 
clearance or cell redistribution [218]. These variations can be mild, and within accepted 
‘normal ranges’, nevertheless, they are representative of physiological differences. 
More extreme alterations in blood parameters indicate underlying pathologies such as: 
anaemia, polycythaemia, disorders of thrombosis and haemostasis, immunodeficiencies 
and cancer (e.g. leukaemia and lymphoma). These variations can also be associated with 
predisposition to different conditions such as metabolic and cardiovascular diseases 
[196, 219-221]. 
 
The alteration in RBC parameters associated with SMIM1 variants suggests that SMIM1 
affects erythropoiesis, although even in homozygous Vel-negative humans no overt 
pathology has been detected. However, the rarity of Vel-negative individuals may have 
limited the ability of these studies to identify phenotypic alterations. Further 
investigation is required to examine the mechanisms by which SMIM1 influences RBC 
physiology, and whether platelet number or function are influenced in humans, as in 
zebrafish. Furthermore, the role of SMIM1 in non-haematopoietic tissues is entirely 
unknown.  
 
4.2 Chapter aims and overview 
In this chapter I had two main aims:  
i) To examine the effect of SMIM1 absence on anthropometric parameters and tissue 
morphology;  
ii) To investigate the role of SMIM1 in the different blood lineages by assessing 
qualitative and quantitative haematological traits in a:  
a. Cohort of Vel-negative blood donors – recruited in this study; 
b. Cohort of Vel-negative/weak individuals – that are a subset of European 
ancestry individuals of the 400,000 participants part of the UK Biobank; 
c. Smim1 mutant (heterozygous and homozygous) mouse model.  
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Initially, I investigated the effect of the absence of SMIM1 in other tissues, by 
performing analyses of organ to body weight ratio and tissue histology in Smim1 mutant 
mice. I showed that body weight is affected by SMIM1 ablation as well as spleen and 
liver body weight ratios in a sex-dependent manner. Moreover, histological analysis 
revealed morphologic alterations in the liver of male Smim1 mutant mice. Analysis of 
body mass index (BMI) in male Vel-negative blood donors also indicated that the 
absence of SMIM1 is associated with higher BMI.  
 
Using two human cohorts and a Smim1 mouse model, I then characterised the 
importance of SMIM1 in blood cells morphology and parameters. While blood smear 
examination did not reveal striking abnormalities, the automated full blood count 
analysis showed that SMIM1 plays a small, but significant role, in the biology of 
different blood cell types: RBCs, WBCs and platelets. However, this role seems to be 
sex and model dependent. Using the mouse model, I further characterised SMIM1 role 
in the mechanical properties of RBCs by real-time deformability cytometry (RT-DC). I 
showed that RBCs obtained from Smim1-/- male mice have reduced deformability. 
 
4.3 Results 
It is well established that fundamental differences between male and female influence 
the incidence, course and severity of the majority of common diseases in humans [222]. 
In fact, sexual dimorphism has been described in several haematological traits such as 
HGB levels, where women present mean levels approximately 12% lower than men 
[223]. However, despite the evidence, many studies (mainly when using the mouse 
model) are still designed and analysed without taking sexual dimorphism into account. 
A large study performed in mice, stressed once more the importance of sex 
consideration by showing that approximately 53% of the quantitative traits analysed in 
wildtype mice were influenced by sex, and that sex modified the genotype effect in 
approximately 17.7% of the quantitative data sets analysed [224]. Therefore, the 
analyses of males and females were performed independently. Additionally, when 
possible and appropriate to control for confounders such as age and body weight or 
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4.3.1 Investigation of the effects of SMIM1 absence in BMI and body 
weight 
4.3.1.1 The Vel-negative donor cohort 
27 Vel-negative European ancestry NHSBT blood donors (12 female and 15 male), who 
had participated in a previous study [186], were recruited by Dr Karola Rehnstrom, 
Study Coordinator at Prof. Ouwehand group - University of Cambridge. Sanger 
sequencing of the SMIM1 locus in these individuals showed that 2/27 donors were 
heterozygous for the 17-bp deletion. These Vel-weak donors had been erroneously 
typed as Vel-negative possibly because of an extremely low level of SMIM1 and were 
thereby excluded from further analysis. In-house data from 178 European ancestry 
control blood donors (99 female and 79 male), which were genotyped as described in 
[195], were used as controls.  
 
Male Vel-negative blood donors in this study presented a mean age of 49.7±14.3 years 
and were significantly younger than the control donors (p=0.0276), which had a mean 
age of 58.2±10.3 years (Figure 4.1 – A). Female Vel-negative blood donors had a mean 
age of 54.5±13.4 years, whereas the female control donors showed a mean age of 
58.3±12.2 years (Figure 4.1 – A). 
 
4.3.1.2 SMIM1 absence is associated with higher BMI in male blood donors 
To determine whether the absence of SMIM1 affects BMI, I compared the BMI of Vel-
negative blood donors with that of control donors by using a linear model with age as a 
covariate (Figure 4.1 – B). Male Vel-negative blood donors presented a mean BMI of 
29.5±8.3 Kg/m2, which was significantly higher (p=0.0156) than the mean BMI (26.2±3 
Kg/m2) of male control donors (Figure 4.1 – B). 25% and 42% of the male Vel-negative 
blood donors were classified as overweight (BMI=25.0-29.9 Kg/m2) and obese (BMI ³ 
30 Kg/m2), respectively. While 48% and 11% of the male control donors were classified 
as overweight and obese, respectively. As the prevalence of higher BMI is associated 
with increasing age [225], and the male Vel-negative blood donors were considerably 
younger, the effect of SMIM1 in BMI may become more evident with increasing age. 
Female Vel-negative blood donors had a mean BMI of 27.8±6.6 Kg/m2, while the 
female control donors showed a mean BMI of 26.6±6.2 Kg/m2 (Figure 4.1 – B). 
Although non-significant, a trend towards an increase in BMI was also observed in 
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female Vel-negative blood donors. 18% and 36% of the female Vel-negative blood 
donors and 33% and 21% of the female control donors were classified as overweight 
and obese, respectively. 
 
 
Figure 4.1 – Demographic and anthropometric parameters of blood donors. A - 
Representation of the age range; B - Representation of the body mass index (BMI, 
Kg/m2). Black squares – control donors and red triangles – Vel-negative blood donors. 
Data represent mean ± standard deviation. Age analysis was performed using the Mann 
Whitney test and BMI analysis was performed using a linear model with age as a 
covariant. Only significant differences are represented. 
 
4.3.1.3 The Smim1 mutant mice 
Smim1 mutant mice used in this study were generated by the Wellcome Trust Sanger 
Institute as part of the International Mouse Phenotyping Consortium 
(http://mousephenotype.org/). These mice were created in C57BL/6N genetic 
background using CRISPR/Cas9 technology that specifically disrupted two critical 
exons present in all Smim1 transcripts (Figure 2.1 - Chapter 2). Heterozygous mutant 
mice (Smim1+/-) received from the Wellcome Trust Sanger Institute were used to 
establish a colony of Smim1 mutant mice in the mouse facility at Central Biomedical 
Services – University of Cambridge. No abnormalities in breeding, development or 
behaviour were observed in Smim1 mutant mice, showing that Smim1 is not critical for 
normal mouse development or reproduction. The genotype of all mice used in this study 
was confirmed by two PCR reactions using gDNA extracted from ear notches. The 
PCRs were designed to amplify specifically the wildtype allele (using primer set 1 - P1) 
and the mutant allele (using primer set 2- P2) as represented in Figure 4.2 - A. 
Homozygous mice for the mutant allele did not originate a PCR product when using P1, 
and originated a PCR product smaller than the wildtype when using P2 (Figure 4.2 - B). 
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Heterozygous mice for the mutant allele originated both a PCR product smaller than the 
wildtype and a PCR product similar to the wildtype when using P2 (Figure 4.2 - B). 
Additionally, a band of approximately 900 bp was also observed in the PCR of 
heterozygous mice when using P2. This 900 bp band might be a PCR heteroduplex, 
which results from the amplification of two allelic DNA segments with different 
sequences (wildtype and mutant). Moreover, Vel/SMIM1 expression was confirmed by 
flow cytometry of whole blood incubated with anti-SMIM1 (Figure 4.2 - C). As 
expected, SMIM1 was detected on WBCs and RBCs of wildtype mice but not in 
Smim1-/- mice (Figure 4.2 - C). Since SMIM1 is not exposed on platelet membranes, I 
assessed SMIM1 expression in platelets by RNA-sequencing (Figure 4.2 - D) and 
western blot (Figure 4.2 - E). Platelet RNA-sequencing showed that the deletion of the 
two crucial exons lead to a reduction of Smim1 expression level in Smim1+/- mice and a 
vestigial expression in Smim1-/- mice when compared with wildtype mice. Western blot 
of platelet lysates confirmed the results obtained in the RNA-sequencing. I detected a 
band of approximately 14 kDa in the wildtype lane, a faint band of the same size in the 
Smim1+/- lane (green arrow, Figure 4.2 - E), and as expected no band was detected in 
the platelet extracts of Smim1-/- mice.  
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Figure 4.2 (A,B and C)- Genotyping of Smim1 mutant mice. A - Schematic 
representation of CRISPR and genotyping strategy; B - Agarose gel of PCR products of 
gDNA amplified by PCR using specific primers; C - Representative flow cytometry dot 
plot for forward and side scatter and histograms of SMIM1 expression of wildtype and 
Smim1 -/- mice whole blood incubated with the SpG213Dc human monoclonal anti-
SMIM1 and or secondary FITC, red line histogram represent results for Smim1 -/- mouse 
(KO: SMIM1-FITC). 
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Figure 4.2 (D and E) - Genotyping of Smim1 mutant mice. D – Platelet expression of 
Smim1 in wildtype, Smim1+/- and Smim1 -/- obtained by RNA-sequencing, TPM – 
transcripts per Kilobase million reads; E – Western blot of wildtype, Smim1+/- and 
Smim1 -/- platelets using polyclonal SMIM1 and b-actin antibodies. 
 
4.3.1.4 SMIM1 ablation leads to the alteration of body weight in age and sex-
dependent manner in the mouse model 
As the absence of SMIM1 is associated with an increase of BMI in male Vel-negative 
blood donors, I then investigated whether the ablation of SMIM1 in the mouse model 
would also affect body weight. Terminal body weight of Smim1 mutant and wildtype 
mice was measured at two (nine to ten weeks), four (16 to 18 weeks) and six-seven (24 
to 31 weeks) months of age (Table 4.1 and Figure 4.3), which corresponds to the range 
of ages used in the other types of experiments in this study. Smim1-/- female at two and 
six-seven months old showed increased of body weight when compared with wildtype 
animals (two months old – p=0.0425; six-seven months old – p= 0.0092; Table 4.1 and 
Figure 4.3 – B). This observation is in agreement with the observed trends in female 
Vel-negative blood donors described in section 4.3.1.2. Opposite to what was observed 
in females, two months old Smim1-/- males did not show significant difference in body 
weight and in fact, four months old Smim1-/- male mice presented a significant decrease 
in body weight when compared with wildtype and Smim1+/- male (Smim1-/- vs wildtype 
p=0.049; Smim1-/-vs Smim1+/- p=0.0009; Table 4.1 and Figure 4.3 – A). However, at 
six-seven months old the trend was inverted and Smim1-/- male mice presented a non-
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significant trend of body weight increase, as it is observed in male Vel-negative blood 
donors (Table 4.1, Figure 4.3 – A and Figure 4.1). In summary, SMIM1 seems to affect 
body weight in age and sex-dependent manner in mice. 
 
 
Figure 4.3 – Characterisation of body weight in Smim1 mutant mice. A - Body 
weight of male mice at two, four and six-seven months old. Slopes comparison of 
Wildtype vs Smim1+/- vs Smim1-/-- F=4.12, DFn=2, DFd=114, p=0.0188; slopes 
comparison of Smim1+/- vs Smim1-/-- F=7.12, DFn=1, DFd=73, p=0.0087. B - Body 
weight of female mice at two, four and six-seven months old. Slopes comparison of 
Wildtype vs Smim1+/- vs Smim1-/-- F=8.7, DFn=2, DFd=73, p=0.0004; slopes 
comparison of Wildtype vs Smim1-/-- F=7.48, DFn=1, DFd=58, p=0.0083; slopes 
comparison of Smim1+/- vs Smim1-/-- F=15.11, DFn=1, DFd=45, p=0.0003. Black 
squares – wildtype; blue circle - Smim1+/-; red triangles - Smim1-/-. The analysis was 
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4.3.2 Assessment of the effect of SMIM1 ablation in different organs 
in the mouse model 
As shown in the previous chapter, SMIM1 is highly expressed also in some non-
haematopoietic tissues and/or its role in haematopoietic cells may also indirectly affect 
the function of other organs. To assess the direct and indirect effects of SMIM1 ablation 
in different organs in Smim1 mutant mice, I weighed and morphologically characterised 
the organs that play a direct or indirect role in haematopoiesis: spleen, liver, kidneys, 
heart and bone marrow.  
 
4.3.2.1 Investigation of the effect of SMIM1 ablation in the organ to body weight 
ratio 
To investigate whether ablation of SMIM1 has an effect on the organ to body weight 
ratio, spleen, liver, kidneys and heart of Smim1 mutant and wildtype mice, were 
dissected and weighed after terminal body weight measurement. The analysis was 
performed in two age groups: four and six-seven months old mice. Analysis of organ to 
body weight ratios showed non-significant differences between Smim1-/- and wildtype 
mice of both age groups (Table 4.1 and Figure 4.4).  
 
However, some significant differences in the organ to body weight ratios were observed 
between Smim1+/- and wildtype and/or Smim1 -/-. Specifically, liver to body weight ratio 
of six-seven months old Smim1+/- male mice was significantly decreased when 
compared with wildtype and Smim1 -/- mice (Smim1+/- vs wildtype p=0.0155; Smim1+/- 
vs Smim1-/-p=0.0045; Table 4.1 and Figure 4.4). In females, I observed a significant 
increase of spleen to body weight ratio in six-seven months old Smim1+/- mice when 
compared with wildtype and Smim1 -/- mice (Smim1+/- vs wildtype p=0.0051; Smim1+/- 
vs Smim1-/-p=0.0001; Table 4.1 and Figure 4.4). I also observed a significant decrease 
in the heart to body weight ratio of six-seven months old Smim1-/- female mice when 
compared to Smim1+/- (p=0.0095; Table 4.1 and Figure 4.4). This alteration, however, 
was due to the significant increase of body weight in Smim1-/- female mice (Table 4.1).  
 
In summary, these results indicate that SMIM1 ablation has no striking effect in organ 
to body weight ratios. Whereas, decreased levels of SMIM1 expression observed in 
Smim1+/- mice affects liver and spleen to body weight ratios, in males and females, 
respectively. Furthermore, the effects of SMIM1 ablation (Smim1-/- mice) and SMIM1 
 
88   
knockdown (Smim1+/- mice) on tissue to body weight ratio seem to be opposite. 
Together, this may indicate that SMIM1 levels affect liver and spleen 
characteristics/function, in males and females, respectively.  
 
Table 4.1 – Effect of SMIM1 ablation in body weight and organ to body weight 
ratio in mice. Summary of body weight and organ to body weight ratio measurements 
in different age groups (two, four and six-seven months old). Data represent mean ± 
standard deviation (SD). The analysis was performed using Anova and Tukey’s 






Parameter Mean SD Number Mean SD Number Mean SD Number p-value
Body (g) 22.30 1.56 4 24.20 1.91 3 23.30 3.24 6 ns
Spleen ratio 2.73E-03 1.54E-04 4 2.90E-03 2.23E-04 3 2.88E-03 2.73E-04 5 ns
Age (months)
Parameter Mean SD Number Mean SD Number Mean SD Number p-value
Body (g) 33.32 3.58 13 36.56 4.06 7 30.23 2.50 16 p=0.0490  (WTvsSmim1
-/-) 
p=0.0009 (Smim+/-vsSmim1-/-)
Spleen ratio 2.65E-03 6.25E-04 11 2.22E-03 3.94E-04 4 3.05E-03 5.79E-04 15 p=0.0452 (Smim+/-vsSmim1-/-)
Heart ratio 4.89E-03 6.36E-04 11 3.79E-03 4.83E-04 2 5.02E-03 4.61E-04 13 ns
Liver ratio 5.15E-02 2.33E-03 7 NA NA NA 5.18E-02 5.45E-03 7 ns
Kidneys ratio 1.49E-02 1.31E-03 7 NA NA NA 1.43E-02 7.28E-04 8 ns
Age (months)
Parameter Mean SD Number Mean SD Number Mean SD Number p-value
Body (g) 36.10 4.55 26 35.04 4.43 16 38.90 6.09 24 ns
Spleen ratio 2.83E-03 6.00E-04 26 2.95E-03 9.07E-04 16 2.65E-03 4.98E-04 23 ns
Heart ratio 4.68E-03 6.38E-04 18 4.43E-03 4.34E-04 9 4.38E-03 4.88E-04 15 ns
Liver ratio 5.76E-02 5.24E-03 22 5.12E-02 4.99E-03 13 5.88E-02 8.09E-03 19 p=0.0155 (WTvsSmim1
+/-) 
p=0.0045 (Smim+/-vsSmim1-/-)
Kidneys ratio 1.37E-02 1.10E-03 17 1.34E-02 2.51E-03 9 1.35E-02 1.56E-03 15 ns
Female
Age (months)
Parameter Mean SD Number Mean SD Number Mean SD Number p-value
Body (g) 18.48 0.73 5 19.00 1.71 5 20.27 0.83 7 p=0.0425 (WTvsSmim1-/-) 
Spleen ratio 3.72E-03 4.23E-04 5 3.75E-03 3.74E-04 5 3.43E-03 2.90E-04 7 ns
Age (months)
Parameter Mean SD Number Mean SD Number Mean SD Number p-value
Body (g) 24.29 2.71 10 29.20 3.30 3 25.96 2.69 10 p=0.0354 (WTvsSmim1+/-)
Spleen ratio 3.15E-03 4.58E-04 10 3.15E-03 3.91E-04 2 3.23E-03 3.49E-04 9 ns
Heart ratio 4.99E-03 6.38E-04 9 4.25E-03 2.95E-04 2 4.72E-03 4.82E-04 9 ns
Liver ratio 4.94E-02 3.94E-03 8 5.69E-02 7.32E-03 2 4.85E-02 1.01E-02 7 ns
Kidneys ratio 1.41E-02 1.44E-03 8 1.22E-02 3.04E-04 2 1.16E-02 4.54E-03 7 ns
Age (months)
Parameter Mean SD Number Mean SD Number Mean SD Number p-value
Body (g) 28.53 4.67 15 24.78 2.28 9 35.84 6.10 15 p=0.0092 (WTvsSmim1
-/-) 
p=8.4E-05 (Smim+/-vsSmim1-/-)
Spleen ratio 3.29E-03 4.57E-04 10 3.96E-03 2.69E-04 6 2.99E-03 3.17E-04 10 p=0.0051 (WTvsSmim1
+/-) 
p=0.0001 (Smim+/-vsSmim1-/-)
Heart ratio 4.28E-03 3.63E-04 6 4.93E-03 5.86E-04 6 3.86E-03 6.26E-04 6 p=0.0095 (Smim+/-vsSmim1-/-)
Liver ratio 5.53E-02 4.83E-03 6 5.39E-02 5.96E-03 6 5.03E-02 3.13E-03 6 ns
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Figure 4.4 –Effect of SMIM1 ablation in organ to body weight ratio in mice. Black 
squares – wildtype mice, blue circles - Smim1+/- mice and red triangles – Smim1-/- mice. 
Data represent mean ± standard deviation. The analysis was performed using Anova and 
Tukey’s multiple comparisons test or Kruskal-Wallis and Dunn’s multiple comparisons 
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4.3.2.2 Investigation of the effect of SMIM1 ablation in tissue morphology 
To determine whether the ablation of SMIM1 has an effect on tissue morphology, I 
performed a histological analysis of spleen, liver, kidneys, heart and bone marrow of 
six-seven months old Smim1 mutant and wildtype mice. Following tissue dissection and 
processing, the histological sections and H&E staining were performed by Mr James 
Wraner, Chief research technician at Wellcome Trust-MRC Institute of Metabolic 
Science. The H&E staining is a common stain used to characterise cell morphology. 
Haematoxylin has a blue-purple colour and stains basophilic structures such as nucleic 
acids, while eosin has a pink colour and stains acidophilic structures such as proteins. 
Therefore, in tissue stained with H&E the cells present the nuclei in purple-blue and the 
cytoplasm and extracellular matrix in pink.  
 
Examination of spleen, kidneys, heart and bone marrow histological sections of Smim1 
mutant mice showed no striking abnormalities in morphology or cellularity (data not 
shown). Liver histological sections of male Smim1 mutant mice showed morphologic 
alterations in the cytoplasm of the hepatocytes (Figure 4.5). Hepatocytes of Smim1+/- 
male mice presented increased eosin staining in their cytoplasm when compared with 
hepatocytes from wildtype and Smim1-/- male mice (Figure 4.5). Whereas hepatocytes 
from Smim1-/- male mice showed reduced eosin staining in their cytoplasm when 
compared with hepatocytes from wildtype and Smim1+/- male mice (Figure 4.5). The 
reason for the reduction of eosin staining in hepatocytes from Smim1-/- male mice could 
be due to an accumulation of glycogen or lipid droplets, which are neutral and therefore 
not stained when using this technique. To characterise this morphologic alteration, it 
would be important to perform a specific staining to glycogen and/or lipids, such as 
Periodic Acid-Schiff and Oil Red O, respectively. The distinct morphologic alterations 
observed in the liver of Smim1+/- and Smim1-/- male mice are in agreement with the 
observations of the liver to body weight ratio alterations described above in section 
4.3.2.1. Examination of liver morphology in female mice showed no differences 
between Smim1-/- and wildtype mice (Figure 4.5). 
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Figure 4.5 – Effect of SMIM1 ablation in the liver morphology of mice. 
Representative pictures of liver histological sections stained with H&E. Histology 
analysis was performed in four wildtype and Smim1-/- mice and three Smim1+/- male 
mice. Scale bar – 50 µm. 
 
4.3.2.2.1  Liver morphological alterations of Smim1-/- male mice are not caused by 
glycogen accumulation 
To further investigate whether the morphologic alteration observed in the liver of 
Smim1-/- male mice was caused by an accumulation of glycogen, I performed a 
histological analysis using PAS staining in a larger group of male mice. PAS staining is 
used to detect polysaccharides such as glycogen. However, PAS is specific for 
aldohexoses and therefore stains all the molecules containing aldohexoses. This staining 
results from the oxidation of carbon-carbon bounds in 1,2-glycols by the periodic acid, 
which leads to the formation of dialdehydes. These aldehydes then react with the Schiff 
reagent to originate a purple-magenta stain. The distinction between glycoproteins and 
glycogen is obtained through the comparison of PAS staining with and without 
treatment with diastase, an enzyme that digests specifically glycogen [226]. This, 
however, is a semi-quantitative method. To perform this analysis, 26 to 27 weeks-old 
male mice were weighted and dissected within 1h (to control for glycogen 
consumption). Their livers were weighted and immediately processed for histology as 
described in section 2.2.6. Semi-quantification of PAS/DPAS staining performed using 
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HALO software as described in section 2.2.6.1, has shown that glycogen content was 
not altered in Smim1-/- mice when compared with wildtype, while it was significantly 
increased in Smim1+/- mice when compared with wildtype and Smim1-/- mice. Moreover, 
this analysis has also shown that the reduction of H&E staining in the cytoplasm of 
hepatocytes from Smim1-/- mice is most likely due to an accumulation of lipid droplets, 
also called steatosis (Figure 4.6). To confirm this finding and to determine if the 
steatosis observed in Smim1-/- male mice is significantly different from the wildtype 
animals, it would be important to perform a lipid-specific stain as described above. In 
summary, this analysis shows that the morphologic alteration in the liver of Smim1-/- 
male mice does not result from glycogen accumulation. 
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Figure 4.6 - Liver glycogen content is unaffected by SMIM1 ablation in mice. A – 
schematic representation of semi-quantitative PAS analysis using HALO software: I. 
Liver histological section analysed, II. PAS staining; III. Identification of steatosis in 
red; IV quantification of PAS staining – yellow/orange/red staining. B – representative 
liver histological sections of PAS and DPAS staining of wildtype, Smim1+/- and Smim1-
/-; C – graphic representation of relative glycogen area (%) vs body weight in wildtype, 
Smim1+/- and Smim1-/-; wildtype - Y = -1.197*X + 107.1; Smim1+/- - Y = -0.2884*X + 
85.17; Smim1-/- - Y = -0.4695*X + 84.05. Slopes comparison show non-significant 
differences. Intercept comparison: wildtype vs Smim1-/- - F = 0.1846, DFn = 1, DFd = 
15, p=0.6736; wildtype vs Smim1+/- - F = 6.368, DFn = 1, DFd = 15 p=0.0234; Smim1-/- 
vs Smim1+/- - F = 5.43, DFn = 1, DFd = 13, p=0.0365; D- graphic representation of 
relative steatosis area (%) vs body weight in wildtype, Smim1+/- and Smim1-/-; Wildtype 
- Y = 0.07692*X + 5 ; Smim1+/- - Y = 0.1285*X + 2.719 ; Smim1-/- - Y = 0.3909*X - 
5.923; Black squares and trend line – wildtype mice, blue circles and trend line - 
Smim1+/- mice and red triangles and trend line – Smim1-/- mice. 
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4.3.3 Assessment of SMIM1 role in different blood cell lineages 
To investigate the possible role of SMIM1 in different blood lineages, I assessed 
qualitative and quantitative traits of blood cells in a: i) Vel-negative blood donors’ 
cohort, ii) Vel-negative/weak individuals’ cohort (UK Biobank) and iii) Smim1 mutant 
mice. Specifically, I performed a morphologic analysis of blood cells by examination of 
blood smears under the microscope, and a more detailed and quantitative analysis of the 
effect of SMIM1 ablation in 31 or 26 blood parameters in humans, and ten blood 
parameters in mice using automated haematology analysers.  
 
4.3.3.1 Qualitative and quantitative analysis of blood cells parameters in Vel-
negative blood donor cohort 
Human blood smears and full blood counts were performed within 5 h after bleeding, as 
described in section 2.1.1.1. Examination of blood smears for assessment of 
morphological abnormalities was performed with the assistance of Professor Wendy 
Erber (University of Western Australia). This qualitative analysis did not reveal any 
striking phenotype in blood cells morphology as shown in Figure 4.7. Red blood cell 
size, shape and colour were unremarkable. Platelet number, size and granularity were 
unremarkable. 3/12 females showed a mild increase of platelet number with normal 
morphology, which may be attributable to intercurrent infection. Moreover, leucocytes 
were also normal.  
 
 
Figure 4.7 – Blood smear of Vel-negative blood donors. Representative blood smear 
of a male and female Vel-negative donor stained with Romanowsky stain (x400). The 
blood smears show red blood cells with little variation in size and shape; platelets with 
normal size and granularity; normal polymorphonuclear neutrophils and a lymphocyte 
in the blood smear of the male donor. 
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Then, I performed a quantitative analysis of SMIM1 effect in different blood lineages 
by assessment of full blood count using a Sysmex XE-5000 hematology analyzer. The 
statistical analysis was performed using a linear model with age and BMI as covariant 
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Table 4.2 – Effect of SMIM1 absence in blood parameters of blood donors. 
Summary of full blood counts of control donors and Vel-negative blood donors 
obtained by Sysmex XE-5000 hematology analyzer. Data represent mean ± standard 
deviation (SD). The analysis was performed using a linear model (Parameter ~ cohort + 
Age + BMI) and Anova type II. Reference ranges were obtained in the INTERVAL 
study (Prof. Ouwehand, personal communication). ns-non-significant; na- non-
applicable. 
 
RBC – red blood cell count; HGB – haemoglobin concentration; HCT – haematocrit; MCV – 
mean cell volume; MCH – mean cell haemoglobin; MCHC – mean cell haemoglobin 
concentration; RET – reticulocyte count, RET-He – reticulocyte haemoglobin equivalent; IRF – 
immature reticulocyte fraction; RDW-SD – red blood cell distribution width - standard 
deviation; RDW-CV – red blood cell distribution width - coefficient of variation; MicroR – 
microcytic RBC count; MacroR – macrocytic RBC count; PLT – platelet count; MPV – mean 
platelet volume; PDW – platelet distribution width; PCT – plateletcrit; P-LCR – platelet larger 
cell ratio; IPF – immature platelet fraction; WBC – white blood cell count; NEUT – neutrophil 










Parameter Mean SD Mean SD p-value Mean SD Mean SD p-value
RBC (10^12/L) 5.12 0.37 4.83 0.24 0.0098 3.5-5.6 4.66 0.31 4.45 0.25 0.0332 3.5-5.6
HGB (g/dL) 15.27 0.95 14.77 0.82 ns 10.7-16.2 13.76 0.94 13.18 1.16 ns 10.7-16.2
HCT (%) 44.60 2.61 42.90 2.41 ns 34.0-51.2 40.91 2.59 39.72 3.31 ns 34.0-51.2
MCV (fL) 87.28 3.87 88.87 4.31 ns 78.1-108.5 87.98 4.22 89.34 5.37 ns 78.1-108.5
MCH (pg) 29.90 1.46 30.61 1.68 ns 23.8-35.1 29.59 1.79 29.41 1.64 ns 23.8-35.1
MCHC (g/dL) 34.25 0.99 34.44 0.95 ns 28.1-35.0 33.62 0.86 33.18 0.65 ns 28.1-35.0
RET (10^12/L) 0.05 0.02 0.04 0.01 0.0038 na 0.04 0.01 0.03 0.01 0.0043 na
RET (%) 0.93 0.29 0.79 0.21 0.0233 na 0.84 0.24 0.66 0.21 0.0115 na
RET-He 33.87 1.99 34.79 1.81 ns na 32.94 2.35 33.78 2.19 ns na
IRF (%) 4.04 2.39 2.24 1.73 0.0024 na 3.16 2.19 1.76 3.25 0.0449 na
RDW-SD (%) 42.07 2.95 44.21 3.33 0.0081 na 43.69 3.23 45.60 3.29 0.0283 na
RDW-CV (%) 13.25 0.75 13.63 0.90 ns na 13.63 1.24 13.95 0.95 ns na
MicroR (%) 1.77 1.20 1.49 1.08 ns na 2.10 2.43 1.87 1.57 ns na
MacroR (%) 6.91 1.33 7.41 1.94 ns na 6.54 1.24 7.65 3.75 ns na
PLT (10^9/L) 201.72 44.44 219.15 51.19 ns 85.6-438.1 226.70 46.17 270.00 61.17 0.0003 85.6-438.1
MPV (fL) 10.59 0.94 11.15 0.90 0.0408 8.5-14.2 10.73 1.01 11.28 1.08 ns 8.5-14.2
PDW (fL) 12.59 2.07 13.69 1.93 ns na 12.85 2.19 13.88 2.85 ns na
PCT (%) 0.21 0.04 0.24 0.05 ns na 0.24 0.05 0.30 0.06 6.4E-06 na
P-LCR (%) 29.65 7.93 34.96 7.84 0.0274 na 30.71 8.48 35.00 8.50 ns na
IPF (%) 4.79 3.02 5.12 2.48 ns na 4.24 2.56 6.89 3.69 0.0037 na
WBC (10^9/L) 5.59 1.36 6.67 2.09 0.0243 1.6-11.9 5.91 1.25 6.29 1.28 ns 1.6-11.9
NEUT (10^9/L) 3.20 1.01 3.93 1.34 0.0065 0 - 7.8 3.52 0.96 3.79 1.05 ns 0 - 7.8
LYMPH (10^9/L) 1.65 0.52 1.93 0.83 ns 0.3 - 3.9 1.76 0.45 1.84 0.43 ns 0.3 - 3.9
Mono (10^9/L) 0.53 0.16 0.59 0.31 ns 0.1 - 1.0 0.46 0.12 0.44 0.11 ns 0.1 - 1.0
Eo (10^9/L) 0.18 0.11 0.18 0.11 ns 0 - 0.6 0.14 0.09 0.19 0.11 ns 0 - 0.6
Baso (10^9/L) 0.03 0.02 0.04 0.02 ns 0 - 0.1 0.03 0.02 0.03 0.02 ns 0 - 0.1
NEUT (%) 56.71 7.85 59.20 7.99 0.0362 na 59.14 6.88 59.68 7.47 ns na
LYMPH (%) 29.77 6.68 29.10 7.91 ns na 30.14 6.48 29.48 5.98 ns na
Mono (%) 9.74 2.31 8.58 2.11 ns na 7.86 1.80 7.04 1.25 ns na
Eo (%) 3.24 2.00 2.65 1.26 ns na 2.37 1.39 3.23 2.35 ns na
Baso (%) 0.54 0.36 0.58 0.36 ns na 0.50 0.25 0.57 0.38 ns na
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4.3.3.1.1 Analysis of RBC parameters in Vel-negative blood donor cohort 
Different parameters of mature and immature RBCs were investigated using the Sysmex 
XE-5000 hematology analyzer (Table 4.2). RBC count and RDW are measurements of 
number and size variation of fully mature RBC, respectively. Whereas reticulocyte 
count and percentage, as well as immature reticulocyte fraction, are measurements of 
anucleate immature RBCs. Reticulocyte absolute counts reflect the efficiency of 
erythropoiesis in the bone marrow, whereas their relative number is indicative of RBC 
life span [227]. Immature reticulocyte fraction is a relative measurement of immature 
reticulocytes that have higher RNA content, and it is an early and sensitive parameter 
for evaluating erythropoiesis [227]. Analysis of RBC parameters assessing mature and 
immature features of RBCs, showed that male and female Vel-negative blood donors 
when compared with control donors, had a weak but significantly decreased of: RBC 
count (RBC (1012/L): M- 4.83±0.24 , p=0.0098; F- 4.45±0.25, p=0.0332), reticulocyte 
percentage (Ret (%): M- 0.79±0.21, p=0.0223; F- 0.66±0.21, p=0.0115), reticulocyte 
count (Ret (1012/L): M- 0.04±0.01, p=0.0038; F- 0.03±0.01, p=0.0443) and immature 
reticulocyte fraction (IRF (%): M-2.24±1.73, p=0.0024; F- 1.76±3.25, p=0.0449). 
RDW-standard deviation (RDW-SD (%): M-44.21±3.33, p=0.0081; F- 45.60±3.29, 
p=0.0283), in turn, was slightly but significantly increased when compared with control 
donors (Table 4.2 and Figure 4.8). Although the alterations observed in this analysis 
were subtle and within the reference range, these are significant and therefore suggest 
that SMIM1 is important during erythropoiesis and possibly for the maturation process 
of RBCs and consequently, for RBC function.  
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Figure 4.8 - Effect of SMIM1 absence in RBCs parameters of blood donors. 
Graphic representation of full blood count results for mature and immature RBCs 
parameters in control donors and Vel-negative blood donors.  Black squares – control 
donors and red triangles – Vel-negative blood donors. Statistical analysis was 
performed using a linear model (Parameter ~ cohort + Age + BMI) and Anova type II. 
Only significant differences are represented. 
 
4.3.3.1.2 Analysis of platelets parameters in Vel-negative blood donor cohort 
Different parameters of mature and immature platelet features were also investigated 
using Sysmex XE-5000 hematology analyzer. Analysis of platelet parameters showed 
that male Vel-negative blood donors, when compared with the control donors exhibited 
a weak but significant increase of mean platelet volume (MPV (fL): M- 11.15±0.90, 
p=0.0408) and platelet large cell ratio (P-LCR (%): 34.96±7.84, p=0.0274) (Table 4.2 
and Figure 4.9). On other hand, female Vel-negative blood donors presented a weak but 
significant increase of platelet count (PLT (109/L): F- 270±61.17, p=0.0003), plateletcrit 
(PCT (%): F- 0.30±0.06, p=6.4 x 10-6 – total platelet mass) and immature platelet 
fraction (IPF (%): F- 6.89±3.69, p=0.0037 – fraction of reticulated platelets with greater 
amount of residual RNA[228]), when compared with control donors (Table 4.2 and 
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Figure 4.9). These observations suggest that SMIM1 plays a role in the regulation of 
platelets traits such as production, count and volume. 
 
 
Figure 4.9 – Effect of SMIM1 absence in platelet parameters of blood donors. 
Graphic representation of full blood count results for platelet-related parameters in 
control donors and Vel-negative blood donors. Black squares – control donors and red 
triangles – Vel-negative blood donors. The analysis was performed using a linear model 
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4.3.3.1.3 Analysis of WBC parameters in Vel-negative blood donor cohort 
Analysis of WBC parameters showed that male Vel-negative blood donors presented a 
weak but significant increase in WBC count (WBC (109/L): M- 6.67±2.09, p=0.0243), 
neutrophils count (NEUT (109/L): M- 3.93±1.34, p=0.0065) and neutrophils percentage 
(NEUT (%): M- 59.20±7.99, p=0.0362) (Table 4.2 and Figure 4.10). Female Vel-
negative blood donors did not present any significant difference in WBC parameters 
when compared to control donors. These observations suggest that SMIM1 role in 
neutrophils is sex-dependent.  
 
 
Figure 4.10 - Effect of SMIM1 absence in WBCs parameters of blood donors. 
Graphic representation of full blood count results for WBC and neutrophil counts in 
control donors and Vel-negative blood donors. Black squares – control donors and red 
triangles – Vel-negative blood donors. Data represent mean ± standard deviation. The 
analysis was performed using a linear model (Parameter ~ cohort + Age + BMI) and 
Anova type II. Only significant differences are represented. 
 
As shown above, in section 4.3.1.2, SMIM1 affects BMI. However, it is still unknown 
if this phenotype is a direct or indirect effect of SMIM1 ablation. Therefore, in order not 
to disregard any phenotype, I performed the analysis of full blood count also without 
BMI as a covariate. Similar phenotypic changes were found when not accounting for 
BMI as a covariate (data not shown). However, some differences were observed in 
reticulocytes and neutrophils. Reticulocyte count and percentage, as well as the 
neutrophil percentage in male Vel-negative blood donors, were not significantly 
different when not using BMI as a covariate. In female Vel-negative blood donors, 
immature reticulocyte fraction was not significantly different when not using BMI as a 
covariate. These observations suggest that the phenotype observed in these parameters 
is also directly affected by BMI. Altogether, this analysis showed that SMIM1 is not 
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crucial but affects different parameters of RBC, platelets and WBCs. Moreover, the 
effect of SMIM1 in particular parameters seems to be sex-dependent. 
 
4.3.3.2 Quantitative analysis of blood cell parameters in Vel-negative/weak 
individuals of the UK Biobank 
Using the subset of individuals of European ancestry in the most recent data release of 
approximately 400,000 participants (244,135 female and 205,576 male) in the UK 
Biobank study, Dr William Astle, Lecturer in Haematological Genomics at University 
of Cambridge, performed an association analysis of SMIM1 17-bp deletion – 
rs566629828 (Vel-negative/weak individuals) with 26 blood parameters (Table 4.3, 
unpublished data – association analysis performed in individuals homozygous (n=79: 
female=40 and male=39, MAF=0.02%) and heterozygous (n=11998: female=6465, 
male=5533, MAF=2.7%) for the 17-bp deletion in SMIM1). This analysis showed a 
positive association of rs566629828 with RDW-CV (p=2.8 x 10-50) and mean sphered 
corpuscular volume (MSCV, p=4.19 x 10-10). Both parameters measure features 
correlated with RBC size. As described above, RDW measures the variability of RBCs 
sizes, whereas MSCV is the measurement of RBC volume in hypo-osmotic solution. 
The increased MSCV in individuals carrying the SMIM1 17-bp deletion indicates an 
increase in the ratio of cell surface area to cell volume. Moreover, a negative association 
of rs566629828 with IRF (p=1.3 x 10-10), reticulocyte count (p=2.6 x 10 -21) and 
percentage (p=4.3 x 10-20), HGB (p=0.0015), MCHC (p=7.0 x 10-8), platelet count 
(p=0.0003) and plateletcrit (p=0.0002) was observed. These observations suggest that 
SMIM1 is important for erythropoiesis and platelet production. Differences in effect of 
SMIM1 on HGB, MCHC, platelet count and plateletcrit measurements were observed 
between the two studies, the UK Biobank (Vel-negative/weak individuals) and my 
study (Vel-negative blood donors). These differences may be due to the fact that: i) the 
individuals in my study are all Vel-negative (homozygous for the SMIM1 17-bp 
deletion), while the majority of the individuals in the UK Biobank are heterozygous for 
the SMIM1 17-bp deletion; and ii) the individuals in my study are active blood donors. 
Vel-negative blood donors are not only selected based on HGB levels (HGB level needs 
to be at least 125g/L for women and 135g/L for men) but are also subject to repeated 
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Table 4.3 – Association analysis of rs566629828 with blood parameters in UK 
Biobank individuals.  
 
Effect average: the average additive allelic effect size combining males and females; P-
value average: P-value for test against the null hypothesis that average effect is zero; 
Effect in female: additive allelic effect size estimated within females; Effect in males: 
additive allelic effect size estimated within males; P-value for sex_interaction: P-value 
for test against null hypothesis that effect size is the same in males and females. For all 
effect sizes: the baseline allele is the wildtype allele and the units are standard 
deviations of the inverse rank normalised trait; RBC – red blood cell count; HGB – 
haemoglobin concentration; HCT – haematocrit; MCV – mean cell volume; MCH – 
mean cell haemoglobin; MCHC – mean cell haemoglobin concentration; RET – 
reticulocyte count or percentage; IRF – immature reticulocyte fraction; RDW-SD – red 
blood cell distribution width - standard deviation; RDW-CV – red blood cell 
distribution width - coefficient of variation; MicroR – microcytic RBC count; MacroR – 
macrocytic RBC count; PLT – platelet count; MPV – mean platelet volume; PDW – 
platelet distribution width; PCT – plateletcrit; P-LCR – platelet larger cell ratio; IPF – 
immature platelet fraction; WBC – white blood cell count; NEUT – neutrophil count or 
percentage; LYMPH – lymphocyte count or percentage; Mono – monocyte count or 
percentage; Eo – eosinophil count or percentage and Baso – basophil count or 
percentage. 
  




RBC (10^12/L) 0.1086 -0.0148 -0.0155 -0.0139 0.9308
HGB (g/dL) 0.0016 -0.0291 -0.0382 -0.0185 0.2870
HCT (%) 0.2020 -0.0118 -0.0184 -0.0040 0.4353
MCV (fL) 0.2738 0.0101 0.0007 0.0210 0.2712
MCH (pg) 0.1480 -0.0134 -0.0232 -0.0020 0.2509
MCHC (g/dL) 7.0E-08 -0.0497 -0.0564 -0.0421 0.4405
RET (10^12/L) 2.7E-21 -0.0886 -0.0743 -0.1052 0.0993
RET (%) 4.3E-20 -0.0859 -0.0711 -0.1030 0.0888
IRF (%) 1.3E-10 -0.0601 -0.0483 -0.0737 0.1768
MSCV (fL) 4.2E-10 0.0584 0.0554 0.0620 0.7247
RDW-CV (%) 2.8E-50 0.1380 0.1623 0.1101 0.0049
PLT (10^9/L) 0.0003 -0.0337 -0.0355 -0.0317 0.8434
MPV (fL) 0.6810 0.0039 0.0075 -0.0002 0.6830
PDW (fL) 0.9659 -0.0004 0.0091 -0.0113 0.2805
PCT (%) 0.0002 -0.0356 -0.0354 -0.0360 0.9758
WBC (10^9/L) 0.2124 -0.0115 -0.0091 -0.0143 0.7776
NEUT (10^9/L) 0.3026 -0.0095 -0.0135 -0.0049 0.6392
LYMPH (10^9/L) 0.4411 -0.0071 0.0039 -0.0198 0.2009
MONO (10^9/L) 0.1707 -0.0127 -0.0149 -0.0101 0.7970
BASO (10^9/L) 0.4636 -0.0068 -0.0111 -0.0018 0.6173
EO (10^9/L) 0.6585 0.0041 0.0094 -0.0021 0.5374
NEUT (%) 0.8288 -0.0020 -0.0136 0.0115 0.1744
EO (%) 0.4205 0.0074 0.0140 -0.0001 0.4478
LYMPH (%) 0.6572 0.0041 0.0145 -0.0080 0.2255
MONO (%) 0.5724 -0.0052 -0.0090 -0.0009 0.6616
BASO (%) 0.8594 -0.0016 -0.0065 0.0039 0.5749
Chapter 4 
   103 
4.3.3.3 Qualitative and quantitative analysis of blood cell parameters in Smim1 
mutant mice 
To characterise the possible role of SMIM1 in different blood parameters in mice, I 
performed terminal blood smears and full blood counts in mice of two age groups: i) 
young - < six months (thirteen to twenty-one weeks), and ii) mature - ³ six months 
(twenty-four to thirty-five weeks). Examination of blood smears did not show any 
striking phenotype as observed in Vel-negative blood donors (data not shown), whereas 
analysis of full blood counts showed that SMIM1 affected different blood lineages in a 
sex-age-dependent manner (Table 4.4 and 4.5). This analysis was performed using a 
linear model with age in weeks as a covariate. In addition, since SMIM1 affects body 
weight in mice, I also performed this analysis with both age in weeks and the body 
weight as covariates. Similar phenotypic changes were found in both analyses (with and 
without body weight as covariant - data not shown) in mice. Taking that into 
consideration and since the dataset without body weight was considerably larger, which 
improves the power of the statistic test, the analysis without body weight as covariant 
was preferred and is presented in Table 4.4 and 4.5. The dataset without body weight 
was considerably larger because I performed full blood counts in several mice that were 
not weighted. 
 
4.3.3.3.1 Analysis of full blood counts in male Smim1 mutant mice 
Analysis of full blood counts in male Smim1 mutant mice showed that WBC count and 
different RBC parameters were affected (Table 4.4 and Figure 4.11). This analysis 
showed, however, that the effect of SMIM1 in RBC parameters is age-dependent, since 
opposite trends and effects were observed between age groups.  
 
Young Smim1-/- male 
Young Smim1-/- male mice showed a significant decrease of RBC count (9.03±0.50 
106/µl, p=0.0391) and haematocrit (HCT: 42.66±2.46 %, p=0.0386) when compared 
with wildtype mice. Additionally, young Smim1-/- male mice showed a significant 
increase of RDW (16.15±0.56 %, p=0.0029) and MPV (5.21±0.14 µm3, p=0.0189) 
when compared with Smim1+/- male mice (Table 4.4 and Figure 4.11).  
 
Mature Smim1-/- male 
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Mature Smim1-/- male mice showed a significant increase of WBC count (8.74±1.63 
103/µl, p=0.0470), RBC count (9.40±1.12 106/µl, p=0.0142), HGB (14.33±1.42 g/dL, 
p=0.0012), HCT (43.61±5.41 %, p=0.0044) and MCV (46.40±1 µm3, p=0.0148) when 
compared with age-matched wildtype mice. Moreover, mature Smim1-/- male mice also 
showed a significant increase of RBC count (p=0.0012), HGB (p=0.0002), HCT 
(p=0.002) and MCV (p=0.0367) when compared with Smim1+/- male mice (Table 4.4 
and Figure 4.11).  
 
 
Figure 4.11 – Effect of SMIM1 ablation in blood parameters of male mice. Graphic 
representation of full blood count results for RBC parameters and WBC count. Black 
squares and trend line – wildtype mice, blue circles and trend line - Smim1+/- mice and 
red triangles and trend line – Smim1-/- mice. 
 
Chapter 4 
   105 
Altogether, these results indicate that Smim1-/- and Smim1+/- male mice have distinct 
trends in some parameters, and that SMIM1 affects erythropoiesis and WBC production 
in male mice. Furthermore, the opposite trends of RBC parameters observed in the two 
age groups of Smim1-/- male mice, may indicate that the phenotype observed in mature 
mice results from a compensatory mechanism or is associated with a metabolic 
alteration, as suggested by body weight alteration.  
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Table 4.4 – Effect of SMIM1 ablation in blood parameters of male mice. Summary of full blood counts of wildtype, Smim1+/- and Smim1-/- young 
and mature mice, obtained by an automated haematology analyser. Data represent mean ± standard deviation. The analysis was performed using a 




WBC – white blood cell count; RBC – red blood cell count; HGB – haemoglobin concentration; HCT – haematocrit; MCV – mean cell volume; MCH 
– mean cell haemoglobin; MCHC – mean cell haemoglobin concentration; RDW – red blood cell distribution width; PLT – platelet count; and MPV – 
mean platelet volume 
mean SD mean SD mean SD mean SD mean SD mean SD
WBC (103/µl) 8.23 1.05 7.88 1.38 8.47 1.38 ns 7.85 1.37 7.94 1.78 8.74 1.63  p=0.0470 (WTvsSmim1 -/- ) 
RBC (106/µl) 9.52 0.70 9.48 0.60 9.03 0.50  p=0.0391 (WTvsSmim1 -/- ) 8.88 0.63 8.69 0.53 9.40 1.12
p=0.0142 (WTvsSmim1 -/- ) 
p=0.0012 (Smim1 +/- vsSmim 1 -/- )
HGB (g/dl) 14.40 1.02 14.35 1.14 13.85 1.07 ns 13.37 0.89 13.23 0.73 14.33 1.42 p=0.0012 (WTvsSmim1
-/- )  
p=0.0002 (Smim1 +/- vsSmim 1 -/- )
HCT (%) 44.91 2.72 44.67 2.83 42.66 2.46  p=0.0386 (WTvsSmim1 -/- ) 40.60 3.04 40.30 2.61 43.61 5.41 p=0.0044 (WTvsSmim1
-/- )  
p=0.0020 (Smim1 +/- vsSmim 1 -/- )
MCV (µm3) 47.08 1.24 47.00 0.94 47.13 0.99 ns 45.71 0.91 46.35 1.09 46.40 1.00  p=0.0148 (WTvsSmim1
-/- ) 
p=0.0367 (Smim1 +/- vsSmim1 -/- )
MCH (pg) 15.16 0.42 15.11 0.41 15.43 0.53 ns 15.07 0.38 15.24 0.49 15.32 0.72 ns
MCHC (g/dl) 32.12 0.88 32.07 0.81 32.59 1.25 ns 32.96 0.76 32.34 2.49 32.96 1.63 ns
RDW (%) 15.76 0.80 15.21 0.79 16.15 0.56 p=0.0029 (Smim1 +/- vsSmim 1 -/- ) 15.88 0.65 16.12 0.87 16.03 0.65 ns
PLT (103/µl) 1150.00 162.87 1142.30 104.26 1151.39 329.27 ns 1479.04 295.02 1357.20 378.61 1334.67 309.18 ns
MPV (µm3) 5.16 0.13 5.08 0.18 5.21 0.14 p=0.0189 (Smim1 +/- vsSmim 1 -/- ) 5.21 0.11 5.24 0.15 5.23 0.15 ns
mean SD mean SD mean SD mean SD mean SD mean SD
WBC (103/µl) 6.40 1.24 7.48 0.32 6.78 1.27 ns 5.91 0.98 6.48 0.94 6.99 1.10   p=0.0054 (WTvsSmim1 -/- )
RBC (106/µl) 8.46 0.48 8.96 0.45 8.44 0.57 ns 8.99 0.70 8.69 0.69 9.29 1.07 ns
HGB (g/dl) 13.40 0.72 14.20 0.71 13.48 0.82 ns 13.78 1.03 13.45 0.90 14.42 1.62 ns
HCT (%) 40.40 2.35 42.58 2.20 40.80 3.13 ns 41.74 3.87 40.54 3.38 43.14 5.58 ns
MCV (µm3) 47.80 0.92 47.50 0.58 48.50 1.68   p=0.0255 (WTvsSmim1 -/- ) 46.31 1.01 46.73 1.19 46.35 0.79 ns
MCH (pg) 15.86 0.44 16.10 1.00 16.01 0.67 ns 15.36 0.48 15.48 0.55 15.54 0.54 ns
MCHC (g/dl) 33.20 1.33 33.40 1.62 33.15 1.93 ns 33.08 1.04 33.25 1.17 33.51 1.14 ns
RDW (%) 16.33 0.60 15.98 0.46 16.33 0.42 ns 15.71 0.45 15.73 0.58 15.66 0.56 ns
PLT (103/µl) 1025.50 78.88 974.25 113.97 1005.42 174.39 ns 1077.50 229.09 1097.18 343.46 1089.65 170.65 ns
MPV (µm3) 5.17 0.09 5.23 0.10 5.18 0.07 ns 5.23 0.13 5.33 0.17 5.22 0.16 ns
Male <6 Months >6 Months
Parameter
Wildtype (n=12) Smim1 +/-  (n=10) Smim1 -/-  (n=15) p-value Wildtype (n=24) Smim1
+/-  (n=20)
Female <6 Months >6 Months
Parameter
Wildtype (n=10) Smim1 +/-  (n=4) Smim1 -/-  (n=12) p-value Wildtype (n=16) Smim1
+/-  (n=11) Smim1 -/-  (n=17) p-value
Smim1 -/-  (n=30) p-value
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4.3.3.3.2 Analysis of full blood counts in female Smim1 mutant mice 
Analysis of full blood counts in female Smim1 mutant mice showed that ablation of 
SMIM1 only affected MCV in young female mice and WBC parameters in mature 
female mice (Table 4.5 and Figure 4.12). The alteration of WBC parameters, however, 
did not seem to be age-dependent, since female Smim1 mutant mice from both group 
ages presented the same trends. Young Smim1-/- female mice showed a significant 
increase of MCV (48.50±1.68 µm3, p=0.0255) when compared with wildtype. However, 
this was the only RBC parameter that was altered, and no differences in MCV were 
observed in mature mice. Mature Smim1-/- female mice showed a significant increase of 
WBC count (6.99±1.10 103/µl, p=0.0054) when compared to wildtype (Table 4.5 and 
Figure 4.12), suggesting that SMIM1 is important for WBC production.  
 
 
Figure 4.12 – Effect of SMIM1 ablation in blood parameters of female mice. 
Graphic representation of full blood count results for WBC count and MCV versus age 
in weeks. Black squares and trend line – wildtype mice, blue circles and trend line- 
Smim1+/- mice and red triangles and trend line– Smim1-/- mice.  
 
In summary, SMIM1 affects different blood parameters in a sex-dependent manner in 
mice. SMIM1 seems to have a stronger effect on RBC parameters in males and WBCs 
parameters in females. Platelet parameters, however, did not show any significant 
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Table 4.5 – Effect of SMIM1 ablation in blood parameters of female mice. Summary of full blood counts of wildtype, Smim1+/- and Smim1-/- young 
and mature mice, obtained by an automated haematology analyser. Data represent mean ± standard deviation. The analysis was performed using a 




WBC – white blood cell count; RBC – red blood cell count; HGB – haemoglobin concentration; HCT – haematocrit; MCV – mean cell volume; MCH 
– mean cell haemoglobin; MCHC – mean cell haemoglobin concentration; RDW – red blood cell distribution width; PLT – platelet count; and MPV – 
mean platelet volume. 
mean SD mean SD mean SD mean SD mean SD mean SD
WBC (103/µl) 8.23 1.05 7.88 1.38 8.47 1.38 ns 7.85 1.37 7.94 1.78 8.74 1.63  p=0.0470 (WTvsSmim1 -/- ) 
RBC (106/µl) 9.52 0.70 9.48 0.60 9.03 0.50  p=0.0391 (WTvsSmim1 -/- ) 8.88 0.63 8.69 0.53 9.40 1.12
p=0.0142 (WTvsSmim1 -/- ) 
p=0.0012 (Smim1 +/- vsSmim 1 -/- )
HGB (g/dl) 14.40 1.02 14.35 1.14 13.85 1.07 ns 13.37 0.89 13.23 0.73 14.33 1.42 p=0.0012 (WTvsSmim1
-/- )  
p=0.0002 (Smim1 +/- vsSmim 1 -/- )
HCT (%) 44.91 2.72 44.67 2.83 42.66 2.46  p=0.0386 (WTvsSmim1 -/- ) 40.60 3.04 40.30 2.61 43.61 5.41 p=0.0044 (WTvsSmim1
-/- )  
p=0.0020 (Smim1 +/- vsSmim 1 -/- )
MCV (µm3) 47.08 1.24 47.00 0.94 47.13 0.99 ns 45.71 0.91 46.35 1.09 46.40 1.00  p=0.0148 (WTvsSmim1
-/- ) 
p=0.0367 (Smim1 +/- vsSmim1 -/- )
MCH (pg) 15.16 0.42 15.11 0.41 15.43 0.53 ns 15.07 0.38 15.24 0.49 15.32 0.72 ns
MCHC (g/dl) 32.12 0.88 32.07 0.81 32.59 1.25 ns 32.96 0.76 32.34 2.49 32.96 1.63 ns
RDW (%) 15.76 0.80 15.21 0.79 16.15 0.56 p=0.0029 (Smim1 +/- vsSmim 1 -/- ) 15.88 0.65 16.12 0.87 16.03 0.65 ns
PLT (103/µl) 1150.00 162.87 1142.30 104.26 1151.39 329.27 ns 1479.04 295.02 1357.20 378.61 1334.67 309.18 ns
MPV (µm3) 5.16 0.13 5.08 0.18 5.21 0.14 p=0.0189 (Smim1 +/- vsSmim 1 -/- ) 5.21 0.11 5.24 0.15 5.23 0.15 ns
mean SD mean SD mean SD mean SD mean SD mean SD
WBC (103/µl) 6.40 1.24 7.48 0.32 6.78 1.27 ns 5.91 0.98 6.48 0.94 6.99 1.10   p=0.0054 (WTvsSmim1 -/- )
RBC (106/µl) 8.46 0.48 8.96 0.45 8.44 0.57 ns 8.99 0.70 8.69 0.69 9.29 1.07 ns
HGB (g/dl) 13.40 0.72 14.20 0.71 13.48 0.82 ns 13.78 1.03 13.45 0.90 14.42 1.62 ns
HCT (%) 40.40 2.35 42.58 2.20 40.80 3.13 ns 41.74 3.87 40.54 3.38 43.14 5.58 ns
MCV (µm3) 47.80 0.92 47.50 0.58 48.50 1.68   p=0.0255 (WTvsSmim1 -/- ) 46.31 1.01 46.73 1.19 46.35 0.79 ns
MCH (pg) 15.86 0.44 16.10 1.00 16.01 0.67 ns 15.36 0.48 15.48 0.55 15.54 0.54 ns
MCHC (g/dl) 33.20 1.33 33.40 1.62 33.15 1.93 ns 33.08 1.04 33.25 1.17 33.51 1.14 ns
RDW (%) 16.33 0.60 15.98 0.46 16.33 0.42 ns 15.71 0.45 15.73 0.58 15.66 0.56 ns
PLT (103/µl) 1025.50 78.88 974.25 113.97 1005.42 174.39 ns 1077.50 229.09 1097.18 343.46 1089.65 170.65 ns
MPV (µm3) 5.17 0.09 5.23 0.10 5.18 0.07 ns 5.23 0.13 5.33 0.17 5.22 0.16 ns
Male <6 Months >6 Months
Parameter
Wildtype (n=12) Smim1 +/-  (n=10) Smim1 -/-  (n=15) p-value Wildtype (n=24) Smim1
+/-  (n=20)
Female <6 Months >6 Months
Parameter
Wildtype (n=10) Smim1 +/-  (n=4) Smim1 -/-  (n=12) p-value Wildtype (n=16) Smim1
+/-  (n=11) Smim1 -/-  (n=17) p-value
Smim1 -/-  (n=30) p-value
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4.3.3.3.3 Analysis of full blood counts of Smim1-/- mice of the International Mouse 
Phenotyping Consortium 
Smim1 mutant mice were generated under the International Mouse Phenotyping 
Consortium and the SMIM1 phenotypic data from this consortium became recently 
available for the community. Therefore, I further analysed the available blood 
parameters of 16 weeks-old Smim1 mutant mice (equivalent to the young mice group 
used in this study). In order to control for daily variation of the automated haematology 
analyser, I performed the analysis using the data of Smim1 mutant mice (seven males 
and seven females) and day control wildtype mice. This analysis showed similar trends 
to the ones observed in mature mice described above. However, some differences were 
also observed. Specifically, Smim1-/- male mice showed a significant increase of RBC 
count (10.31±0.28 106/µl, p=0.01), HGB (14.79±0.39 g/dl, p=0.03), HCT (46.80±1.26 
%, p=0.013), decrease of MCH (14.33±0.14 pg, p=0.031) and MCHC (31.53±0.22 g/dl, 
p=0.015) but not MCV, whereas Smim1-/- female mice showed an increase of WBC 
count (6.14±01.18 103/µl, p=0.0072), MCV (46.14±0.38 µm3, p=0.0199) and also MCH 
(14.91±0.36 g/dl, p=0.0101) (Table 4.6). The differences observed in the two studies are 
related to alterations in MCV. These results indicate that the phenotypes observed in 
mature mice, were present earlier in the Sanger Smim1 mutant mice, suggesting that the 
phenotype may be influenced by environmental factors that are related with different 
housing conditions and/or by the haematology analyser used.  
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Table 4.6 – Effect of SMIM1 ablation in blood parameters of mice of the 
International Mouse Phenotyping Consortium. Data represent mean ± standard 
deviation (SD). The analysis was performed using an unpaired two tailed T-test or 
Mann-Whitney test.  
WBC – white blood cell count; RBC – red blood cell count; HGB – haemoglobin 
concentration; HCT – haematocrit; MCV – mean cell volume; MCH – mean cell 
haemoglobin; MCHC – mean cell haemoglobin concentration; RDW – red blood cell 
distribution width; PLT – platelet count; and MPV – mean platelet volume. 
 
4.3.3.3.4 Assessment of RBCs deformability of Smim1 mutant mice by real-time 
deformability cytometry 
RBCs morphologic and mechanical properties are critical for their role of oxygen 
transport from the lungs to the tissues [155, 230]. The deformability of RBCs, which is 
dependent on structures of the membrane cortex and viscosity of the cell cytoplasm 
[231], determines RBCs ability to pass through the narrowest capillaries in the tissues 
and therefore alterations in RBC deformability have been associated with various 
conditions such as hereditary disorders and metabolic disorders [155, 232-236]. Since 
SMIM1 is a membrane protein in RBCs and its expression is associated with alteration 
of parameters like RDW and MCV, I further investigated if the deformability, 
smoothness and area of Smim1 mutant mice RBCs were affected by real-time 
deformability cytometry. This experiment was performed by Ms Katie Bashant – PhD 
student in Professor Dr Edwin Chilvers group – University of Cambridge, and a more 
detailed explanation of the technique is described in section 2.2.15. Analysis of whole 
blood of six months old mice by real-time deformability cytometry showed that SMIM1 
did not affect RBC area and smoothness (Figure 4.13 - A) in either males or females, 
suggesting no alteration in skeletal integrity of the cell membrane. Moreover, analysis 
of RBCs that passed through a microfluid constriction channel under pressure gradients 
and shear stresses that induced cell deformation showed that SMIM1 did not affect 
female RBCs deformability but interestingly affected male RBCs deformability (Figure 
mean SD mean SD mean SD mean SD
WBC (103/µl) 6.31 0.96 6.17 1.30 ns 5.05 0.87 6.14 1.18 0.0072
RBC (106/µl) 9.89 0.39 10.31 0.28 0.010 9.98 0.28 10.01 0.36 ns
HGB (g/dl) 14.35 0.48 14.79 0.39 0.030 14.64 0.40 14.91 0.53 ns
HCT (%) 45.06 1.66 46.80 1.26 0.013 45.55 1.34 46.17 1.79 ns
MCV (µm3) 45.51 0.66 45.50 0.55 ns 45.59 0.56 46.14 0.38 0.0199
MCH (pg) 14.52 0.22 14.33 0.14 0.031 14.67 0.17 14.91 0.36 0.0101
MCHC (g/dl) 31.87 0.34 31.53 0.22 0.015 32.14 0.25 32.30 0.64 ns
RDW (%) 14.72 0.36 14.47 0.25 ns 14.43 0.21 14.47 0.27 ns
PLT (103/µl) 980.00 144.55 988.29 44.12 ns 848.47 63.34 895.71 65.95 ns
MPV (µm3) 5.07 0.17 4.91 0.11 0.016 5.06 0.17 5.03 0.17 ns
Parameter
Male Female
Smim1-/- (n=7)Wildtype (n=35) Wildtype (n=34) Smim1-/- (n=7)p-value p-value
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4.13 - B). Male Smim1-/- RBCs were significantly less prone to deformation (p=0.0338), 
suggesting that the lack of SMIM1 increases RBC stiffness. However, this experiment 
was performed only in three male mice per genotype and therefore it would be 




Figure 4.13 - Effect of SMIM1 ablation on morphologic and mechanical properties 
of RBCs of mice. Data represent mean ± standard deviation. The analysis was 
performed using Anova and Tukey’s multiple comparisons test. Black squares – 
wildtype mice, blue circles - Smim1+/- mice and red triangles – Smim1-/- mice. Only 
significant differences are represented. 
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4.4 Discussion 
Haemolytic reactions during transfusions and haemolytic disease in newborns are the 
only known clinical manifestations related to the absence of SMIM1. Nevertheless, the 
alteration of RBC parameters associated with SMIM1 common variant, rs1175550, and 
with the 17-bp deletion responsible for the Vel-negative phenotype, suggests that 
SMIM1 is important for RBC biology. Also, the high expression levels of SMIM1 in 
other blood cells such as MKs and platelets, and in non-haematopoietic tissues (Chapter 
3), may indicate that SMIM1 plays a role in MK and/or platelet physiology, as well as 
in other tissues. Despite this evidence, a deeper understanding of SMIM1 role in RBC 
biology and the investigation of its possible role in other blood cells and non-
haematopoietic tissues is still missing.  
 
In this chapter, using two human cohorts (Vel-negative blood donors recruited in this 
study and Vel-negative/weak individuals of the released 400,000 UK Biobank study) 
and a Smim1 mutant mouse model, I assessed the effect of SMIM1 absence on: i) 
different blood traits; ii) BMI and body weight, iii) organ to body weight ratios and iv) 
tissue morphology. I have demonstrated that SMIM1 is associated with weak but 
significant alterations in several blood traits, specifically in RBC, platelets and 
neutrophils. However, the directionality of these alterations and their significance was 
model specific. Besides, some of the observed associations were sex-dependent in both 
human and mice, suggesting a possible hormonal regulation. Additionally, the male 
mouse model showed that some of the effects were also age-dependent. Here, I 
described how SMIM1 is associated with two metabolic phenotypes. Specifically, 
analysis of BMI and body weight in humans and mice, respectively, revealed that 
absence of SMIM1 leads to an increase in BMI of male Vel-negative blood donors, and 
increased body weight in Smim1-/- female mice. Histological and organ to body weight 
ratio analyses uncovered an alteration in liver morphology in male Smim1 mutant mice, 
with potential clinical implications. 
 
Analysis of blood traits in Vel-negative blood donors 
i) RBCs 
Examination of RBC traits in the Vel-negative blood donor cohort has revealed that the 
absence of SMIM1 results in an impairment in erythropoiesis in both female and male 
 
114   
blood donors (Table 4.7). The number of reticulocytes and immature reticulocytes, 
which are the immature RBCs released in the bloodstream few days before their 
maturation is complete, was decreased, and consequently, the RBC count was also 
reduced. Although the reduction of reticulocytes observed falls within the reference 
range, these observations suggest an inappropriate bone marrow response during RBC 
formation. This might be caused by an alteration of erythrocyte proliferation, maturation 
or rate of delivery into the peripheral blood. A previous study performed by Storry et al. 
showed that in vitro CD34+ cells, as well as bone marrow cells cultured towards 
erythropoiesis, presented an increased SMIM1 expression towards the end of the 
process, suggesting that SMIM1 may play a role during erythroid maturation [188]. This 
observation supports the idea that the reduction of immature reticulocytes and 
reticulocytes in Vel-negative blood donors results from an impairment of erythroid 
maturation. Additionally, Cveijc et al. reported similar findings in Smim1 knockdown 
zebrafish [186]. 
 
This analysis has also shown an increase in RBC size variability in Vel-negative blood 
donors, which has been previously described by Astle et al., [196]. Morphologic 
examination of blood smears, however, did not show any striking anisocytosis. This is 
not surprising since the observed alteration in RDW was subtle and falls within the 
reference range. The increased RBC size variability observed in Vel-negative blood 
donors, suggests that SMIM1 is important for the regulation of RBCs size. The size and 
shape of RBCs is largely dependent of its membrane complex structure. The membrane 
of RBCs comprises a phospholipid bilayer with membrane skeletal proteins and a 
complex network of cytoskeleton proteins (spectrin) that connect/interact with the 
bilayer. As SMIM1 is a membrane protein on RBCs surface, its absence in the 
phospholipid bilayer may disrupt this complex network, which may alter not only their 
size but also their deformability. RBC small size and flexibility are essential features of 
its biological function – those features enable RBC to pass through the narrowest 
capillaries and consequently delivery oxygen to the tissues. Together, these findings 
suggest that SMIM1 is important for erythroid maturation and RBC size. These 
phenotypic alterations, in turn, may impact RBC function, with physiological 
implications yet to be identified. For instance, one could speculate that absence of 
SMIM1 might be associated with higher incidence of different conditions related to an 
increase in RBC size variability, such as cardiovascular diseases and liver disease [237, 
238].  
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ii) Neutrophils and platelets 
In addition to its function in erythropoiesis, I observed that SMIM1 has a positive 
association with platelet and neutrophil production in blood donors (Table 4.7). 
Interestingly, this association seems to be sex-dependent. While there was no 
morphological alteration in neutrophils of male Vel-negative blood donors, I observed a 
weak but significant increase in their number. An increase of absolute neutrophil count, 
can result from: i) increased proliferation and differentiation of precursor cells in the 
bone marrow; ii) increased release of mature neutrophils from the bone marrow into the 
blood; iii) alteration in margination and egress of neutrophils from the blood into the 
tissues (where neutrophils play their function); and/or iv) decreased clearance and 
spontaneous apoptosis of mature neutrophils [218, 239]. These processes are regulated 
by a highly dynamic feedback system that is influenced by genetic and environmental 
factors (see for review [240]). Sexual-dimorphism of neutrophil biology has previously 
been described, as well as some of the responsible mechanisms. For example, the 
regulation of neutrophil apoptosis is mediated by female hormones via an oestradiol-
receptor mechanism causing a delay in apoptosis. Both oestradiol receptors subtypes 
(ER-a and b) are present in male and female neutrophils, however, the response of ER-
b to oestradiol is sex-dependent [241]. This regulatory mechanism seems to be 
associated with physiologic neutrophilia during pregnancy and labour [242]. Another 
example of neutrophil sexual-dimorphism is the stronger response of male neutrophils 
to chemokine CXCL6 in diverse acute inflammatory situations, resulting in increased 
stimulation and trafficking of bone marrow neutrophils [243]. Furthermore, several 
studies have shown that neutrophil sexual-dimorphism results in different prevalence, 
severity and mortality of disorders related with prolonged or excessive innate immune 
responses [244-246]. As previously described in Chapter 3, SMIM1 seems to be 
expressed on the neutrophil membrane. Thus, one could speculate that exposure of 
SMIM1 in the membrane of neutrophils may contribute to the retention mechanism 
within the bone marrow or to their clearance/apoptosis, which may be hormonally 
regulated. Moreover, Grassi et al. have shown that SMIM1 is highly expressed in the 
initial steps of neutrophil differentiation, which are important for the establishment of 
neutrophil cytotoxic capability [247]. Altogether, these observations suggest that 
SMIM1 plays a role in the function of neutrophils. 
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Analysis of platelet traits of Vel-negative blood donors on an automated haematology 
analyser revealed that SMIM1 is associated with platelet production (Table 4.7). The 
effects of SMIM1 however, manifest in a different sex-dependent manner. In female 
blood donors, the absence of SMIM1 leads to a higher production of platelets, reflected 
in higher immature platelet fraction, platelet count and plateletcrit. Male donors lacking 
SMIM1, in turn, shown production of larger platelets, reflected by an increase of 
platelet large cell ratio and mean platelet volume. The alterations observed in platelets 
of female Vel-negative blood donors suggest an increased platelet turnover, while the 
alterations observed in males suggest an impairment in proplatelet/platelet formation. 
Immature and large platelets are enzymatically and metabolically more active than 
mature platelets [248, 249], and are associated with an increased platelet reactivity 
(increased aggregation, increased expression of adhesion molecules). Importantly, it has 
been reported that the increase of these traits is associated with an increased risk of 
myocardial infarction in healthy individuals and with adverse health outcomes in 
patients with cardiovascular disease [250-255].  
 
Analysis of blood traits in Vel-negative/weak individuals of the UK Biobank 
In this chapter, I described an association analysis of Vel-negative/weak individuals 
(part of 400,000 participants of UK Biobank) with several blood traits. UK Biobank 
participants were not selected for any specific trait. Though, they are not fully 
representative of the general population, as they live in less socioeconomically deprived 
areas and are “healthier” (“healthy participant” selection bias) than the general 
population (https://www.ukbiobank.ac.uk). The extrapolation of prevalence and 
incidence rate of Vel-negative blood type in this study is, therefore, not accurate. 




Herein, I showed associations between SMIM1-17-bp deletion (rs566629828 – 
homozygous and heterozygous individuals) and a number of RBC traits, suggesting a 
role during erythropoiesis (Table 4.7). Specifically, I observed a negative association of 
rs566629828 with immature reticulocyte and reticulocytes; and a positive association 
with RDW. These findings are in agreement with observations in Vel-negative blood 
donors. Furthermore, rs566629828 presented a negative association with HGB and 
MCHC traits. Together, these observations suggest that SMIM1 may regulate 
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erythropoiesis and possibly HGB synthesis. However, SMIM1 role in the latter process 
is likely to be dependent on other factors, since Vel-negative blood donors did not show 
significant differences in HGB or MCHC. Intriguingly, given the reduced number of 
reticulocytes, the RBC count was unaffected.  
 
i) Neutrophils and platelets 
Contrary to the observations in Vel-negative blood donors, Vel-negative/weak 
individuals did not show differences in neutrophil count (Table 4.7). Moreover, 
rs566629828 was negatively associated with platelet count and plateletcrit in both male 
and female Vel-negative/weak individuals, as opposed to a positive association in Vel-
negative donors. This suggests that SMIM1 is a regulator of platelet formation, but its 
role is influenced by other factors not yet identified. As previously mentioned, the 
differences observed in both cohorts (Vel-negative blood donors and Vel-negative/weak 
individuals) may be explained by i) different associations between heterozygous and 
homozygous individuals and/or ii) the alteration of iron homeostasis in blood donors by 
repeated blood donation [229]. Altogether, these findings indicate that SMIM1 is 
important for the regulation of platelet production, with a possible role during 
megakaryocyte maturation. Consequently, these alterations may impact platelet 
function, a hypothesis further investigated in Chapter 5.  
 
Analysis of blood traits in Smim1 mutant mice 
Using the Smim1 mutant mice model, I discovered that the effect of SMIM1 in 
qualitative and quantitative traits of blood cells in mice are less pronounced and with 
different trends than the observed in humans (Table 4.7). Mature Smim1 mutant male 
mice had an increase of RBC, HGB, HCT and MCV, suggesting that SMIM1 is 
important for the regulation of erythroid differentiation. As HGB and MCV are 
associated with characteristics that are developed during erythroid maturation, this may 
suggest that SMIM1 is important for the regulation of erythroid maturation. Moreover, 
decreased RBC deformability without alteration of cell smoothness in Smim1-/- male 
mice, suggests that the lack of SMIM1 in the phospholipid bilayer may affect the 
spectrin-network binding, and in turn, RBC function. Young and mature Smim1-/- male 
mice presented opposite trends in RBC traits (i.e. a decrease of RBC traits of younger 
male mice). Interestingly, the same inversion of trends was observed in the body weight 
of these mice. Taking into consideration the opposite trends in RBC parameters, as well 
as, the alteration in liver morphology in mature mice, the increase observed in RBC 
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parameters of mature mice could be due to: i) a compensatory mechanism to overcome 
a deficit of functional RBCs, and/or ii) an impaired clearance of stressed RBCs. The 
increase of stressed RBCs could contribute to increased levels of tissue-damaging iron, 
heme and HGB in the circulation, and consequently induce oxidative stress in the liver, 
possibly explaining the alterations observed in the liver. On the other hand, the liver 
alterations may also result from an accumulation of lipid droplets, which may be related 
to increased body weight. In addition, SMIM1 seems to be important for regulation of 
WBC production and appears to have a stronger effect in female mice, suggesting that 
SMIM1 role is hormonally regulated. Female hormones have been shown to regulate 
not only apoptosis in neutrophils (as described above), but also apoptosis and activation 
of lymphocytes-B, specifically oestrogen protects lymphocyte-B receptor-mediated 
apoptosis [256].  
 
The differences in the effect of SMIM1 in human and mice blood traits may indicate a 
distinct molecular mechanism behind its function in blood cells of mice and human. 
However, one cannot exclude the possibility that those differences could be age-
dependent. The mice used in this study were considerably younger than the Vel-
negative blood donors. In addition, these mice were not in reproductive senescence 
[257], while the average of Vel-negative blood donors taking part in this study falls into 
reproductive senescence. In the eventuality that the effects of SMIM1 are proven to be 
hormonally regulated, as some of the observations suggest, this can have an impact in 
the observed phenotypes. 
  
Chapter 4 
   119 
 
Table 4.7 – Summary of full blood count parameters significantly altered in the 
different cohorts. 
 
RBC – red blood cell count; HGB – haemoglobin concentration; HCT – haematocrit; 
MCV – mean cell volume; MCHC – mean cell haemoglobin concentration; Ret – 
reticulocyte count; Ret % – reticulocyte percentage; IRF – immature reticulocyte 
fraction; RDW – red blood cell distribution width; PLT – platelet count; MPV – mean 
platelet volume; PCT – plateletcrit; P-LCR – platelet larger cell ratio; IPF – immature 
platelet fraction; WBC – white blood cell count; NEUT – neutrophil count; NEUT % – 
neutrophil percentage. 
 
Novel metabolic phenotype 
The examination of BMI and body weight in Vel-negative blood donors and Smim1 
mutant mice, respectively, showed that the absence of SMIM1 results in an increased 
BMI in male Vel-negative blood donors, and in an increased body weight in Smim1-/- 
female mice. This implies some common features in both models, that may or may not 
be a direct consequence of SMIM1 effect. These findings suggest that directly or 
indirectly SMIM1 may be an important regulator of glucose and/or lipids metabolism 
and therefore, its ablation results in an increase of body weight. Given the distinct blood 
phenotypes in both models, this metabolic phenotype is most likely independent of the 
effect of SMIM1 in blood cells. A tissue-specific Smim1 knockout in haematopoietic 
Increase Decrease Increase Decrease
RDW-SD (p=0.0283) RBC (p=0.0332) RDW-SD (p=0.0081) RBC (p=0.0332)
__ RET (p=0.0043) __ RET (p=0.0038)
__ RET % (p=0.0115) __ RET % (p=0.0233)
__ IRF (p=0.0449) __ IRF (p=0.0024)
PLT (p=0.0003) __ MPV (p=0.0408) __
PCT (p=6.4E-6) __ P-LCR (p=0.0274) __
IPF (p=0.0037 __ __ __
__ __ WBC (p=0.0243) __
__ __ NEUT (p=0.0065) __
__ __ NEUT % (p=0.0362) __
RDW-CV (p=2.8E-50) RET (p=2.7E-21) RDW-CV (p=2.8E-50) RET (p=2.7E-21)
MSCV (p=4.2E-10) RET % (p=4.3E-20) MSCV (p=4.2E-10) RET % (p=4.3E-20)
__ IRF (p=1.3E-10) __ IRF (p=1.3E-10)
__ MCHC (p=7.0E-8) __ MCHC (p=7.0E-8)
__ HGB (p=0.0016) __ HGB (p=0.0016)
__ PLT (p=0.0003) __ PLT (p=0.0003)
__ PCT (p=0.0002) __ PCT  (p=0.0002)
WBCs __ __ __ __
MCV (p=0.0255) __ __ RBC (p=0.0391)
__ __ __ HCT (p=0.0386)
Platelets __ __ __ __
WBCs __ __ __ __
__ __ RBC (p=0.0142) __
__ __ HCT (p=0.0044) __
__ __ HGB (p=0.0012) __
__ __ MCV (p=0.0148) __
Platelets __ __ __ __
WBCs WBC (p=0.0054) __ WBC (p=0.0470) __
RBCs









Vel-negative        
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cells or a bone marrow transplant of a Smim1-/- mouse into a wildtype mouse, would be 
important to clarify if the body weight increase, as well as, the liver alteration observed 
in male mice are a direct cause of Smim1 ablation or a consequence of its ablation effect 
in blood cells. This investigation may have clinical implications not yet identified, since 
excess body weight is strongly associated with several chronic diseases such as 
diabetes, and cardiovascular and liver diseases [258].  
 
An obvious pitfall of this study is the small size of both Vel-negative cohorts. It would 
be important to confirm these findings in a larger study, such as the 500,000 individuals 
- UK Biobank study and 50,0000 blood donors - INTERVAL study, which will be soon 
available for the research community. Additionally, it would be important to further 
investigate the consistency of these findings in a cohort representative of the general 
population. On the other hand, it would be important to further investigate the molecular 
mechanism underlying the phenotypes here identified and assess if other metabolic 
markers of both humans and mice are affected. 
 
In conclusion, my work has shed new light on the role of SMIM1 on multiple blood cell 
types traits, and it has revealed a novel association with body composition and liver 
morphology. These findings may have important clinical implications, as several of the 
associations I described here are known to increase the risk for diseases such as 
cardiovascular and liver disease. 
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CHAPTER 5 | 
CHARACTERISATION OF SMIM1 
ROLE IN MEGAKARYOPOIESIS AND 
PLATELET FUNCTION 
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5.1 Introduction 
The fact that SMIM1 displays high levels of gene and protein expression in MKs and 
platelets (Chapter 3), raised the possibility that SMIM1 may play a role in the 
development and function of these cell types. Indeed, the characterisation of blood traits 
in human natural SMIM1 knockouts in Chapter 4, showed that SMIM1 absence leads to 
an alteration of platelet production. Specifically, an increase in platelet counts in Vel-
negative/weak donors and a decrease in platelet counts in Vel-negative individuals from 
UK Biobank was observed. These observations suggest that SMIM1 may be relevant for 
the regulation of important aspects of megakaryopoiesis and/or thrombopoiesis and also 
platelet function. The determination of the role of SMIM1 in those processes and its 
underlying molecular mechanism is yet to be uncovered. Uncovering the underlying 
molecular mechanism of SMIM1 role in these processes will lead to a better 
understanding of the biology. In turn, this may provide important information for the 
development of new therapies to treat conditions related with 
megakaryopoiesis/thrombopoiesis and to improve protocols for in vitro MK/platelet 
production. 
 
Defects in megakaryopoiesis and thrombopoiesis can lead to quantitative and qualitative 
defects in platelet production, that may affect platelet function and/or clearance, and 
culminate in the findings noted in platelet inherited disorders (for review [83, 84, 259]). 
Defects in megakaryopoiesis and thrombopoiesis arise from alterations in the following 
stages: MK lineage commitment and differentiation, MK maturation and platelet release 
[84]. Defects in platelet function result from alterations in the different steps of this 
process, which are described below [83]. Resting platelets in the bloodstream respond to 
a blood vessel injury by adhering at the injury site, which then leads to a drastic change 
of their shape, secretion of their granule content, and aggregation to form a platelet clot 
[144]. Platelet response is tightly regulated by a complex network of inhibitory and 
activation signals [136]. Defects in platelet function can, therefore, be categorised as 
defects in: adhesion, receptors and signalling that control platelet secretion and 
aggregation, granules biogenesis and secretion, aggregation and procoagulant activity 
(for review [83, 119]). A dysregulation in platelet responses can either lead to a hyper-
reactive or to a hypo-reactive state, which can increase the chance of arterial and venous 
thrombotic events (e.g. tissue ischemia or infarction) or can lead to bleeding disorders, 
respectively.  
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Models to study megakaryopoiesis/thrombopoiesis – forward programming of human 
iPSC (hiPSC)  
The understanding of megakaryopoiesis and thrombopoiesis was greatly advanced with 
the discovery of mpl receptor and the function of its ligand, TPO, in megakaryopoiesis 
[39, 56, 260-262]. This discovery and subsequent cloning of TPO allowed the 
development of several culture systems to study megakaryopoiesis/thrombopoiesis[263-
267]. These culture systems have been successfully developed using a variety of human 
stem cells, including cord blood and adult CD34+-hematopoietic progenitors, embryonic 
stem cells and more recently iPSC, that all differentiate into MKs. While using CD34+-
hematopoietic progenitors has the advantage of allowing the recapitulation of definitive 
(adult) megakaryopoiesis, this system is donor-dependent and limited: first these cells 
cannot be maintained indefinitely in culture; second, its genetic manipulation is 
challenging. Embryonic stem cells and iPSCs thus constitute a good alternative to 
CD34+-hematopoietic progenitors, as they are able to be maintained in culture and can 
be easily genetically manipulated. However, the differentiation potential of these cells is 
limited, because most of the derived-MKs recapitulate primitive (embryonic) 
megakaryopoiesis [268]. The majority of the culture systems described in the literature 
are based on a direct sequential differentiation using cytokines and/or stromal cells 
[263-265]. However, a new method was developed recently, in which the generation of 
MKs in chemically defined conditions is achieved by using a forward programming 
approach that relies on the exogenous expression of three transcription factors: 
GATA1, FLI1 and TAL1. This method gives higher cell yields and purity compared 
with a standard MK-directed differentiation approach [207]. 
 
5.2 Chapter aims and overview 
In this chapter I describe two main aims: i) the characterisation of SMIM1 role during 
megakaryopoiesis/thrombopoiesis and ii) the investigation of SMIM1 role in platelet 
function.  
 
Using a SMIM1- knockout and a SMIM1-overexpression hiPSC line, created by 
CRISPR/Cas9n technology and lentiviral overexpression, respectively, I have 
investigated the importance of SMIM1 during megakaryopoiesis. I assessed the ability 
of these hiPSC lines to form MKs and I characterised MK maturation markers and 
ploidy during this process. These experiments showed that SMIM1 is not crucial for 
 
124   
megakaryopoiesis in this in vitro model. Furthermore, analysis of MK number within 
the bone marrow of Smim1 mutant mice, as well as analysis of platelet morphology by 
transmission electron microscopy (TEM), also showed no striking differences, 
suggesting that SMIM1 is not crucial for MK formation and platelet morphology in the 
mouse.  
 
Next, I have investigated the role of SMIM1 in platelet function. Firstly, using platelets 
of Vel-positive donors, I characterised the surface expression of SMIM1 during platelet 
activation by flow cytometry and Western blot. I showed that upon human platelet 
activation SMIM1 does not become exposed on the platelet membrane, but interestingly 
it is phosphorylated, suggesting a function during platelet activation. To further 
investigate this hypothesis, I have performed different platelet activation assays using 
platelets of Smim1 mutant mice. Whereas a decrease of basal P-selectin exposure on 
platelets of male Smim1-/- mice was detected, no difference in platelet response to 
different agonists or platelet spreading in both male and female Smim1 mutant mice 
were observed. 
 
5.3  Results 
5.3.1  Assessment of SMIM1 importance during megakaryopoiesis  
To investigate the relevance of SMIM1 during megakaryopoiesis, I created a SMIM1-
knockout hiPSC line and a SMIM1-overexpression hiPSC line, which were forward 
programmed into MKs.  
5.3.1.1  hiPSC SMIM1 knockout using CRISPR/Cas9n  
As a first step CRISPR/Cas9n target gene editing was used in hiPSC, to create a SMIM1 
knockout line. Three pairs of sgRNA were designed to target the coding region of the 
SMIM1 genomic locus. More specifically, the guide sequences were designed to bind 
close to the N-terminal of the protein (start codon), increasing the possibility that the 
indel created would lead to a true null allele (Figure 5.1 – B). The different guide 
sequences were individually cloned into a plasmid containing a scaffold and the Cas9n 
(Figure 5.2 – C), as described in section 2.3.2. This strategy was preferentially used 
because it has been shown to have a reduced number of off-target effects [269]. The 
sequence of sgRNAs was confirmed by Sanger sequencing and the plasmid was 
expanded as described in section 2.3.2.2.  
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Figure 5.1 – Targeting SMIM1 using CRISPR/Cas9n. A - Schematic representation 
of CRISPR/Cas9n strategy to target a genomic sequence. The Cas9n is targeted to 
genomic DNA by an sgRNA consisting of a 20-nt guide sequence (blue) and a scaffold 
(red). The guide sequence pairs with the complementary DNA target (DNA target - blue 
bar on opposite strand, upstream of a requisite PAM sequence in red). Cas9n mediates a 
cleavage of the DNA strand 3 bp upstream of the PAM (red triangle). Panel adapted 
from [269]; B - Representation of the binding pattern of different pairs of sgRNA used 
to target SMIM1; C - Map of the plasmid containing the Cas9n and scaffold, which was 
used to clone the guide sequences. 
 
A previously characterised hiPSC line, S4, was used to perform the genomic editing of 
SMIM1 by CRISPR/Cas9n [201]. hiPSCs were transfected by nucleofection with 
increasing concentrations (2 and 10 µg) of sgRNA/Cas9n pairs. Nucleofection 
efficiency was determined by fluorescent microscopy 24h after, and it was estimated to 
be approximately 10% (Figure 5.2 A and B). Several colonies for the three different 
pairs were obtained after puromycin selection. In all the three pairs, it was observed a 
higher number of colonies in the nucleofection with 10 µg of DNA (data not shown). 
Eight, four and six individual colonies of pair 1, 2 and 3, respectively, were manually 
picked and expanded. The gDNA of these colonies was extracted for screening and 
amplified as described in section 2.3.2.2. Sanger sequencing of the SMIM1 locus has 
shown that CRISPR/Cas9n system was very effective in SMIM1 editing. An indel in the 
target region was observed for all the analysed clones. In addition, the clone obtained in 
the negative control (PX462) had no mutation in the SMIM1 locus, as expected. 
Moreover, it was observed that the heterozygous editing (n=17) was more frequent than 
homozygous editing (n=1).  
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Figure 5.2 – CRISPR/Cas9n approach for SMIM1 editing in hiPSCs. A - Timeline 
showing relevant time points for the targeting and screening of SMIM1 editing; B - 
Determination of nucleofection efficiency through fluorescent microscopy of hiPSCs 
transfected with positive control (pGFP); C - Overview of the experiments and results 
obtained for each sgRNA/Cas9n pair.  
 
Sanger sequencing of the homozygous clone obtained using pair 2, showed a 
homozygous 39-bp deletion (Figure 5.3). This deletion, however, has a conserved 
reading frame and even though the sequence of the protein is unaltered after the 
deletion, most likely it will originate a non-functional protein (Figure 5.3). To determine 
the different haplotypes in the heterozygous clones, I performed Sanger sequencing of 
several bacterial colonies obtained by cloning the PCR product of each clone. The 
analysis of two heterozygous clones, one from pair 1 and another from pair 3, 
demonstrated that the clone from pair 1 had two haplotypes, while the clone from pair 3 
had three haplotypes, indicating that it was a mixed clone. For pair 1, the observed 
haplotypes were: i) a 46-bp deletion (this haplotype was observed in six colonies of the 
eleven analysed; 6/11) and ii) a 25-bp insertion plus 2-bp deletion (5/11). These 
haplotypes give rise to an early stop codon in the beginning of the protein and, most 
probably, the short protein produced is not functional and/or is degraded (Figure 5.3). 
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As SMIM1 is not expressed in hiPSC, it was not possible to confirm SMIM1 ablation by 
western blot. The SMIM1-knockout hiPSC line created with pair 1, named S4-Cas9n-




Figure 5.3 – SMIM1 mutations obtained by CRISPR/cas9n technology. A - 
Alignment of SMIM1 WT sequence with the SMIM1 sequence obtained in the 
heterozygous clone of pair 1 (haplotypes 1 and 2) and in the homozygous clone of pair 
2. The sequence of the resultant protein is also represented. B - Schematic 
representation of the SMIM1 protein structure with the initial targeting of each 
haplotype analysed. Arrows in red correspond to pair 1 (haplotype 1 and 2) and in green 
to pair 2.  
 
5.3.1.2 SMIM1 overexpression in hiPSCs 
To further characterise the role of SMIM1 during megakaryopoiesis and determine 
SMIM1 interactome in MKs, an hiPSC line overexpressing tagged SMIM1 was created 
using a lentiviral plasmid. The lentiviral plasmid, carrying an in-frame fusion of tandem 
affinity purification (TAP)-tag at the N-terminal coding region of SMIM1 gene, was 
created as described in section 2.3.4.1. The TAP-tag is composed by an N-terminal 
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calmodulin binding domain and a C-terminal 3x Flag repeated separated by a TEV 
cleavage site. This tag was chosen because its small size is expected to reduce possible 
allosteric constraints with SMIM1 interactors, and also because it allows a two-step 
purification, which reduces unspecific binding of interactors. The lentivirus of TAP and 
TAP-SMIM1 lentiviral plasmids were produced in HEK293T cells and used to 
transduce Bobc hiPSC as described in section 2.3.4.2. Transduced hiPSCs were then 
sorted by FACS based on GFP expression at NIHR Cambridge BRC Cell Phenotyping 
Hub, University of Cambridge and then expanded. At the time of writing, I have not 
been able to optimise the pull-down protocol to obtain the purity of protein required for 
proteomic studies. Therefore, the interactome of SMIM1 is still unknown. Bobc hiPSCs 
were chosen because of an improvement of the forward programming method to a 2D 
system by Dr Thomas Moreau. The 2D system improved the efficiency of MK 
production, which would be relevant for the pull-down experiment. The increased MK 
production, however, was cell-line dependent and not as efficient in S4 (personal 
communication of Dr Thomas Moreau). 
5.3.1.3 Forward programming of SMIM1 knockout and SMIM1 overexpression 
hiPSC line towards MK  
To investigate the effect of SMIM1 ablation during megakaryopoiesis, the S4-Cas9n-
SMIM1 hiPSC line was differentiated towards MK using a 3D-forward programming 
method that was developed by Moreau et al. (see section 2.3.3 [207]). Briefly, the S4-
control and S4-Cas9n-SMIM1 hiPSC lines were transduced with the transcription 
factors GATA1, TAL1 and FLI1, that together with medium containing BMP and FGF 
induced hiPSC into a mesoderm commitment. Then using MK differentiation medium 
(containing TPO and SCF) cells were differentiated into MK progenitors and finally 
towards mature MKs, in an approximately twenty-days (Figure 5.4 – A). The ability of 
S4-Cas9n-SMIM1 to form MKs was assessed by following the surface expression of 
CD235a, CD41a and CD42a overtime by flow cytometry (as described in section 2.3.3). 
It was observed that the S4-Cas9n-SMIM1 line, like the S4-control line, was able to 
form EBs and differentiate towards MKs. No differences in surface expression of 
CD235a, CD41a and CD42a were detected during the differentiation process of S4-
Cas9n-SMIM1 line, when compared to S4-control line (Figure 5.4 – B). The role of 
SMIM1 in megakaryopoiesis was further examined by forward programming of 
SMIM1-overexpressing hiPSC line into MKs. Six rounds of Bobc-TAP-SMIM1 and 
Bobc-TAP forward programming were followed by flow cytometry as described above 
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and the cultures were collected for pull-down experiments when reached at least 60% of 
mature MKs (CD41a/CD42a positive cells). This experiment showed that SMIM1 
overexpression also does not affect the expression level of CD235a, CD41a and CD42a 
(Figure 5.4 – C).  
 
 
Figure 5.4 -SMIM1 does not affect megakaryopoiesis in vitro. A - Schematic 
representation of hiPSCs 3D forward programming into MKs [207]. B - Flow cytometry 
time course of 3D forward programming of S4 and S4-Cas9n-SMIM1 into MKs, 
showing percentage of MK progenitor (%CD41a+/CD235a+ cells - green), MK lineage 
committed (%CD41a+ cells - purple) and mature MK (%CD42a+ cells - blue) from 
whole culture (n=1, from day 9 to day 17 of forward programming). C- Flow cytometry 
time course of 2D forward programming of Bobc-TAP and Bobc-TAP-SMIM1 into 
MKs, showing percentage of MK progenitor (%CD41a+/CD235a+ cells - green), MK 
lineage committed (%CD41a+ cells - purple) and mature MK (%CD42a+ cells - blue) 
from whole culture (n=6, from day 10 to day 25 of forward programming). Analysis 
performed using Student T-test. D – Ploidy analysis of Bobc-TAP and Bobc-TAP-
SMIM1 mature MKs (CD41/CD42+ cells) by flow cytometry. Histograms of DNA 
content were obtained by gating cells positive for Hoechst and double positive for CD41 
and CD42. Representative results of 2 independent experiments. 
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DNA ploidy was also assessed as a marker for MK differentiation by flow cytometry. 
The DNA content of TAP-SMIM1 mature MKs (CD41/CD42 positive MKs) obtained 
in two independent experiments of forward programming, did not differ from the DNA 
content of TAP mature MKs (control, Figure 5.4 - D). It should be noted that both TAP-
SMIM1 and TAP mature MKs, presented low levels of ploidy, which is in agreement 
with previous observations using the same method [207].  
 
During maturation, MKs in the bone marrow migrate from the osteoblastic niche 
towards the sinusoids, where through a tight process of proplatelet formation they then 
release platelets to the bloodstream [75]. To determine whether proplatelet formation 
was affected by overexpression of SMIM1, cultures of forwarded programmed mature 
MKs were placed onto fibrinogen-coated coverslips for 48h. Very few MKs with 
proplatelet formation could be detected in both conditions, TAP-SMIM1 and TAP. This 
impaired any quantification of proplatelets and therefore halted any conclusion on the 
role of SMIM1 in proplatelet formation. This result was observed in two independent 
forward programming experiments, suggesting that the reduced level of proplatelets 
formation is most likely due to the maturation level of the MKs.  
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5.3.1.4 Bone marrow MK counts and platelet ultrastructure are unaffected in 
Smim1 mutant mice 
Megakaryopoiesis was also characterised in the Smim1 mutant mouse model, through 
the examination of MK number in the bone marrow of six-month-old Smim1 mutant 
mice. Sections of mouse hind legs bones were stained with H&E and MKs, were 
manually quantified (Figure 5.5 – A). As shown in Figure 5.5 – B, no differences were 
observed in the MK number present in the bone marrow in Smim1 mutant mice when 
compared with the wildtype control. 
 
 
Figure 5.5 - Megakaryocyte number is not altered in Smim1 mutant mice. A- 
Representative images of bone marrow sections of six-month old wildtype, Smim1+/- 
and Smim1-/- male mice that were stained with H&E. These images represent only a 
section of a field of view. Green arrows indicate MKs (x10). B- Quantification of MKs 
in the bone marrow was performed blinded by manual count of MKs in ten fields per 
mouse. Data show mean ± standard deviation. Black square – wildtype, blue circle – 
Smim1+/-, red triangle – Smim1-/-. Statistical analysis was performed using Anova for 
males and unpaired T-test for females (no significant differences were observed). 
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To investigate whether SMIM1 was relevant for platelet ultrastructure, washed platelets 
of four months old Smim1-/- and wildtype mice were fixed and prepared for TEM. Fixed 
platelets were processed by Dr James McMillan at Cambridge Advanced Imaging 
Centre and, sections and imaging were performed by me with Dr James McMillan’s 
support. Analysis of platelet ultrastructure by TEM did not reveal abnormalities in 
Smim1-/- platelets structure as shown in Figure 5.6.  
 
Figure 5.6 - SMIM1 does not affect ultrastructure of mice platelets. Platelets were 
isolated and fixed for TEM as described in section 2.2.7 and 2.2.10, respectively. TEM 
representative pictures of wildtype and Smim1-/- mice platelets. Scale bar - 500 nm. 
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5.3.1.5 RNA-sequencing of Smim1 mutant mice platelets 
Although platelets are anucleate cells, they have a rich repertoire of RNAs, including 
messenger RNAs, structural and catalytic RNAs, and regulatory RNAs, that are 
obtained from MKs and are crucial for platelet function. Thus, alterations in the platelet 
transcriptome may give key clues to understand the role of SMIM1 not only in platelet 
function but also in MKs and platelet formation [270]. To explore this hypothesis, I 
have assessed the platelet transcriptome of Smim1-/- mice by RNA-sequencing. Platelet 
pellets of three to four six-month-old male mice were pooled together, to obtain enough 
high-quality RNA for the RNA-sequencing analysis. The sequencing and analysis were 
performed in four and three independent pools of wildtype and Smim1-/- mouse platelets, 
respectively. This strategy not only improved the quality of the RNA but also reduced 
the inter-mouse variability in gene expression, therefore making it easier to identify the 
effects caused by SMIM1 ablation. After RNA extraction, four wildtype and three 
Smim1-/- RNA-sequencing libraries were prepared by Ms Frances Burden, Research 
Associate in Prof. Ouwehand group. The differential expression analysis at a 5% false 
discovery rate performed by Dr Denis Seyres, Research Associate in Prof. Ouwehand 
group, showed that the transcriptome of wildtype and Smim1-/- platelets was similar 
(Figure 5.7 - A), with only 12 genes being differentially expressed (four down-regulated 
and eight up-regulated) (Figure 5.7- B, Table 5.1). Manual annotation of the 
differentially expressed genes showed no particular enrichment for a biological process 
or pathway, and most of the genes were uncharacterised in platelets 
(http://pantherdb.org/geneListAnalysis.do). Five genes encode for binding proteins 
(Arrdc3, Tnfaip2, Gng4, Lrrc41 and Afdn), two genes encode for transporter proteins 
(Slc38a6 and Nacad) and three genes encoding for motor and cytoskeleton proteins 
(Dcdc2a, Sfi1 and Myo1g) (http://pantherdb.org/geneListAnalysis.do). The 
Unconventional myosin-Ig (Myo1g) gene, which was up-regulated, encodes a predicted 
actin/ATP binding protein that has been described as part of phosphatidylinositol 3,4,5- 
trisphosphate (PtdIns(3,4,5)P3) interactome/signalosome in platelets, which is important 
for platelet activation [271].  
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Figure 5.7 – Differential gene expression of Smim1-/- platelets. A - Principal 
component analysis showing the variance between wildtype (WT-blue) and Smim1-/- 
(SMIM1Homo - red) platelets. B - Volcano plot showing the genes differentially 
expressed between wildtype and Smim1-/- platelets at a 5% false discovery rate. Up-
regulated genes are highlighted in blue and down-regulated genes are highlighted in red. 
 
Table 5.1 – Genes differentially expressed in Smim1-/- platelets. Differential 
expression analysis at a 5% false discovery rate, up-regulated genes in blue and down-
regulated genes in red. 
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5.3.2 Investigation of SMIM1 role in platelet function 
Although the observation described above suggests that SMIM1 does not affect 
megakaryopoiesis nor platelet ultrastructure, it cannot be excluded a possible role of 
SMIM1 in platelet function. Therefore, I then characterised the SMIM1 role in platelet 
function using different assays that assessed distinct features of activated platelets.  
 
As the Vel-negative donors that took part of this study were recruited across the UK, 
and platelet function needs to be performed within 30 minutes after blood collection 
[272], it was not possible to perform platelet function studies in these donors. Therefore, 
to investigate the role of SMIM1 in platelet function, I have used Vel-positive donors 
and taken advantage of Smim1 mutant mice model. Mice constitute a good model to 
study platelet function, not only due to its platelet function similarity with humans [273-
275], but also because it provides access to a large number of samples with an identical 
genetic background, which reduces the interindividual variability in platelet function 
observed in human subjects [276-279], therefore making it easier to discriminate the 
effects, if any, caused by the absence of SMIM1.  
 
5.3.2.1 SMIM1 is phosphorylated upon platelet activation in humans 
In Chapter 3, it was shown that SMIM1 has a cytoplasmic localisation in human 
platelets and co-localises in the fractions enriched for α-granule´s proteins, suggesting 
that SMIM1 has an intracellular distribution similar to these proteins. To address 
whether SMIM1 localisation would change upon platelet activation, as is observed for 
P-selectin (an a-granule protein), whole blood of Vel-positive donors was stimulated 
with TRAP. Platelet response to the agonist and SMIM1 localisation was determined by 
P-selectin and SMIM1 surface expression using flow cytometry. Flow cytometry 
analysis showed that SMIM1 is not detected on the platelet membrane upon platelet 
activation (Figure 5.8 - A). To further characterise SMIM1 during platelet activation, 
washed platelets were stimulated with TRAP, and SMIM1 was detected by western 
blot. Western blot of stimulated platelet lysates showed an increase of SMIM1 
molecular weight upon activation (Figure 5.8 – B-C). As it has been shown that SMIM1 
undergoes to post-translation modifications, such as phosphorylation [182, 188, 208, 
212], to determine if the changes of electrophoretic mobility observed upon platelet 
activation were due to phosphorylation, platelet lysates were then treated with either 
phosphatase Lambda or with a phosphatase inhibitor. Stimulated platelet lysate treated 
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with phosphatase Lambda showed a reduction of SMIM1 molecular weight when 
compared with the stimulated platelet lysate treated with the phosphatase inhibitor 
(Figure 5.8 – B-C). The molecular weight of stimulated platelet lysate treated with 
phosphatase Lambda was similar to the molecular weight observed in resting platelets 
lysates treated with phosphatase Lambda or with a phosphatase inhibitor (Figure 5.8 - 
C). Thus, indicating that SMIM1 is phosphorylated upon platelet activation. 
 
 
Figure 5.8 - SMIM1 is not expressed on the platelet membrane but is 
phosphorylated upon platelet activation. A - SMIM1 expression during platelet 
activation was assessed by flow cytometry of whole blood stimulated with TRAP 
agonist (3µM) and stained with anti-CD62-PE-Cy5 (which detects P-selectin), anti-
SMIM1 (SpG213Dc human monoclonal) and FITC-secondary antibody against 
SMIM1. Dot plot of gated platelets shows no expression of SMIM1 and 39% of P-
selectin expression on platelets after stimulation with TRAP agonist. B - Washed 
platelets were prepared as described in section 2.1.3.1 and treated with either platelet 
inhibitors (Resting) or agonist (TRAP – 5µM). Platelet response to agonist was assessed 
by P-selectin (CD62P-APC) expression on platelet membrane (% of P-selectin+cells) 
using flow cytometry. C - Western blot of platelets lysates obtained in (B) were then 
treated either with phosphatase Lambda or phosphatase inhibitor. Detection of SMIM1 
using the polyclonal anti-SMIM1 antibody (Sigma) shows a reduction of SMIM1 
molecular weight in activated platelets treated with phosphatase lambda, indicating that 
SMIM1 is phosphorylated upon activation. β- actin was used as loading control and the 
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5.3.2.2 Basal levels of P-Selectin surface exposure are decreased in male Smim1 
mutant mice but platelet activation is unaffected 
During platelet activation, platelets secrete their granule contents, this consequently 
leads to the activation of more platelets and contribute to platelet aggregation and clot 
formation [144]. During this process, various phenomena can be observed. Among 
those, P-selectin, an a-granule protein, becomes exposed on the platelet membrane and 
the GPIIbIIIa complex (CD41/CD61 complex, fibrinogen receptor) is activated 
inducing fibrinogen binding and thus promoting platelet aggregation. To investigate 
whether ablation of Smim1 affected platelet activation, whole blood from four-month-
old Smim1 mutant and wildtype mice was stimulated with a range of concentrations of 
cross‐linked collagen‐related peptide (CRP-XL) and thrombin. Platelet response to the 
different agonists was determined by flow cytometry, measuring the expression of P-
selectin (detected by anti-mouse P-selectin- PE antibody) and fibrinogen binding 
(detected by anti-human fibrinogen-FITC) (analysis strategy is described in section 
2.2.11).  
 
In the resting state, platelets from Smim1 mutant male mice showed a significant 
reduction in the basal level of P-selectin exposure (Smim1+/- - p=0.0134, Smim1-/- - 
p=0.0176) and a trend, albeit not significant, of reduction in the basal level of fibrinogen 
binding when compared to wildtype platelets (Figure 5.9 A). In contrast, no significant 
differences were observed in the basal level of P-selectin exposure and fibrinogen 
binding between platelets of Smim1-/- and wildtype female mice (Figure 5.9 – B). Upon 
platelet activation, platelets from Smim1-/- male mice treated with low concentrations of 
thrombin, showed a significant difference in fibrinogen binding between wildtype 
platelets (Smim1-/-: Thr (0.01 U/ml) - p=0.0204, Thr (0.1 U/ml) - p=0.0432) (Figure 5.9 
– D). The expression levels of P-selectin and fibrinogen binding in these conditions, 
however, are similar to the expression levels observed in the resting state (Figure 5.9 A 
and D). This suggests that the observed difference is due to a reduced basal level of 
fibrinogen binding and not to platelet response to thrombin. The difference observed 
between the two conditions, resting and thrombin low concentrations can be explained 
by the smaller number of mice analysed in the latter condition, which occurred due to a 
technical experimental problem when preparing the samples. In platelets of female 
mice, no significant differences in platelet response were observed between Smim1-/- 
and wildtype platelets (Figure 5.9 E-F). A trend, albeit not significant, of P-selectin and 
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fibrinogen binding reduction was observed in Smim1-/- platelets of female mice 
stimulated with CRP (Figure 5.9 -E). In summary, SMIM1 ablation does not affect 
platelet response to agonists in vitro. 
 
Figure 5.9 - Basal level of P-Selectin surface expression is decreased in platelets of 
Smim1 mutant males, but platelet activation is unaffected. Platelet response to no 
agonist, CRP and thrombin was assessed by flow cytometry of whole blood incubated 
with antibodies against P-selectin, fibrinogen and CD41. A-B - percentage of CD41+ 
platelets expressing P-selectin (left panel) and fibrinogen (right panel) in male (A) and 
female (B) mice whole blood not treated (without agonist). Data represents mean± 
standard deviation. Statistical analysis was performed using Student T-test and 
ANOVA-Tukey for females and males, respectively. 
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Figure 5.9 - Basal level of P-Selectin surface expression is decreased in platelets of 
Smim1 mutant males, but platelet activation is unaffected. C-E - percentage of 
CD41+ platelets expressing P-selectin (left panel) and fibrinogen (right panel) in male 
(C) and female (E) mice whole blood treated with CRP-XL. D-F - percentage of CD41+ 
platelets expressing P-selectin (left panel) and fibrinogen (right panel) in male (D) and 
female (F) mice whole blood treated with thrombin. Data represents mean± standard 
deviation. Statistical analysis was performed using Student T-test and ANOVA-Tukey 
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5.3.2.3 Platelet spreading is unaffected in Smim1 mutant mice 
Upon platelet attachment at the injury site, platelets undergo a drastic change in their 
shape, from a small discoid form to a spread and larger form, which results from the 
reorganisation of their cytoskeleton. To investigate whether SMIM1 ablation affected 
the ability of platelets to spread, washed platelets from four-month-old Smim1-/- and 
wildtype male mice were incubated on fibrinogen-coated coverslips for 30 minutes at 37 
°C. Fixed platelets were stained with phalloidin-A555 and both attached and spread 
platelets per field were quantified. No differences in platelet spreading were detected 
between Smim1-/- and wildtype mice (Figure 5.10). 
 
 
Figure 5.10 - SMIM1 does not affect mice platelet attachment and spreading. 
Washed platelets of wildtype and Smim1-/- male mice were prepared as described in 
section 2.2.9 and incubated onto fibrinogen-coated coverslips for 30 minutes at 37°C. 
Fixed platelets were stained with phalloidin-A555 and imaged using a wide-field 
fluorescence microscope. Attached (orange arrow) and spread (green arrow) platelets 
were manually counted in ten pictures per mouse using ImageJ software. Data represent 
the mean ± standard deviation of % platelets attached and spread per mouse (n=3). 
Statistical analysis was performed using the Mann-Whitney test. 
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5.3.2.4 Assessing expression level of a-granules proteins in platelets of Smim1-/- 
mice  
As evidence has pointed to a reduction in the basal level of P-selectin exposure, I 
looked at expression level of P-selectin and other a-granules proteins, such as VWF, 
THBS1 and VEGFA, in platelets of Smim1-/- and wildtype male mice by western blot. 
Platelet lysates of four months Smim1-/- and wildtype male mice were prepared as 
described in section 2.2.7 and immunoblotted with specific antibodies for the different 
a-granule proteins (described in section 2.2.8). No differences in protein level of P-
selectin and the other a-granule proteins were detected between Smim1-/- and wildtype 




Figure 5.11 – SMIM1 does not affect the expression level of P-selectin, VWF, 
THBS1 and VEGF-a. Western blot of platelet lysates from wildtype and Smim1-/- male 
mice show no differences in expression level of VWF, THBS1, P-selectin and VEGF-a. 
Platelet lysates of three animals per genotype were loaded in duplicate (20 µg/ lane) and 
β-actin was used as protein loading control.  
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5.4 Discussion 
SMIM1 is expressed in MKs and platelets and affects platelet count in humans (Chapter 
3 and 4). However, the molecular mechanism through which SMIM1 affects platelet 
formation, be it either an alteration in megakaryopoiesis, thrombopoiesis and/or platelet 
function/clearance, remains unknown. The identification of SMIM1 role in these 
processes and the characterisation of its molecular mechanism will improve the general 
knowledge of these processes. In turn, these findings may be important for the 
development of novel therapies for MK/platelets disorders and to prevent/treat disorders 
that Vel-negative individuals may acquire that are not yet characterised. 
 
In the present chapter, I have investigated the role of SMIM1 in megakaryopoiesis and 
in platelet activation in vitro. Firstly, I have characterised the role of SMIM1 in 
megakaryopoiesis using two models, hiPSC and mouse. The characterisation of 
megakaryopoiesis in SMIM1-knockout and SMIM1-overexpressing hiPSCs 
differentiated into MKs by forward programming, showed that SMIM1 does not alter 
the differentiation, maturation and ploidy in this model. This suggests that the alteration 
of platelet number in Vel-negative individuals, observed in the previous chapter, is not 
due to an impairment of megakaryopoiesis. As the forward programming model has 
several limitations regarding the maturity of the formed MKs and platelet production 
[207], it would be important to confirm these findings and further characterise the role 
of SMIM1 in proplatelet formation using a different model, such as Vel-negative CD34+ 
cells differentiated towards MKs.  
 
In the mouse model, bone marrow MK counts did not differ between Smim1-/- and 
wildtype mice, and the ultrastructure of Smim1-/- platelets was unaffected. Not 
surprisingly, given the absence of striking phenotypes in mouse MK and platelets, the 
characterisation of the platelet transcriptome in mice showed small differences in the 
transcription profile of Smim1-/- platelets. This resulted in a short list of genes 
differentially expressed. Among the identified genes, two of them seem to be involved 
in platelet function: Myo1g and Guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-4 (Gng4). Myo1g, which was up-regulated, encodes an unconventional 
non-muscle myosin. These types of myosin are important motor proteins that are 
thought to regulate exocytosis in different cell types [280]. It has been shown that 
MYO1C is part of PtdIns (3,4,5)P3 signalosome, which plays an important role in 
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platelet activation and thrombus formation [271]. The Gng4 gene, which was down-
regulated, encodes for a protein with GTPase activity predicted to be a transducer in 
various transmembrane signalling pathways important in platelet activation, such as 
ADP signalling through P2Y purinoceptor 1 and 12, prostacyclin signalling through 
prostacyclin receptor and also PI3K-Akt signalling 
(http://pantherdb.org/genes/gene.do?acc=MOUSE%7CMGI%3DMGI%3D102703%7C
UniProtKB%3DP50153). Even though most of the genes identified were 
uncharacterised in platelets, some of those genes are involved or predicted to be 
involved in cytoskeleton structure (Dcdc2a, Sfi1 and Myo1g) and in signalling 
transduction. As platelet formation and function involves rearrangements of the 
cytoskeleton, this could suggest that SMIM1 has a role in proplatelet formation and/or 
platelet function. However, as platelet count and MPV in six-months old Smim1-/- mice 
was shown to be unaffected in the previous chapter, together these findings suggest that 
ablation of SMIM1 in mouse does not affect megakaryopoiesis and by inference 
thrombopoiesis. 
 
In this chapter, I have also investigated the role of SMIM1 upon platelet activation. To 
this end, I used two models, human and mice, and I have assessed different features of 
activated platelets through a range of assays. The assessment of Smim1-/- platelets’ 
ability to spread was performed in static conditions and showed that Smim1-/- platelets 
spreading ability is unaffected. RNA-sequencing showed that some genes differentially 
expressed are implicated with cytoskeleton structure (Dcdc2a, Sfi1 and Myo1g), and 
given that the cytoskeleton constitutes a highly dynamic structure during 
proplatelet/platelet formation and in both resting and activated platelets, [137], it would 
be important to further characterise whether SMIM1 ablation affects these cellular 
dynamics in vivo. To assess proplatelet and platelet formation, two-photon intravital 
microscopy of the bone marrow of Smim1-/- mice could be performed as described by 
Dütting et al.[93]. While to specifically assess the cytoskeleton dynamics of resting and 
activated platelets, time-lapse microscopy of Smim1-/- platelets expressing end-binding 
protein 3(EB3)- GFP (EB3, is a protein that regulates microtubules dynamics) it could 
be performed as described by Patel-Hett et al. [137].  
 
The assessment of platelet response to different agonists by flow cytometry showed that 
the ablation of SMIM1 does not affect platelet response. Platelets of female Smim1-/- 
mouse stimulated with CRP, however, showed a trend of reduced platelet response 
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(Figure 5.9 - E). Interestingly, it was also observed that SMIM1 ablation in resting 
platelets of male mice leads to a significant reduction of P-selectin exposure and a 
reduction of fibrinogen binding (not significant). These observations indicate that 
SMIM1 has a subtle effect on platelet activation. In support of this, I have shown that 
SMIM1 is phosphorylated upon human platelet activation in vitro, which suggests that 
SMIM1 may require phosphorylation in order to be functional. The molecular 
mechanism behind these findings and its possible implications are still unclear. One 
could speculate that these trends of reduction in platelet response may result from subtle 
alterations in the cytoskeleton rearrangement, which may affect granule secretion. 
 
Platelet homeostasis and thrombus formation are tightly controlled by a complex 
network of inhibitory and activation signalling pathways, which are regulated by several 
protein kinases [136]. As SMIM1 is phosphorylated in serine residues [182, 188, 208, 
212], it would be important to investigate which serine/threonine protein kinase is 
responsible for SMIM1 phosphorylation, in order to better understand SMIM1 role 
during platelet activation. Several serine/threonine protein kinases have important roles 
during platelet activation, such as protein kinase C (PKC), which has been shown to 
mediate platelet secretion and thrombus formation [281] and 3-phosphoinositide-
dependent protein kinase 1 (PDK1), which has been shown to activate serine/threonine 
kinase protein kinase B (Akt) and inhibit glycogen synthase kinase 3 beta (GSK3b) thus 
enhancing platelet aggregation, clot retraction, platelet spreading and thrombin 
formation [282]. Identification of the serine/threonine protein kinase responsible for 
SMIM1 phosphorylation, could be performed by assessing SMIM1 phosphorylation 
state upon platelet activation either in wildtype/Vel-positive platelets treated with 
different protein kinase inhibitors, or in platelets of genetic models in which the 
expression of a single kinase is affected. These experiments would give important clues 
to further explore the molecular mechanism of SMIM1 role in platelets. 
 
After platelet activation and aggregation, a stable thrombus is formed. In this chapter, I 
have shown that SMIM1 ablation does not affect platelet spreading and response to 
different agonists. However, I have not addressed whether SMIM1 ablation affects 
thrombus formation and degradation. It still remains to be investigated if SMIM1 
ablation affects thrombus formation and stability in vivo. To that end, a ferric chloride 
or laser injury thrombosis intravital microscopy model could be used [283-285]. In 
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these models, an injury is induced in the vessel wall and thrombus development is 
imaged in real-time using intravital video-microscopy [283]. In the ferric chloride-
injury model thrombosis is induced with an oxidative injury, which severely damages 
the vessel wall, exposing the subendothelial matrix. While in the laser-injury model 
thrombosis is induced with a heat injury, which does not damage the vessel wall. This 
injury is similar to an injury caused by inflammation and this technique allows a 
temporal and spatial resolution of the thrombus [283]. These models allow the 
characterisation of the different cell types playing a role in thrombus formation, 
including platelets, neutrophils, blood coagulation proteins, endothelium, and the vessel 
wall [283]. As SMIM1 is expressed in neutrophils (Chapter 3 and 4), and those like 
platelets have an important role for thrombus formation [286, 287], both models may 
give important clues on SMIM1 role in platelets and neutrophils during thrombus 
formation and stability.  
 
In conclusion, in this chapter, I showed that SMIM1 does not affect megakaryopoiesis 
in the models used and that it plays a subtle role during platelet activation. However, the 
molecular mechanisms involved and therefore the biological relevance of these 
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CHAPTER 6 | CONCLUSIONS 
AND FINAL REMARKS 
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The advance of sequencing technologies enabled the mapping of the gene that underpins 
the Vel-blood group system. The discovery of SMIM1, which had remained unknown 
for more than 60 years, has opened new avenues to investigate this blood group system 
[182, 186, 188]. SMIM1 protein has been preliminarily characterised on the RBC 
membrane [182, 186, 188, 208, 212] but its function in RBCs and its potential function 
in other cells remains largely unknown. For this reason, the molecular characterisation 
of SMIM1 will lead to a better understanding of the physiological processes in which 
this gene may be involved. In turn, these studies may have the potential to reveal 
unknown clinical phenotypes and to inform their prevention and treatment. 
 
In my thesis, I have characterised the role of SMIM1 in haematopoiesis and other 
organs through two main approaches, in vivo and in vitro, and using three models 
(human subjects, mouse and cell lines). This work has led to four main findings:  
i) detection of SMIM1 expression in other mature blood cell types;  
ii) association of SMIM1 absence with hematologic alterations in RBC, platelet and 
neutrophil traits.  
iii) observation of molecular evidence of SMIM1 role in platelet activation;  
iv) discovery of a metabolic phenotype in human and mouse SMIM1 knockouts. 
 
These findings are important clues of novel roles of SMIM1 in multiple blood cells and 
possibly in other non-hematopoietic cells. They also open new questions regarding the 
role of SMIM1 in these cells and its clinical relevance.  
 
6.1 Molecular characterisation of SMIM1 
The molecular characterisation of SMIM1 was performed in blood cells of Vel-positive 
blood donors. I have specifically shown that SMIM1 is expressed in RBCs, as well as in 
neutrophils, naïve, memory and class-switched B-lymphocytes, MKs and platelets, 
through gene expression analysis of multiple blood lineages (Chapter 3). It was further 
observed that both the localisation of SMIM1 and the molecular weight of its multimers 
are cell-dependent through biochemical and flow cytometry assays (Chapter 3). These 
findings suggest that SMIM1 may play a role in the development and/or function of 
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6.2 Investigation of the role of SMIM1 in blood traits 
To further investigate the role of SMIM1 in blood cells, I performed a quantitative and 
qualitative comparison of haematological traits between Vel-negative blood donors, 
Vel-negative/weak individuals of UK Biobank (European individuals of the UK 
Biobank 400,000 individuals) and Smim1 mutant mice (Chapter 4). These analyses have 
shed new light on SMIM1’s association with traits in RBC, platelets and neutrophils.  
 
6.2.1 Investigation of the role of SMIM1 in blood traits in humans 
The analysis of the Vel-negative blood donors cohort showed that SMIM1 absence is 
associated with a small but significant decrease in the number of RBC and reticulocytes, 
with an increase of the percentage of RDW, with an increase in the number and size of 
platelets, and with an increase in the number of neutrophils. Furthermore, it was shown 
that the alteration of platelets and neutrophil traits was sex-dependent, suggesting a 
possible hormonal regulation. Interestingly, some of these alterations in blood traits did 
not overlap with those observed in the UK Biobank cohort. A decreased number of 
platelets in both sexes and no alteration of RBC and neutrophil counts were observed in 
this study. Moreover, Vel-negative/weak individuals in the UK Biobank cohort have 
also shown a negative association with HGB and MCHC that suggest a possible role of 
SMIM1 in iron metabolism. Together this suggests that other factors not yet identified 
may potentially influence the association of SMIM1 with some blood traits.  
 
It is important to note that the differences observed between Vel-negative blood donors 
and Vel-negative/weak individuals of UK Biobank may be due to: i) distinct 
associations in Vel-negative and Vel-weak individuals (which are the majority of the 
individuals in the UK Biobank), ii) the result of a positive selection for healthier 
individuals in the UK Biobank cohort, and iii) the result of a positive selection for 
individuals able to withstand several blood donations, and/or with an alteration in iron 
metabolism in the blood donors cohort. Recent results from the INTERVAL study have 
shown that active blood donors (that give regular donations) present altered iron 
metabolism resulting in decreased HGB and ferritin concentrations [229]. Although the 
association of frequent donations with platelet traits have not been investigated in this 
study, other studies have shown that altered iron metabolism is associated with 
increased platelet counts [288-293].  
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It would be important to further explore these differences through a follow-up study in a 
larger population of unselected individuals and blood donors. It would be particularly 
relevant to confirm these findings and to assess whether SMIM1 absence affects 
metabolic parameters related to iron metabolism. The complete data set of the UK 
Biobank (500,000 individuals), which was not available during the writing-up of this 
project, and the INTERVAL study (50,000 blood donors) represent two potential 
avenues for this next step. However, as the UK Biobank is not representative of the 
general population, a follow-up study in a larger population representative of the 
general population should also be prioritised. 
 
6.2.2 Investigation of the role of SMIM1 in blood traits in mice 
There were also phenotypical differences between the Vel-negative blood donors, the 
Vel-negative/weak individuals of the UK Biobank and the Smim1 mutant mice. The ³ 
six-months old Smim1-/- male mice had an increased number of RBC and no alteration 
in the number of platelets. Since the equivalent age of this observation was not 
represented in the human cohorts, the age-dependency of the SMIM1’s effect on the 
RBC number in humans would have to be investigated. This could be done either by 
performing this analysis in a younger human cohort or in an older mice model.  
 
6.3 Characterisation of SMIM1 role in megakaryopoiesis and 
thrombopoiesis  
The investigation of the association of SMIM1 with platelet traits in both human cohorts 
(Vel-negative blood donors and Vel-negative/weak individuals of UK Biobank) have 
shown that SMIM1 is a regulator of platelet production. For this reason, I then focused 
on the investigation of the role of SMIM1 in megakaryopoiesis, thrombopoiesis and 
platelet function. I showed that SMIM1 does not affect MK differentiation and 
maturation by characterising two models of hiPSC line forward programmed into MKs: 
a SMIM1 knockout model and a SMIM1 overexpression model.  
 
Testing an alternative SMIM1 knockout hiPSC lines would enable further confirmation 
of this phenotype. It is also important to note that the differentiation model adopted in 
this study only enables a restricted level of MKs maturity, which consequently limits 
the assessment of thrombopoiesis. The analysis of thrombopoiesis would be feasible in 
a differentiation model such as the Vel-negative CD34+ cells differentiated into MKs 
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through a proplatelet formation assay of human SMIM1 knockout MKs. Since some of 
the genes showing differential expression in platelets of Smim1-/- mice seem to be 
involved in the structure of the cytoskeleton (Dcdc2a, Sfi1 and Myo1g, Chapter 5), it 
would be particularly interesting to analyse by immunofluorescence other cytoskeleton 
proteins (e.g. tubulin, myosin and actin) to detect if these display any alterations.  
 
As the association of SMIM1 absence with alteration of platelet traits was only 
observed in humans, the study of thrombopoiesis in a human model would be highly 
relevant. However, as the recruitment of Vel-negative individuals might be potentially 
challenging. Another way to overcome the technical limitation of the model adopted in 
this study would be the assessment of thrombopoiesis in the Smim1 mutant mouse 
model. Similarly to the alternative proposed human model, the Smim1-/- mouse CD34+ 
cells could be differentiated into MKs and enable the study of thrombopoiesis through 
proplatelet formation assay. This mouse model could also allow the characterisation of 
platelet formation in vivo, in which the microenvironment is maintained (as suggested in 
Chapter 5). 
 
6.4 Characterisation of SMIM1 role in platelet function 
The effect of SMIM1 ablation in platelet function was also assessed. Two main 
observations suggest the involvement of SMIM1 in platelet activation: i) a reduced 
basal level of P-selectin surface expression in platelets of Smim1-/- male mice compared 
with wildtype mice; and ii) SMIM1 phosphorylation in human platelets during platelet 
activation in vitro (Chapter 5). The molecular mechanism behind these findings and its 
possible implications are still unclear.  
 
Further insight into the role of SMIM1 in platelets will require further clarification of 
molecular mechanisms underpinning the observed phenotype. As suggested in Chapter 
5, it would be particularly interesting to i) assess if the detected SMIM1 
phosphorylation is indeed involved in platelet activation, ii) to determine the protein 
kinase responsible for this phosphorylation pattern and, more broadly, iii) to 
characterise SMIM1’s interactome, as described below. 
 
The characterisation of SMIM1’s interactome may provide important clues to 
understand the molecular mechanisms in which it is involved. I complemented the 
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aforementioned results by taking steps towards the characterisation of SMIM1’s 
interactome. The strategy I adopted for this section of the study assumes that, since 
platelets acquire their RNA and proteins from MKs, the interactome of these two cell 
types should extensively overlap. Indeed, this extrapolation is also adopted in 
transcriptomic studies [270]. I created a hiPSC line overexpressing SMIM1-tagged with 
a TAP-tag (Bobc-TAP-SMIM1), which was then forward programmed into MKs. The 
mature MKs were collected for the intended immunoprecipitation and mass 
spectrometry studies. The time scale of this project did not allow for the optimisation of 
the immunoprecipitation protocol, which would have enabled the purification of protein 
required for proteomics studies. 
 
Beyond the experiments proposed above and the study of other aspects of the molecular 
characterisation of SMIM1, it would also be important to perform functional assays 
assessing thrombus formation. Since platelets and neutrophils are involved in thrombus 
formation, the in vivo assessment of this process could provide new insights into the 
function of SMIM1 in these two cell types (as suggested in Chapter 5). 
 
6.5 Assessment of SMIM1 role in erythropoiesis and RBC function 
Alterations in the maturity, number, size and deformability of SMIM1 knockout RBCs 
were observed in the different models (Vel-negative blood donors, Vel-negative/weak 
individuals of UK Biobank and Smim1 mutant mice; Chapter 4). This suggests that 
SMIM1 may be important for the formation and/or function of RBCs. The primary 
function of this cell type is the transportation of oxygen from the lungs to the tissues, 
which involves their mobility through the narrowest capillaries and for which 
morphologic and mechanical properties such as size and deformability are critical. 
Alterations in RBC traits such as RDW are associated with a higher incidence of 
cardiovascular diseases and liver disease [237, 238].  
 
The role of SMIM1 during erythropoiesis could be further characterised through the 
adoption of an erythroid culture system of iPSC or CD34+ cells generated/isolated from 
Vel-negative individuals differentiated into RBC. In addition, it would be interesting to 
assess if the decreased membrane deformability detected in the RBCs of Smim1-/- male 
mice is also observed in Vel-negative individuals. 
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6.6 A novel metabolic phenotype in human and mouse SMIM1 
knockouts  
The characterisation of the Vel-negative donor cohort and Smim1 mutant mouse model 
in this study identified two metabolic signatures: i) an increase of BMI and body weight 
in male Vel-negative blood donors and female Smim1-/- mice, respectively, and ii) an 
increase of lipid droplets or glycogen accumulation in the liver of Smim1 mutant mice. 
These findings suggest the existence of a metabolic phenotype, which is probably 
independent of SMIM1 role in blood cells. In turn, this might have an important impact 
on the health of Vel/SMIM1-negative individuals, since these phenotypes may be 
associated with conditions such as non-alcoholic liver disease, insulin resistance and 
cardiovascular diseases. 
 
This idea is further supported by two observations indicative of alterations in glucose 
metabolism, described by the International Mouse Phenotyping Consortium 
(http://mousephenotype.org/): i) Smim1-/- mice show increased levels of circulating 
fructosamine (p=7.12 x 10-5, which is a glycated protein that reflects average glycemia 
level over the previous 2-3 weeks). Increased levels of circulating fructosamine have 
been associated with coronary artery atherosclerosis [294, 295] and prospectively 
associated with risk of morbidity and mortality of cardiovascular disease in patients 
with and without diabetes [296, 297]. Furthermore, this trait is an independent predictor 
of vascular outcomes [298]; and ii) the knockout mouse model of the Nacad gene, 
which was down-regulated in Smim1-/- platelets (p=2.57 x 10-5), shows a decreased 
level of circulating glucose.  
 
6.7 Investigation of SMIM1 role in metabolism 
Since SMIM1 does not seem to be expressed in liver and adipose subcutaneous and 
visceral tissue (https://gtexportal.org/home/gene/SMIM1), these phenotypes are most 
likely an indirect effect of SMIM1 absence in other cells. To advance the understanding 
of SMIM1 association with metabolism it would be important to i) confirm the increase 
of BMI in Vel-negative individuals in a larger cohort such as the complete UK Biobank 
study (500,000 individuals); ii) assess whether metabolic parameters associated with 
glucose metabolism and liver damage (e.g. glucose, insulin and alanine 
aminotransferase) are affected by SMIM1 ablation; iii) assess whether the liver 
morphologic alteration (possibly steatosis) observed in mice is also present in Vel-
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negative individuals (e.g. by examination of the liver with MRI in the complete UK 
Biobank or in the Vel-negative blood donors); iv) assess whether the metabolic 
phenotype is caused by SMIM1 absence in blood cells. For the latter study, a 
conditional Smim1 knockout in haematopoietic cells or a bone marrow transplant of an 
Smim1-/- mouse into a wildtype mouse would be necessary. These experiments would 
clarify if the observed metabolic phenotype is a direct effect of SMIM1 ablation in 
blood cells but would not enable the determination of the cell type responsible for the 
observed phenotypes. 
 
If the absence of SMIM1 is proven to induce metabolic syndrome, it will be important 
to determine the molecular mechanisms causing this phenotype. This may be 
particularly relevant for the treatment of these conditions, as well as for the prevention 
and treatment of Vel/SMIM1-negative individuals. Obesity, diabetes and liver-related 
diseases have a tremendous societal and economic impact in both developed and 
developing countries [299]. More specifically, these epidemic conditions represent a 
significant burden on national health care providers. Only in the UK, the national health 
system (NHS) estimates that £9.7 billion will be required to address overweight and 
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Table 8.1 – Collection of SMIM coding proteins. SMIM coding proteins described in 
the Human Gene Organization (HUGO - https://www.genenames.org/) and Gene 




Gene symbol Location (chromosome) Protein size (KDa) Function
SMIM1 1 8.7 Regulator of RBC formation
SMIM2 13 9.4 Unknown
SMIM3 5 6.5 Unknown
SMIM4 3 8.7 Unknown
SMIM5 17 8.5 Unknown
SMIM6 17 7 Unknown
SMIM7 19 8.6 Unknown
SMIM8 6 11 Unknown
SMIM9 X 10.8 Unknown
SMIM10 X 9.2 Unknown
SMIM10L2A X 8.4 Unknown
SMIM10L1 X 7.4 Unknown
SMIM10L2B X 8.4 Unknown
SMIM11A 21 6.9 Unknown
SMIM11B 21 7.9 Unknown
SMIM12 1 10.8 Unknown
SMIM13 6 10.4 Unknown
SMIM14 4 10.7 Unknown
SMIM15 5 8.6 Unknown
SMIM17 19 13.3 Unknown
SMIM18 8 11.1 Unknown
SMIM19 8 12.4 Unknown
SMIM20 4 7.7 Required for mitochondrial cytochrome c oxidase biogenesis
SMIM21 18 11.7 Unknown
SMIM22 16 14.6 Unknown
SMIM23 5 20 Unknown
SMIM24 19 14.9 Unknown
SMIM26 20 10.9 Unknown
SMIM27 9 6.4 Unknown
SMIM28 6 16.6 Unknown
SMIM29 6 11.6 Unknown
SMIM30 7 6.1 Unknown
SMIM31 4 8.4 Unknown
SMIM32 5 10.9 Unknown
SMIM33 5 14.1 Unknown
SMIM34A 21 15 Unknown
SMIM34B 21 15 Unknown
SMIM35 11 9.4 Unknown
SMIM36 17 10.1 Unknown
SMIM37/MTLN 2 6.5 Micropeptide regulator of Beta-oxidation
SMIM38 11 5.8 Unknown
SMIM39 2 6 Unknown
SMIM40 6 9 Unknown
SMIM41 12 9.3 Unknown
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Figure 8.1 – SMIMs mRNA expression level in blood cells. Heat map of human SMIMs mRNA expression in different blood cell types based on 
RNA-Sequencing data from the Blueprint project [197]. SMIM5 and SMIM7 are highly expressed in platelets. Expression levels are color coded 
according with expression in Log2 (fpkm) – fragments per Kilobase million reads; Vb- venous blood; Cb- cord blood; MSC- mesenchymal stem cells; 
BOEC- blood outgrowth endothelial cells; HUVEC- human umbilical vein endothelial cells; Plat- platelet; MK- megakaryocyte; EB- erythroblast; 
Neut- neutrophil; Mono- monocytes; M0- macrophage; M1- macrophage M1; CD4+ T-cell- T helper cell; CM- central memory T cells; EM- effector 
memory T cell; CD8+ T cell- cytotoxic (killer) T cell; CD8 TDEM- terminally differentiated effector memory T cell ; T-reg- regulatory T cell; NK-
natural killer cell. Data obtained through Blood RNAexpress- https://blueprint.haem.cam.ac.uk/mRNA/. 
 



















Figure 8.2 – Schematic representation of UK Biobank genotype data-variant and sample QC. Scheme adapted from the internal technical report 
from the Cardiovascular Epidemiology Unit at the University of Cambridge. 
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